0001213900-21-058900.txt : 20211115 0001213900-21-058900.hdr.sgml : 20211115 20211115060504 ACCESSION NUMBER: 0001213900-21-058900 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 64 CONFORMED PERIOD OF REPORT: 20210930 FILED AS OF DATE: 20211115 DATE AS OF CHANGE: 20211115 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Generation Hemp, Inc. CENTRAL INDEX KEY: 0001527102 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-BUSINESS SERVICES, NEC [7389] IRS NUMBER: 263119496 STATE OF INCORPORATION: CO FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55019 FILM NUMBER: 211406010 BUSINESS ADDRESS: STREET 1: 5128 HORSESHOE TRAIL CITY: DALLAS STATE: TX ZIP: 75209 BUSINESS PHONE: (469) 209-6154 MAIL ADDRESS: STREET 1: P.O. BOX 540308 CITY: DALLAS STATE: TX ZIP: 75354 FORMER COMPANY: FORMER CONFORMED NAME: Home Treasure Finders, Inc. DATE OF NAME CHANGE: 20110801 10-Q 1 f10q0921_generation.htm QUARTERLY REPORT

 

  

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

(Mark One)

 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2021

 

or

 

 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from         to        

 

Commission File Number: 000-55019

 

GENERATION HEMP, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   26-3119496
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)
     
8533 Midway Road    
Dallas, Texas   75209
(Address of principal executive offices)   (Zip code)

 

(469) 209-6154

(Registrant’s telephone number, including area code)

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, no par value   GENH   OTC MARKETS

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company    

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No 

 

As of November 15, 2021, the registrant had 111,486,996 shares of common stock outstanding.

 

 

 

 

 

TABLE OF CONTENTS

 

    Page
  PART I. FINANCIAL INFORMATION  
Item 1. Financial Statements 1
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 16
Item 3. Quantitative and Qualitative Disclosures about Market Risk 20
Item 4. Controls and Procedures 20
     
  PART II. OTHER INFORMATION  
Item 1. Legal Proceedings 21
Item 1A. Risk Factors 21
Item 4. Mine Safety Disclosures 21
Item 6. Exhibits 22
     
SIGNATURES 23

 

i

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q (the “Quarterly Report”) includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of historical fact included in this report, regarding our strategy, future operations, financial position, estimated revenue, projected costs, prospects, plans and objectives of management are forward-looking statements. When used in this Quarterly Report, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements described under, but not limited to, the heading “Item 1A. Risk Factors” included in the Annual Report of Generation Hemp, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 (the “Annual Report”) and our other filings with the Securities and Exchange Commission (“SEC”).

 

Forward-looking statements may include statements about:

 

  the risk that our results could be adversely affected by natural disaster, public health crises (including, without limitation, the COVID-19, outbreak), political crises, negative global climate patterns, or other catastrophic events;

 

  the marketability of our products;

 

  financial condition and liquidity of our customers;

 

  competition in the hemp markets;

 

  industry and market conditions;

 

  requisition of our services by major customers and our ability to renew processing and services contracts;

 

  credit and performance risks associated with customers, suppliers, banks and other financial counterparties;

 

  availability, timing of delivery and costs of key supplies, capital equipment or commodities;

 

  our future capital requirements and our ability to raise additional capital to finance our activities;

 

  the future trading of our common stock;

 

  legal and regulatory risks associated with OTC Markets;

 

  our ability to operate as a public company;

 

  our ability to protect our proprietary information;

 

  general economic and business conditions; the volatility of our operating results and financial condition;

 

  our ability to attract or retain qualified senior management personnel and research and development staff;

 

  timing for completion of major acquisitions or capital projects;

  

  our ability to obtain additional financing on favorable terms, if required, to complete acquisitions as currently contemplated or to fund the operations and growth of our business;

 

  operating or other expenses or changes in the timing thereof;

 

  compliance with stringent laws and regulations, as well as changes in the regulatory environment, the adoption of new or revised laws, regulations and permitting requirements, especially with respect to the industry in which we operate;

 

  potential legal proceedings and regulatory inquiries against us; and

 

  other risks identified in this report that are not historical.

 

ii

  

We caution you that these forward-looking statements are subject to a number of risks, uncertainties and assumptions, which are difficult to predict and many of which are beyond our control, including risks specific to the industry in which we operate. Moreover, we operate in a very competitive and rapidly changing environment and new risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements we make in this Quarterly Report are reasonable, we can give no assurance that these plans, intentions or expectations will be achieved or occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

 

All forward-looking statements, expressed or implied, included in this report are expressly qualified in their entirety by this cautionary statement and speak only as of the date of this Quarterly Report. This cautionary statement should also be considered in connection with any subsequent written or oral forward-looking statements that we or persons acting on our behalf may issue.

 

Except as otherwise required by applicable law, we disclaim any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this report.

 

iii

 

PART I - FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Balance Sheets

 

   September 30,   December 31, 
   2021   2020 
Assets        
Current Assets        
Cash  $134,165   $2,776,425 
Accounts receivable   127,665    
-
 
Prepaid expenses   14,232    
-
 
Total Current Assets   276,062    2,776,425 
           
Property and Equipment          
Property and equipment   3,012,316    1,222,430 
Accumulated depreciation   (417,135)   (102,938)
Total Property and Equipment, Net   2,595,181    1,119,492 
           
Operating lease right-of-use asset   286,839    
-
 
Intangible assets, net   2,474,136    
-
 
Goodwill   509,701      
Other assets   407,000    23,077 
           
Total Assets  $6,548,919   $3,918,994 
           
Liabilities and Equity (Deficit)          
Current Liabilities          
Accounts payable  $1,061,873   $1,053,542 
Accrued liabilities   375,521    337,588 
Payables to related parties   167,482    448,271 
Operating lease liability - related party   98,749    
-
 
Notes payable – related parties   2,360,000    3,336,592 
Other indebtedness - current   516,359    619,461 
Common stock issuable   
-
    50,000 
Current liabilities of discontinued operations held for sale   137,068    140,068 
Total Current Liabilities   4,717,052    5,985,522 
Operating lease liability - related party, net of current portion   188,090    
-
 
Other indebtedness - long-term   
-
    25,200 
Long-term liabilities of discontinued operations held for sale   158,498    144,149 
Total Liabilities   5,063,640    6,154,871 
           
Commitments and Contingencies   
 
    
 
 
           
Series B redeemable preferred stock, no par value, $10,000 stated value, 300 shares authorized, 118 and 135 shares issued and outstanding at September 30, 2021 and December 31, 2020   591,558    729,058 
           
Equity (Deficit)          
Series A preferred stock, $0.00001 par value; $1.00 stated value; 6,500,000 shares authorized, none and 6,328,948 shares issued and outstanding at September 30, 2021 and December 31, 2020   
-
    4,975,503 
Common stock, $0.00001 par value; 200,000,000 shares authorized, 111,070,329 shares issued and outstanding at September 30, 2021   1,111    
-
 
Common stock, no par value; 100,000,000 shares authorized, 17,380,317 shares issued and outstanding at December 31, 2020   
-
    6,083,480 
Additional paid-in capital   23,776,409    4,436,018 
Accumulated deficit   (22,644,284)   (18,220,705)
Generation Hemp equity   1,133,236    (2,725,704)
Noncontrolling interest   (239,515)   (239,231)
Total Equity (Deficit)   893,721    (2,964,935)
           
Total Liabilities and Equity (Deficit)  $6,548,919   $3,918,994 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Statements of Operations

 

   For the three months ended September 30,   For the nine months ended September 30, 
   2021   2020   2021   2020 
                 
Revenue                
Post-harvest and midstream services  $487,088   $
-
   $535,053   $- 
Rental   15,000    22,500    60,000    67,500 
Total revenue   502,088    22,500    595,053    67,500 
                     
Costs and Expenses                    
Cost of revenue (exclusive of items shown separately below)   279,621    
-
    549,881    - 
Depreciation and amortization   315,729    16,038    1,006,804    54,961 
Merger and acquisition costs   -    6,856    16,115    99,880 
General and administrative   1,128,298    108,728    2,763,529    883,565 
Total costs and expenses   1,723,648    131,622    4,336,329    1,038,406 
                     
Operating loss   (1,221,560)   (109,122)   (3,741,276)   (970,906)
                     
Other expense (income)                    
Interest and other income   -    -    (25,424)   (1)
Change in fair value of marketable security   -    (1,826)   (11,770)   14,736 
Interest expense   155,505    68,475    651,807    204,875 
Total other expense   155,505    66,649    614,613    219,610 
                     
Loss from continuing operations   (1,377,065)   (175,771)   (4,355,889)   (1,190,516)
Loss from discontinued operations   (1,630)   (7,989)   (11,349)   (5,457)
                     
Net loss  $(1,378,695)  $(183,760)  $(4,367,238)  $(1,195,973)
Less: net loss attributable to noncontrolling interests   (1,137)   (4,904)   (284)   (44,266)
                     
Net loss attributable to Generation Hemp  $(1,377,558)  $(178,856)  $(4,366,954)  $(1,151,707)
                     
Earnings (loss) per common share:                    
Loss from continuing operations                    
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Loss from discontinued operations                    
Basic  $
-
   $
-
   $
-
   $
-
 
Diluted  $
-
   $
-
   $
-
   $
-
 
Earnings (loss) per share                    
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2

 

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Statements of Equity

 

   Series B
Redeemable
Preferred Stock
   Series A Preferred Stock   Common Stock  

Additional

Paid-In

   Accumulated   Noncontrolling   Total
Equity
 
   Shares   Amount   Shares   Amount   Shares   Amount   Capital   Deficit   Interest   (Deficit) 
                                         
Balance at January 1, 2020   
-
   $
-
    6,328,948   $4,975,503    17,130,317   $6,029,328   $3,426,946   $(16,722,036)  $(184,551)  $(2,474,810)
Issuance of common stock units   
-
    
-
    
-
    
-
    250,000    54,152    45,848    
-
    
-
    100,000 
Net loss   -    
-
    -    
-
    -    
-
    
-
    (712,566)   (30,075)   (742,641)
                                                   
Balance at March 31, 2020   
-
    
-
    6,328,948   $4,975,503    17,380,317    6,083,480    3,472,794    (17,434,602)   (214,626)   (3,117,451)
Net loss   -    
-
    -    
-
    -    
-
    
-
    (260,285)   (9,287)   (269,572)
                                                   
Balance at June 30, 2020   -    -    6,328,948   $4,975,503    17,380,317    6,083,480    3,472,794    (17,694,887)   (223,913)   (3,387,023)
Net loss   -    -    -    -    -    -    -    (178,856)   (4,904)   (183,760)
                                                   
Balance at September 30, 2020   
-
   $
-
    6,328,948   $4,975,503    17,380,317   $6,083,480   $3,472,794   $(17,873,743)  $(228,817)  $(3,570,783)
                                                   
Balance at January 1, 2021   135   $729,058    6,328,948   $4,975,503    17,380,317   $6,083,480   $4,436,018   $(18,220,705)  $(239,231)  $(2,964,935)
Acquisition of Certain Assets of Halcyon Thruput, LLC   
-
    
-
    
-
    
-
    6,250,000    2,500,000    
-
    
-
    
-
    2,500,000 
Issuances of common stock units   
-
    
-
    
-
    
-
    800,000    136,707    263,293    
-
    
-
    400,000 
Warrant exercises   
-
    
-
    
-
    
-
    8,428,976    4,771,669    (1,804,669)   
 
    
-
    2,967,000 
Issuance of common shares for Convertible Promissory Note   
-
    
-
    
-
    
-
    618,660    217,769    
-
    
-
    
-
    217,769 
Issuance of common shares for Senior Secured Promissory Note   
-
    
-
    
-
    
-
    1,000,000    1,942,500    
-
    
-
    
-
    1,942,500 
Stock-based compensation   
-
    
-
    
-
    
-
    500,000    42,250    
-
    
-
    
-
    42,250 
Series B preferred stock dividend   -    
-
    -    
-
    -    
-
    
-
    (20,250)   
-
    (20,250)
Net loss   -    
-
    -    
-
    -    
-
    
-
    (1,836,882)   3,668    (1,833,214)
                                                   
Balance at March 31, 2021   135    729,058    6,328,948    4,975,503    34,977,953    15,694,375    2,894,642    (20,077,837)   (235,563)   3,251,120 
Stock-based compensation   
-
    
-
    
-
    
-
    
-
    38,750    
-
    
-
    
-
    38,750 
Series B preferred stock redemption   (17)   (137,500)   -    
-
    -    
-
    
-
    
-
    
-
    
-
 
Series B preferred stock dividend   -    
-
    -    
-
    -    
-
    
-
    (20,250)   
-
    (20,250)
Net loss   -    
-
    -    
-
    -    
-
    
-
    (1,152,514)   (2,815)   (1,155,329)
                                                   
Balance at June 30, 2021   118    591,558    6,328,948    4,975,503    34,977,953    15,733,125    2,894,642    (21,250,601)   (238,378)   2,114,291 
Common shares issued to vendor for services   -    -    -    -    125,000    117,500    -    -    -    117,500 
Issuance of common shares for extension of secured note   
-
    
-
    
-
    
-
    20,000    18,000    
-
    
-
    
-
    18,000 
Change in common stock par value due to change in corporate domicile   -    -    -    -    -    (15,868,273)   15,868,273    -    -    - 
Stock-based compensation   -    -    -    -    -    -    38,750    -    -    38,750 
Conversion of Series A preferred stock             (6,328,948)   (4,975,503)   75,947,376    759    4,974,744    -    -    - 
Series B preferred stock dividend   -    -    -    -    -    -    -    (16,125)   -    (16,125)
Net loss   -    -    -    -    -    -    -    (1,377,558)   (1,137)   (1,378,695)
                                                   
Balance at September 30, 2021   118   $591,558    -   $-    111,070,329   $1,111   $23,776,409   $(22,644,284)  $(239,515)  $893,721 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3

 

Generation Hemp, Inc.

Unaudited Condensed Consolidated Statements of Cash Flows

 

   For the nine months ended September 30, 
   2021   2020 
Cash Flows From Operating Activities        
Net loss  $(4,367,238)  $(1,195,973)
Loss from discontinued operations   (11,349)   (5,457)
Net loss from continuing operations   (4,355,889)   (1,190,516)
Adjustments to reconcile net loss from continuing operations to net cash from operating activities:          
Depreciation expense   1,006,804    54,961 
Amortization of debt discount   380,282    
-
 
Stock-based compensation   119,750    
-
 
Common shares issued to vendor for services   117,500    
-
 
Other income - PPP Loan forgiveness   (25,424)   
-
 
Loss on disposal of property and equipment   
-
    539 
Change in fair value of marketable securities   (11,770)   14,736 
Changes in operating assets and liabilities:          
Accounts receivable   (52,195)   
-
 
Prepaid expenses   (14,232)   
-
 
Accounts payable and accrued liabilities   176,969    466,533 
Net cash from operating activities – continuing operations   (2,658,205)   (653,747)
Net cash from operating activities – discontinued operations   
-
    31,716 
Net cash from operating activities   (2,658,205)   (622,031)
           
Cash Flows From Investing Activities          
Capital expenditures   (77,716)   
-
 
Acquisition of certain assets of Halcyon Thruput, LLC, net of acquired cash of $224,530   (1,525,470)   
-
 
Proceeds from sale of investment in common stock   34,847    
-
 
Net cash from investing activities – continuing operations   (1,568,339)   
-
 
Net cash from investing activities – discontinued operations   
-
    
-
 
Net cash from investing activities   (1,568,339)   
-
 
           
Cash Flows From Financing Activities          
Proceeds for common stock issuable   
-
    150,000 
Issuance of common stock units   350,000    100,000 
Redemptions of Series B preferred stock   (137,500)   
-
 
Series B preferred stock dividends paid   (16,500)   
-
 
Proceeds from warrant exercises   2,967,000    
-
 
Repayment of Halcyon bank note   (995,614)   
-
 
Proceeds from SBA PPP Loan   
-
    25,200 
Proceeds from  subordinated notes   620,000    340,000 
Repayment of subordinated notes   (1,100,000)   
-
 
Payment of mortgage payable   (103,102)   (11,740)
Net cash from financing activities – continuing operations   1,584,284    603,460 
Net cash from financing activities – discontinued operations   
-
    
-
 
Net cash from financing activities   1,584,284    603,460 
           
Net change in cash   (2,642,260)   (18,571)
           
Cash, beginning of period   2,776,425    101,337 
Cash, end of period  $134,165   $82,766 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

4

 

Generation Hemp, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

 

1. Business

 

Generation Hemp, Inc. (the “Company”), formerly known as Home Treasure Finders, Inc. (“HTF”), was incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated on July 28, 2008 in the State of Colorado. On November 27, 2019, HTF purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger (the “Transaction”). Upon closing of the Transaction, HTF changed its name to Generation Hemp, Inc.

 

On January 11, 2021, we completed the acquisition of certain assets of Halcyon Thruput, LLC (“Halcyon”). With this acquisition, we commenced providing post-harvest and midstream services to growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot leased facility located in Hopkinsville, Kentucky. Additionally, the Company offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. In August 2021, the Company launched its small animal bedding consumer goods product line (“Rowdy Rooster”) made from the hemp hurd byproduct that is produced from its hemp processing operations.

 

We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to an unaffiliated hemp seed company.

 

As of September 30, 2021, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.

 

Our management team has been and continues to actively review acquisition candidates involved in the hemp industry that operate within a number of vertical businesses, predominantly within the midstream sector that are attractive to us and are within the hemp supply chain.

 

Liquidity – The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.

 

In the nine months ended September 30, 2021, the Company used $2.7 million of cash for its operating activities. At September 30, 2021, the Company’s current liabilities, including financing obligations due within one year, totaled $4.7 million as compared with its current assets of $276 thousand. Cash payments under several financing obligations were initially due in September and October of 2021. As disclosed in Notes 5 and 6 below, these were subsequently amended to extend these payments by one to six months.

 

The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Impact of COVID-19 Pandemic on Our Business – Our business, results of operations and financial condition have been adversely affected by the COVID-19 pandemic, beginning in mid-March 2020. The COVID-19 pandemic and measures taken to contain it have subjected our business, results of operations, financial condition, stock price and liquidity to a number of material risks and uncertainties, all of which may continue or may worsen.

 

2. Summary of Significant Accounting Policies

 

Basis of Presentation – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.

 

5

 

Revenue Recognition – Post-harvest and midstream services revenue is typically determined based on volumes processed at agreed-upon contractual prices and is recognized when performance obligations under the terms of a contract with our customers are satisfied. This occurs when control of the product is transferred to our customers upon completion of our processing.

 

Rental revenue is recognized based on the contractual cash rental payments for the period. Oil & gas revenue is recognized for discontinued operations based on delivered quantities in the amount of the consideration to which the Company is entitled.

 

Stock-based Compensation – We account for employee stock-based compensation using the fair value method. Compensation cost for equity incentive awards is based on the fair value of the equity instrument generally on the date of grant and is recognized over the requisite service period. Forfeitures are recognized as they occur.

 

Fair Value Measurement – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and notes payable. The fair values of these instruments approximate their carrying amounts at each reporting date.

 

The Company’s non-financial assets measured at fair value on non-recurring basis include impairment measurements of oil and gas properties and warrants issued as part of financing transactions. These are considered Level 3 measurements as they involve significant unobservable inputs.

 

Major Customer and Concentration of Credit Risk – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2021 or December 31, 2020.

 

During the three and nine months ended September 30, 2021, one customer accounted for approximately 99% and 90% of our post-harvest and midstream services revenue, respectively. Amounts outstanding from this customer represented 99% of total accounts receivable at September 30, 2021.

 

Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2021 or December 31, 2020.

 

Recent Accounting Pronouncements – In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company elected to early adopt ASU 2020-06 in 2021. Adoption of this new guidance had no impact on its financial statements at the date of adoption but is applicable to newly issued instruments.

 

There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.

 

6

 

3. Acquisition

 

On January 11, 2021, the Company completed the acquisition of certain assets of Halcyon pursuant to the Asset Purchase Agreement dated March 7, 2020, as amended on January 11, 2021. The purchase consideration totaled approximately $6.1 million consisting of 6,250,000 shares of Company common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year), $1.75 million in cash, a promissory note for $850,000 issued by the Company’s subsidiary, GenH Halcyon Acquisition, LLC, and guaranteed by Gary C. Evans, CEO of the Company, and assumption of approximately $1.0 million of new indebtedness of Halcyon. The Company was granted an option to purchase the real estate occupied by Halcyon for $993,000. This option is exercisable at any time before its expiration on January 11, 2022.

 

The acquisition was accounted for as a business combination where the Company is the acquirer and the acquisition method of accounting was applied in accordance with GAAP. Accordingly, the aggregate value of the consideration we paid to complete the acquisition was allocated to the assets acquired based upon their estimated fair values on the acquisition date.

 

The following table summarizes the purchase price allocation for the assets acquired. This allocation is preliminary. In the third quarter of 2021, we made adjustments to the previously recognized amounts for inventory, intangibles, goodwill and the real estate purchase option based on the preliminary results of a valuation study. The final allocation of the purchase price will be determined at a later date and is dependent on a number of factors, including the final evaluation of the fair value of tangible and identifiable intangible assets acquired. Final adjustments, including increases and decreases to depreciation and amortization resulting from the allocation of the purchase price to amortizable tangible and intangible assets, may be material.

 

Accounts receivable  $75,470 
Other working capital   224,530 
Property and equipment, other   1,712,170 
Intangibles:     
Non-competition agreements   64,691 
Customer relationships   3,102,052 
Other assets - Purchase option on real estate   407,000 
Goodwill   509,701 
Assets acquired  $6,095,614 

 

Intangible assets consist of customer relationships and non-compete agreements, each having definite-lives. These intangible assets are being amortized over the estimated useful life on an accelerated basis reflecting the anticipated future cash flows of the Company post acquisition of Halcyon.

 

The results of operations for the acquired Halcyon assets have been included in the Company’s consolidated financial statements since the January 11, 2021 acquisition date.

 

Concurrent with the closing of the asset acquisition, the Company entered into term employment agreements with two executives to serve as vice presidents of the Company for a term of at least two years. The term employment agreements each provide for the issuance of 250,000 shares of restricted common stock of the Company as a signing bonus. Such shares are subject to restrictions on the trading or transfer of such common stock.

 

Further, the term employment agreements each provide for the payment by the executives of liquidated damages if the employee terminates his employment without good reason during the initial term, other than due to the employee’s death or disability. Such liquidated damages total $600,000 if such termination occurs on or prior to January 11, 2022 or $375,000 if such termination occurs after January 11, 2022 and prior to January 11, 2023.

 

On March 3, 2021, the Company repaid the outstanding principal and interest balance on the $850,000 promissory note issued in connection with the acquisition.

 

Supplemental Pro Forma Information – The supplemental pro forma financial information presented below is for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the acquisition of certain assets of Halcyon had been completed on the date indicated, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that management believes are reasonable under the circumstances.

 

7

 

The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the acquisition had occurred on January 1, 2020, to give effect to certain events that management believes to be directly attributable to the acquisition. These pro forma adjustments primarily include:

 

  an increase to depreciation and amortization expense that would have been recognized due to acquired tangible and intangible assets; and

 

  an adjustment to interest expense to reflect the reduced borrowings due to the repayment of Halcyon’s historical debt in conjunction with the acquisition;

 

The supplemental pro forma financial information for the periods presented is as follows:

 

   For the three months ended September 30,   For the nine months ended September 30, 
   2021   2020   2021   2020 
Revenue, continuing operations  $502,088   $974,434   $596,291   $1,106,440 
Income (loss) from continuing operations   (1,377,065)   59,631    (4,424,786)   (1,528,788)
Earnings (loss) per common share:                    
Basic and diluted  $(0.03)  $0.00   $(0.11)  $(0.09)

 

4. Discontinued Operations

 

In connection with the Transaction, management determined to fully divest of EHR’s oil and gas activities. As such, these activities are presented as discontinued operations for each of the periods presented.

 

The following is a summary of the carrying amounts of major classes of assets and liabilities of the discontinued operations to assets and liabilities held for sale:

 

   September 30,   December 31, 
   2021   2020 
Assets -        
Oil and natural gas properties held for sale, at cost  $1,874,849   $1,874,849 
Accumulated DD&A   (1,874,849)   (1,874,849)
Total assets of discontinued operations held for sale  $
-
   $
-
 
           
Liabilities          
Accrued liabilities  $32,583   $31,117 
Asset retirement obligations   52,368    56,834 
Revenue payable   52,117    52,117 
Current liabilities of discontinued operations held for sale   137,068    140,068 
           
Asset retirement obligations -          
Long-term liabilities of discontinued operations held for sale   158,498    144,149 
Total liabilities of discontinued operations held for sale  $295,566   $284,217 

 

The following is a summary of the major classes of line items constituting loss on discontinued operations shown in the consolidated statements of operations:

 

   For the three months ended September 30,   For the nine months ended September 30, 
   2021   2020   2021   2020 
Revenue -                
Oil and gas sales  $55,140   $13,036   $93,248   $93,361 
                     
Costs and Expenses                    
Lease operating expense   53,919    16,762    94,714    77,099 
Depreciation, depletion & amortization   
-
    -    
-
    9,942 
Accretion   2,851    4,263    9,883    12,868 
Gain on disposal of oil & gas property interests   
-
    -    
 
    (24,008)
Total costs and expenses   56,770    21,025    104,597    75,901 
                     
Interest expense   
-
    -    
-
    22,917 
                     
Loss from discontinued operations  $(1,630)  $(7,989)  $(11,349)  $(5,457)

 

 

8

 

5. Notes Payable – Related Parties

 

Notes payable – related parties consisted of the following:

 

   September 30,   December 31, 
   2021   2020 
         
Senior Secured Promissory Note  $
-
   $1,500,000 
Convertible Promissory Note   
-
    208,874 
Subordinated Promissory Note to CEO   490,000    490,000 
Convertible Promissory Note to CEO   620,000    - 
Secured Promissory Note to Coventry Asset Management, LTD.   1,000,000    1,000,000 
Subordinated Promissory Note to Investor   250,000    500,000 
           
Total   2,360,000    3,698,874 
Less debt discounts   -    (362,282)
           
Total Notes Payable – Related Parties  $2,360,000   $3,336,592 

 

Senior Secured Promissory Note – On March 9, 2021, the total principal, interest and accrued fees under the Senior Secured Promissory Note was contributed to the Company and exchanged into 1,000,000 common shares.

 

Convertible Promissory Note – On March 9, 2021, the convertible promissory note issued in October 2019, together with accrued interest thereon, was converted into 618,660 common shares under the terms of the note.

 

Subordinated Promissory Note to CEO – Our CEO made advances to the Company during 2020 under a subordinated promissory note due September 30, 2021. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $28,508 at September 30, 2021 and $22,393 at December 31, 2020. This note was amended to a new maturity date of January 31, 2022.

 

Convertible Promissory Note to CEO – In the third quarter of 2021, our CEO made advances totaling $620,000 to the Company under a convertible promissory note. The convertible note matures on January 1, 2022, bears interest at 10%. The principal and interest due on the convertible note may be converted, at the option of the holder, into restricted shares of the Company’s common stock at a conversion price equal to $0.50 per share. Accrued interest on this subordinated promissory note totaled $5,047 at September 30, 2021.

 

Secured Promissory Note and Warrants to Coventry Asset Management, LTD. – On December 30, 2020, the Company received proceeds from issuance of a secured promissory note in principal amount of $1,000,000 to Coventry Asset Management, LTD. The promissory note is secured by the property acquired in the acquisition of certain assets of Halcyon. The unpaid balance of the secured promissory note bears interest at a rate of 10% per annum and initially matured on June 30, 2021. Effective June 30, 2021, the promissory note was extended to a new maturity date of December 31, 2021. The Company agreed to issue 20,000 restricted common shares as a first extension fee, make a payment of $50,000 of accrued interest and a principal payment of $250,000 on October 1, 2021. The accrued interest and principal payment were not made but were subsequently amended. As amended in November 2021, the promissory note’s required payments and maturity date were extended to January 31, 2022. If before December 31, 2021 the Company raises new equity capital of $10 million or more, then the full amount outstanding under the promissory note is due within five days. Additionally, the holder of the promissory note was given an option exercisable in November 2021 to convert $250,000 of the outstanding principal balance into shares of the Company’s common stock at an exercise price of $0.60 per share. The Company agreed to issue 20,000 restricted common shares as a second extension fee. Accrued interest on this secured note totaled $75,069 at September 30, 2021.

 

The holder of the secured promissory note received a warrant to purchase 1,000,000 shares of common stock exercisable at an exercise price of $0.352 per share upon origination of the promissory note in 2020. This warrant was subsequently exercised in the first quarter of 2021.

 

Subordinated Promissory Note and Warrants to Investor – On December 30, 2020, the Company issued a subordinated promissory note in principal amount of $500,000 to an accredited investor. The unpaid balance of the Subordinated Note bears interest at a rate of 10% per annum. The Company made a principal payment of $250,000 in April 2021. The subordinated note principal together with accrued and unpaid interest was due September 30, 2021 but was subsequently extended. As amended, payments of $125,000 each are due on January 31, 2022 and March 31, 2022 together with accrued interest thereon. If at any time prior to the note’s maturity the Company raises new equity capital of $12.5 million or more, then the full amount outstanding under the note is due within five days. Accrued interest on this subordinated promissory note totaled $18,733 at September 30, 2021.

 

9

 

The holder of the subordinated note received a warrant to purchase 500,000 shares of common stock exercisable until December 30, 2022 at an exercise price of $0.352 per share.

 

6. Other Indebtedness

 

Other indebtedness consisted of the following:

 

   September 30,   December 31, 
   2021   2020 
         
Mortgage Payable  $516,359   $619,461 
Paycheck Protection Program Loan   
-
    25,200 
           
Total   516,359    644,661 
Less current portion   (516,359)   (619,461)
Total Other Indebtedness - Long-Term  $
-
   $25,200 

 

Mortgage Payable and Operating LeaseThe Company is obligated under a mortgage payable, dated September 15, 2014 and as amended October 1, 2019, secured by its warehouse property located in Denver, Colorado. The note provided for a 25-year amortization period and an initial interest rate of 9% annually. As amended, the note matured on January 15, 2021 but was extended under terms of the amendment to July 15, 2021 after payment by the Company of an extension fee of 1% of the then outstanding principal. The rate during this extension period was 11% annually.

 

In July 2021, the mortgage payable was amended to a new maturity date of October 15, 2021. The Company made a $100,000 principal payment and paid an extension fee of $6,000 in July 2021 for this amendment. The rate during the extension period was increased to 12% annually and the new monthly payment is $5,279.

 

In October 2021, the mortgage payable was amended to a new maturity date of January 15, 2022. The Company will pay an extension fee of $1,000 each month beginning November 15, 2021. The new monthly payment of the note is $5,500 including interest at an effective rate of approximately 13%.

 

The Company leases the Denver warehouse property to a tenant under an operating lease which was renewed with a new tenant and extended to August 1, 2023 for a monthly rent of $7,500. The lease requires a true-up with the tenant for property taxes and insurance paid by the Company and requires the tenant to maintain the interior and exterior of the warehouse (except for the roof). The lease provides for a rent abatement in the first and last month of the contracted extension. Minimum future rents for the remainder of 2021 are $22,500, for 2022 are $90,000 and for 2023 are $52,500.

 

Paycheck Protection Program Loan – Congress created the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) to provide forgivable loans to eligible small businesses facing economic hardship to retain U.S. employees on their payroll during the Coronavirus Disease 2019 (“COVID-19”) pandemic.

 

PPP loan recipients may be eligible to have their loans forgiven if the funds were used for eligible expenses over the eight-week coverage period commencing when the loan was originally disbursed. The amount of forgiveness may be reduced if the percentage of eligible expenses attributed to nonpayroll expenses exceeds 25% of the loan, if employee headcount decreases, or compensation decreases by more than 25% for each employee making less than $100,000 per year, unless the reduced headcount or compensation levels are restored.

 

On April 29, 2020, we received disbursement of an approved PPP loan in the amount of $25,200. The Company received notice from the SBA that the PPP Loan principal and interest thereon was fully forgiven on April 20, 2021.

 

7. Commitments and Contingencies

 

Leases – The Company assumed Halcyon’s lease of office space in Fort Worth, Texas for managerial offices. This lease requires monthly payments of $2,000 and is month-to-month. Lease expense for this facility totaled $6,000 and $16,000 in the three and nine months ended September 30, 2021, respectively.

 

The Company leases its operating facility in Kentucky from Oz Capital, LLC, a related party, under a lease expiring May 31, 2024. The lease provides for monthly payments of $10,249. Oz Capital, LLC is responsible for all taxes and maintenance under the lease. Lease expense for this facility totaled $30,747 and $88,604 in the three and nine months ended September 30, 2021, respectively. A right-of-use asset and lease liability is recorded for this lease.

 

10

 

The right-of-use asset represent the right to use the underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. A right-of-use asset and lease liabilities were recognized at the commencement date based on the present value of lease payments over the lease term. As the lease does not provide an implicit rate, the Company used its estimated incremental borrowing rate of 10% in determining the present value of the lease payments.

 

Pending Insurance Claim – In 2019, drying equipment that Halcyon purchased from a third party was being placed into service when a fire loss subsequently occurred and destroyed the equipment causing significant business interruption. The cost of this drying equipment totaled $1.1 million. In 2020, Halcyon received, as partial payment, insurance proceeds of $595,000 from its insurance carrier. The Company has made a formal claim against the insurance carrier and is pursuing all available options to recover the unpaid amounts.

 

Litigation – From time to time, we are subject to various litigation and other claims in the normal course of business. Below is a discussion of specific matters. We cannot predict the ultimate outcome of these matters.

 

JDONE, LLC v. Grand Traverse Holdings, LLC and John Gallegos, Denver District Court Case No. 2019CV33723

 

JDONE, LLC (“JDONE”) is a wholly owned subsidiary of the Company and landlord of a commercial warehouse building that was leased to Grand Traverse Holdings, LLC on December 31, 2018 for a term of 61 months, with a personal guaranty from Defendant, John Gallegos. On April 12, 2019, Grand Traverse presented JDONE with an alleged forged, signed copy of the draft early termination amendment that JDONE had previously rejected. JDONE has suffered damages due to Defendant’s alleged misconduct of approximately $823,504 plus interest and attorney’s fees exceeding $300,000. A court ordered mediation was held in May 2020 without success. All material defendant motions have been denied by the court. The case is set for jury trial in January 2022. We believe that Grand Traverse Holdings, LLC and John Gallegos are jointly liable for the asserted damages which exceed $1 million and continue to vigorously pursue our claims.

 

KBSIII Tower at Lake Carolyn, LLC and Prime US-Tower at Lake Carolyn, LLC (collectively – “KBSIII”) vs. Energy Hunter Resources, Inc.

 

Plaintiff/Counterdefendant KBSIII was seeking lost rent on office space for periods after EHR vacated office premises located in Las Colinas, Texas. EHR filed a counter suit alleging specific damages due to uninhabitable premises of the office space due to the intolerable conduct of other tenants located on the same floor. On December 23, 2020, the trial court entered a summary judgment against EHR for $230,712. The judgment provides for post-judgment interest at a rate of 5% per annum until paid and further provides for additional amounts owed should EHR pursue unsuccessful appeals to higher courts. At September 30, 2021, the Company had accrued $252,583 for this judgment, which is exclusively an EHR obligation.

  

8. Equity

 

Change of Corporate Domicile – On August 21, 2021, the Company changed its domicile from the State of Colorado to the State of Delaware. The change of domicile had no effect on the number of outstanding securities of the Company. The Company is authorized for 200 million shares of capital stock, par value $0.00001 per share and 20 million shares of preferred stock, par value $0.00001 per share.

 

Series A Preferred Stock – On September 8, 2021, holders of the Company’s Series A Preferred Stock elected to convert such shares into shares of the Company’s common stock. As a result, 6,328,948 shares of Series A Preferred Stock were converted into 75,947,376 shares of common stock, with each share of Series A Preferred Stock converting into 12 shares of restricted common stock pursuant to the applicable Certificate of Designations. The Series A Preferred Stock was originally issued in connection with the Company’s merger transaction completed in December 2019.

 

Series B Preferred Stock Units – On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share.

 

The sale of the preferred stock units for $10,000 each resulted in aggregate gross proceeds of approximately $1.35 million, before deducting estimated offering expenses payable by the Company. Substantially all of the proceeds raised in the offering were used to fund the acquisition of assets of Halcyon, expenses related thereto and for general corporate purposes.

 

11

 

Each share of Series B Preferred Stock is initially convertible into 25,000 shares of common stock, subject to adjustment. Holders of Series B Preferred Stock are entitled to receive dividends of 6.00% per annum based on the stated value equal to $10,000 per share. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the related certificate of designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of its common stock, (e) enter into any agreement with respect to any of the foregoing, or (f) pay cash dividends or distributions on any equity securities of the Company other than pursuant to the terms of the outstanding Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.

 

Beginning the later of June 30, 2021 or the effectiveness of any registration statement registering the underlying common shares, all or any portion of the Series B Preferred Stock may be converted, at their holder’s option, into 25,000 shares of common stock, as adjusted for any stock dividends, splits, combinations or similar events.

 

At any time after the occurrence of a “Qualifying Event,” the Company, upon 5-day written notice, shall have the right to cause each share of Series B Preferred Stock (and all accrued in-kind dividends with respect thereto) to be converted into common stock. For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00. In each instance, a conversion may not be made unless the Company has filed an amendment to its Articles of Incorporation effecting an increase in its authorized common stock so that the Company has a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares.

 

The Series B Preferred Stock may be redeemed by the Company for its stated value, plus accrued and unpaid dividends, at any time. Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021.

 

In May, June and October of 2021, the three holders of the Series B Preferred Stock, including the Company’s chief executive officer, entered into transactions in which they accepted the mandatory redemption payment required pursuant to the Series B Preferred Stock certificate of designation in a number of Series B Units to effectively waive the redemption requirement. All other terms of the Series B Units remain unchanged and the holders’ ownership interest in the Series B Preferred Units remains the same as it was before such transactions.

 

Common Stock – At September 30, 2021, the Company had 111,070,329 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:

 

  February 2020 Issuance of Common Stock Units – In February 2020, the Company issued 250,000 common units for $100,000. Each unit consisted of one share of common stock and a warrant for purchase of one common share for $0.40 per share. The warrant expires March 1, 2022 and contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price. Proceeds of this issuance were used for general corporate purposes.

 

The common stock issued in the exchange was valued using the trading price of the common stock on February 20, 2020. The warrants were valued at $45,848 using a binomial lattice valuation model using inputs as of the exchange date. Our expected volatility assumption was based on the historical volatility of the Company’s common stock (252%). The expected life assumption was based on the expiration date of the warrant (two years). The risk-free interest rate for the expected term of the warrant was based on the U.S. Treasury yield curve in effect at the time of measurement (1.39%). The warrants are classified within equity in the consolidated balance sheets. Under GAAP, the anti-dilution provisions will be accounted for if and when these provisions are triggered.

 

12

 

  Acquisition of Certain Assets of Halcyon – the Company issued 6,250,000 shares of common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year) in the acquisition. Refer to Note 3.

 

  2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.  

 

  Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants.

 

  Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt. Refer to Note 5.

 

  Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.

 

  Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021. Refer to Note 5.

 

  Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.

 

  Stock-based Compensation – The Company issued 500,000 restricted common shares as incentive compensation to two executives who joined the Company in the first quarter of 2021.

 

Common Stock Warrants Outstanding – Following is a summary of warrants outstanding:

 

   # of Warrants   Exercise Price
(each)
   Expiration Date  Method of Exercise
               

Issued upon exchange of EHR Series C Preferred Stock (1)

   1,065,340   $0.352   November 27, 2021  Cash
Issued upon exchange of EHR Series C Preferred Stock (1)   7,244,316   $0.352   November 27, 2021  Cashless
Issued in February 2020 with common stock units (2)   250,000   $0.400   March 1, 2022  Cash
Issued in December 2020 with Series B preferred units (1)   5,500,000   $0.352   December 30, 2022  Cash
Issued in December 2020 with subordinated note to investor (1)   500,000   $0.352   December 30, 2022  Cash
Issued in Q1 2021 with common stock units (1)   1,600,000   $0.500   Jan-Feb, 2023  Cash
Total warrants outstanding at September 30, 2021   16,159,656            

 

(1) May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.

 

(2) Contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price.

 

Following is a summary of outstanding stock warrants activity for the periods presented:

 

Warrants as of January 1, 2020   14,488,632 
Issued   250,000 
Warrants as of September 30, 2020   14,738,632 
      
Warrants as of January 1, 2021   22,988,632 
Issued   1,600,000 
Exercised   (8,428,976)
Warrants as of September 30, 2021   16,159,656 

 

13

 

9. Stock-Based Compensation

 

We award restricted stock or stock options as incentive compensation to employees. Generally, these awards include vesting periods of up to three years from the date of grant.

 

The 2021 Omnibus Incentive Plan (“2021 Plan”) was adopted by our Board on July 1, 2021. The 2021 Plan provides for the initial reservation of 15 million shares of common stock for issuance, and provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 15 million. The number of shares of common stock available for issuance under the 2021 Plan constituted approximately 13.1% of the Company’s fully diluted common shares outstanding as of the date of Board approval, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis. On the one-year anniversary date of the 2021 Plan, the number of shares of common stock reserved for issuance thereunder shall automatically increase to 20% of the fully diluted common shares outstanding, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis.

 

In the first quarter of 2021, the Company issued 500,000 restricted shares valued at $158,500 as incentive compensation to two executives who joined the Company. Compensation expense related to these awards totaled $38,750 and $119,750 for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, there was $38,750 of total unrecognized compensation cost related to unvested awards to be recognized over a weighted-average period of three months.

 

On April 6, 2021, the Company announced that Chad Burkhardt has joined the Company as its Vice President and General Counsel, effective April 1, 2021. In addition to his annual salary, the Company agreed to make a future grant to Mr. Burkhardt of $750,000 worth of options for the purchase of our common stock at an exercise price equal to the fair market value of the Company’s common stock on the date of grant. Such options will vest annually in equal installments over a three-year period from his date of hire.

 

10. Income Taxes

 

Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. An income tax benefit for the three and nine months ended September 30, 2021 or 2020 was not recognized because tax losses incurred were fully offset by a valuation allowance against deferred tax assets. There were no uncertain tax positions as of September 30, 2021.

 

11. Supplemental Cash Flow Information

 

   For the nine months ended
September 30,
 
   2021   2020 
         
Cash paid for interest  $127,812   $
-
 
Cash paid for taxes   
            -
    
                 -
 
           
Noncash investing and financing activities:          
Acquisition of certain assets of Halcyon Thruput, LLC          
- issuance of common shares   2,500,000    
-
 
- issuance of subordinated note   850,000    
-
 
- assumption of Halcyon bank note   995,614    
-
 
Series B preferred stock dividend payable   39,137    
-
 
Issuance of common stock units previously subscribed   50,000    
-
 
Issuances of common shares for exchange or conversion of debt   2,160,269    
-
 

 

14

 

12. Earnings (Loss) per Share

 

The following is the computation of earnings (loss) per basic and diluted share:

 

   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2021   2020   2021   2020 
Amounts attributable to Generation Hemp:                
Numerator                
Loss from continuing operations attributable to common stockholders  $(1,376,030)  $(171,367)  $(4,356,315)  $(1,146,592)
Loss from discontinued operations   (1,528)   (7,489)   (10,639)   (5,115)
Less: preferred stock dividends   (16,125)   
-
    (56,625)   
-
 
Net loss attributable to common stockholders  $(1,393,683)  $(178,856)  $(4,423,579)  $(1,151,707)
                     
Denominator                    
Weighted average shares used to compute basic EPS   54,109,797    17,380,317    38,693,679    17,500,308 
Dilutive effect of convertible note   
-
    
-
    
-
    
-
 
Dilutive effect of preferred stock   59,913,657    75,947,376    72,641,084    75,947,376 
Dilutive effect of common stock warrants   9,042,419    
-
    11,126,327    
-
 
Weighted average shares used to compute diluted EPS   123,065,873    93,327,693    122,461,090    93,447,684 
                     
Earnings (loss) per share:                
Loss from continuing operations                
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)
(Loss) income from discontinued operations                    
Basic  $
-
   $
-
   $
-
   $
-
 
Diluted  $
-
   $
-
   $
-
   $
-
 
Earnings (loss) per share                    
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)

 

The computation of diluted earnings per common share excludes the assumed conversion of the Series B Preferred Stock and outstanding convertible notes and exercise of common stock warrants in periods when we report a loss. The dilutive effect of the assumed exercise of outstanding warrants was calculated using the treasury stock method.

 

13. Subsequent Events

 

In October 2021, the Company issued 416,667 common stock units to an accredited investor for total proceeds of $250,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of one share of common stock for $0.60 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance.

 

As disclosed in Note 5 above, (i) we amended the subordinated note to our CEO in the amount of $490,000 to a new maturity date of January 31, 2022, (ii) we amended the secured promissory note to Coventry Asset Management, LTD. to a new maturity date of January 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed and granted the holder a limited option to convert part of the principal to common stock and (iii) we amended the subordinated promissory note with an investor to a new maturity date of March 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed.

 

In October 2021, our CEO made advances totaling $15,000 to the Company. The existing convertible promissory note was amended and restated to a new balance of $635,000. The interest rate of 10% per annum and maturity date of January 1, 2022 were unchanged.

 

As disclosed in Note 6 above, the mortgage payable was amended to a new maturity date of January 15, 2022.

 

*      *      *      *      *

 

15

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the “Management’s Discussion and Analysis of Financial Condition and Results of Operations” contained in our Annual Report on Form 10-K (“Annual Report”) for the year ended December 31, 2020 filed with the Securities and Exchange Commission (“SEC”), as well as the financial statements and related notes appearing therein and elsewhere in this Quarterly Report. The following discussion contains forward-looking statements that reflect our future plans, estimates, beliefs and expected performance. The forward-looking statements are dependent upon events, risks and uncertainties that may be outside our control. We caution you that our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences are discussed elsewhere in this Quarterly Report, particularly in the “Cautionary Note Regarding Forward-Looking Statements” and in our Annual Report under the heading “Item 1A. Risk Factors,” all of which are difficult to predict. In light of these risks, uncertainties and assumptions, the forward-looking events discussed may not occur. We do not undertake any obligation to publicly update any forward-looking statements except as otherwise required by applicable law.

  

Overview

 

We are a holding company active within the “hemp” space. We were incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated on July 28, 2008 in the State of Colorado. On November 27, 2019, we purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger (the “Transaction”). Upon closing of the Transaction, we changed our name to Generation Hemp, Inc.

 

There is limited historical financial information about our Company upon which to base an evaluation of our future performance. We cannot guarantee that we will be successful in the hemp business. We are subject to the risks associated with the regulatory environment in the industry in which we operate. In addition, we are subject to risks inherent in a small company, including limited capital resources, delays and cost overruns due to price and cost increases. There is no assurance that future financing will be available to our Company on acceptable terms. Additional equity financing could result in dilution to existing shareholders.

 

On January 11, 2021, we completed the acquisition of certain assets of Halcyon Thruput, LLC (“Halcyon”). With this acquisition, we commenced providing post-harvest and midstream services to growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot facility located in Hopkinsville, Kentucky. Additionally, the Company offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. In August 2021, the Company launched its animal bedding consumer goods product line made from the hemp hurd byproduct that is produced from its hemp processing operations.

 

In 2020, Halcyon had revenues of $3.0 million for the processing of approximately 8.5 million pounds of hemp biomass. With additional contracts executed in 2021, we expect to process at least 10 million pounds during the remainder of 2021 and the first six months of 2022.

 

We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to a hemp seed company.

 

As of September 30, 2021, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.

 

Liquidity – The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.

 

In the nine months ended September 30, 2021, the Company used $2.7 million of cash for its operating activities. At September 30, 2021, the Company’s current liabilities, including financing obligations due within one year, totaled $4.7 million as compared with its current assets of $276 thousand. Cash payments under several financing obligations were initially due in September and October of 2021. These were subsequently amended to extend these payments by one to six months.

 

The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

16

 

Impact of COVID-19 Pandemic on Our Business – Our business, results of operations and financial condition have been adversely affected by the COVID-19 pandemic, beginning in mid-March 2020. The COVID-19 pandemic and measures taken to contain it have subjected our business, results of operations, financial condition, stock price and liquidity to a number of material risks and uncertainties, all of which may continue or may worsen.

 

Results of Operations

 

Three Months Ended September 30, 2021 Compared to Three Months Ended September 30, 2020

 

The net loss for the three months ended September 30, 2021 was $1.4 million as compared with a net loss of $179 thousand for the same period of 2020. We completed the acquisition of Halcyon in January 2021. The first part of each calendar year is typically a slower period for midstream operations within the hemp industry until the annual harvest begins in late-summer. We had $487 thousand of revenue for post-harvest and midstream services in the three months ended September 30, 2021. Cost of revenue was $280 thousand during this same period resulting in a gross margin of 43%. The net loss for the three months ended September 30, 2021 includes $316 thousand for depreciation and amortization as compared with $16 thousand in the 2020 period due to the Halcyon acquisition. General and administrative expenses were higher by approximately $1.0 million because of corporate staffing additions made this year and higher legal and professional fees incurred.

 

The Company reports its oil & gas activities as discontinued operations. Loss from discontinued operations was $2 thousand for the three months ended September 30, 2021 as compared with a loss of $8 thousand in the 2020 period. Results of operations for the Company’s remaining oil & gas activities have been significantly reduced due to downturns in oil & gas pricing and production and disposals of property interests.

 

Revenue. Revenue from continuing operations for the third quarter of 2021 totaled $502 thousand as compared with $22 thousand for the same period of 2020. Post-harvest and midstream services commenced regular operations for new and renewed customer contracts executed in the third quarter of 2021. Rental revenue totaled $15 thousand in the 2021 period as compared with $22 thousand in the 2020 period. The lease of the Company’s Denver warehouse was recently extended with a new tenant to August 1, 2023 for $7.5 thousand per month.

 

Cost of Revenue. Cost of revenue for the third quarter of 2021 was $280 thousand and consisted of direct labor, supplies and overhead for the Company’s post-harvest and midstream services operations. The gross margin on revenue was 43% for the third quarter of 2021.

 

Merger and Acquisition Costs. We incurred $7 thousand of costs for evaluating acquisition opportunities during the three months ended September 30, 2020. The amount of future expenses of this type that we incur will depend upon our future acquisition activities.

 

General and Administrative Expense. General and administrative expenses totaled $1.1 million for the three months ended September 30, 2021 as compared with $109 thousand in 2020 period. The increase in general and administrative expense in the 2021 period is principally due to corporate staffing additions made this year and higher legal and professional fees incurred. In the third quarter of 2021, the Company paid $189 thousand for legal fees and $33 thousand of interest in settlement of arbitration with a law firm. General and administrative expense for the third quarter of 2021 also includes $39 thousand of non-cash stock-based compensation expense.

 

Depreciation and Amortization. Depreciation and amortization expense totaled $316 thousand in the three months ended September 30, 2021 as compared with $16 thousand for the same period of 2020. The increase in the 2021 period is due to completion of the Halcyon acquisition including $201 thousand for amortization of acquired intangible assets. The allocation of the purchase price to the assets acquired in the Halcyon acquisition is preliminary. Final adjustments, including increases and decreases to depreciation and amortization resulting from the allocation of the purchase price to amortizable tangible and intangible assets, may be material.

 

Other Income/Expense. Total other expense was $156 thousand for the three months ended September 30, 2021 as compared with $67 thousand for the comparable 2020 period. The largest item of total other expense is interest expense which has increased due to having higher levels of indebtedness. Interest expense for the 2021 period includes $34 thousand of amortization of debt discounts and $33 thousand of interest for the arbitration settlement discussed above.

 

Loss from Discontinued Operations. In the three months ended September 30, 2020, we recognized a loss from discontinued operations of $8 thousand as compared with a loss of $2 thousand in the three months ended September 30, 2021. The major classes of line items constituting the loss on discontinued operations are presented in Item I, “Financial Statements – Note 4 – Discontinued Operations.” Until we fully dispose of our remaining oil & gas property interests, we expect lower future revenues and costs as production activities have declined substantially. We do not anticipate making future investment of growth capital into these properties.

 

17

 

Nine Months Ended September 30, 2021 Compared to Nine Months Ended September 30, 2020

 

The net loss for the nine months ended September 30, 2021 was $4.4 million as compared with a net loss of $1.2 million for the same period of 2020. The net loss for the nine months ended September 30, 2021 includes $1.0 million for depreciation and amortization as compared with $55 thousand in the 2020 period principally due to the Halcyon acquisition. Our remaining operating expenses were higher by approximately $2.3 million because of the Halcyon acquisition, other corporate staffing additions made this year, the payment of bonus compensation in the first quarter of 2021 and the arbitration settlement discussed above.

 

The Company reports its oil & gas activities as discontinued operations. Loss from discontinued operations was $11 thousand for the nine months ended September 30, 2021 as compared with a loss of $5 thousand in the 2020 period.

 

Revenue. Revenue from continuing operations for the first nine months of 2021 includes post-harvest and midstream services revenue of $535 thousand. Post-harvest and midstream services commenced regular operations for new and renewed customer contracts executed in the third quarter of 2021. These revenues are typically limited due during the first half of each year until harvest. Rental revenue was $60 thousand in the 2021 as compared with $68 thousand in the 2020 period. The lease of the Company’s Denver warehouse was recently extended with a new tenant to August 1, 2023 for $7.5 thousand per month.

 

Cost of Revenue. Cost of revenue for the first nine months of 2021 was $550 thousand and consisted of direct labor, supplies and overhead for the Company’s post-harvest and midstream services operations. We operated with limited staffing until harvest.

 

Merger and Acquisition Costs. We incurred $16 thousand and $100 thousand of costs for evaluating acquisition opportunities during the nine months ended September 30, 2021 and 2020, respectively. These costs principally related to the Halcyon acquisition. The amount of future expenses of this type that we incur will depend upon our future acquisition activities.

 

General and Administrative Expense. General and administrative expenses totaled $2.8 million for the nine months ended September 30, 2021 as compared with $884 thousand in 2020 period. The increase in general and administrative expense in the 2021 period is principally due the Halcyon acquisition, other corporate staffing additions made this year and the payment of bonus compensation in the first quarter of 2021. Bonus compensation totaling $600 thousand was paid to our CEO for successful completion of the Halcyon acquisition. In the third quarter of 2021, the Company paid $189 thousand for legal fees and $33 thousand of interest in settlement of the arbitration with Jones & Keller, P.C. General and administrative expense for the 2021 period also includes $120 thousand of non-cash stock-based compensation expense.

 

Depreciation and Amortization. Depreciation and amortization expense totaled $1.0 million in the nine months ended September 30, 2021 as compared with $55 thousand for the same period of 2020. The increase in the 2021 period is due to completion of the Halcyon acquisition including $693 thousand for amortization of acquired intangible assets. The allocation of the purchase price to the assets acquired in the Halcyon acquisition is preliminary. Final adjustments, including increases and decreases to depreciation and amortization resulting from the allocation of the purchase price to amortizable tangible and intangible assets, may be material.

 

Other Income/Expense. Total other expense was $615 thousand for the nine months ended September 30, 2021 as compared with $220 thousand for the comparable 2020 period. The largest item of total other expense is interest expense which has increased due to having higher levels of indebtedness. Interest expense for the 2021 period includes $380 thousand of amortization of debt discounts and $33 thousand of interest for the arbitration settlement discussed above.

 

In the first quarter of 2021, we sold our investment in the common stock we held for total proceeds of $35 thousand. This publicly traded security was marked to market each fiscal quarter until its eventual sale.

 

We received notice from the SBA that the Company’s PPP Loan principal and interest thereon was fully forgiven on April 20, 2021. As such, we recognized forgiveness income of $25,424 in the second quarter of 2021.

 

18

 

Loss from Discontinued Operations. In the nine months ended September 30, 2020, we recognized a loss from discontinued operations of $5 thousand as compared with a loss of $11 thousand in the nine months ended September 30, 2021. The major classes of line items constituting the loss on discontinued operations is presented in Item I, “Financial Statements – Note 4 – Discontinued Operations.” Until we fully dispose of our remaining oil & gas property interests, we expect lower future revenues and costs as production activities have declined substantially. We do not anticipate making future investment of growth capital into these properties.

 

Liquidity and Capital Resources

 

Our primary source of cash from continuing operations includes post-harvest and midstream services and rental revenue. Our primary uses of cash include our operating costs, general and administrative expenses and merger and acquisition expenses.

 

Cash flow information from continuing operations for the first nine months of 2021 was as follows:

 

  Cash used in operating activities was $2.7 million principally due to the net loss adjusted for non-cash items.

 

  Net cash used in investing activities totaled $1.6 million including an expenditure of $1.5 million for the cash portion of the total consideration for the Halcyon acquisition and proceeds from the sale of our investment in common stock of $35 thousand. We made capital expenditures totaling $78 thousand for new processing equipment to expand our business lines to include post-processing of biomass.

 

  Net cash from financing activities totaled $1.6 million. This amount included $3.3 million of cash inflows from the issuance of common stock units and proceeds from warrant exercises. We used $2.1 million of cash for repayment of outstanding indebtedness and $154 thousand for payment of scheduled redemptions and dividends on the Series B preferred stock. In the third quarter of 2021, our CEO advanced $620 thousand under a convertible promissory note.

 

We had no cash flows from discontinued operations in the first nine months of 2021.

 

Funding Requirements

 

We expect to continue to incur significant expenses and operating losses for the foreseeable future. We anticipate that our expenses may increase substantially as we grow our hemp business.

 

We expect that we will require additional capital to fund operations, including hiring additional employees, completing acquisitions and funding capital expenditures during the next twelve-month period.

 

Because of the numerous risks and uncertainties associated with the development and commercialization of our business, we are unable to estimate the amounts of increased capital outlays and operating expenses. Our future capital requirements will depend on many factors, including:

 

  our success in identifying and making acquisitions of profitable operations;

 

  our ability to negotiate operating contracts with growers and others within the hemp industry on favorable terms, if at all;

 

  deriving revenue from our assets and operations; and

 

  the cost of such operations and costs of being a public company.

 

Until such time, if ever, as we can generate substantial revenues, we expect to finance our cash needs through a combination of equity offerings and debt financings. We do not have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our shareholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of common shareholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our growth plans and future commercialization efforts.

 

19

 

Indebtedness

 

The Company’s indebtedness at September 30, 2021 is presented in Item I, “Financial Statements – Note 5 – Notes Payable – Related Parties” and in Item I, “Financial Statements—Note 6—Other Indebtedness.”

 

Off-Balance Sheet Arrangements

 

As of September 30, 2021, we had no material off-balance sheet arrangements.

 

Item 3. Quantitative and Qualitative Disclosures about Market Risk

 

Quantitative and qualitative disclosures about market risk are included in Item 7A, “Quantitative and Qualitative Disclosures about Market Risk,” of our Annual Report.

 

Item 4. Controls and Procedures

 

Disclosure Controls and Procedures

 

As required by Rule 13a-15(b) of the Exchange Act, we have evaluated, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this quarterly report. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed by us in reports that we file under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure, and is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. Based upon that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this quarterly report, at the reasonable assurance level.

 

Changes in Internal Control over Financial Reporting

 

We regularly review our system of internal control over financial reporting and make changes to our processes and systems to improve controls and increase efficiency, while ensuring that we maintain an effective internal control environment. Changes may include such activities as implementing new, more efficient systems, consolidating activities and migrating processes.

 

There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2021 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

20

 

PART II. OTHER INFORMATION

 

Item 1. Legal Proceedings

 

Due to the nature of our business, we may become, from time to time, involved in routine litigation or subject to disputes or claims related to our business activities. While the outcome of these proceedings cannot be predicted with certainty, in the opinion of our management, there are no pending litigation, disputes or claims against us which, if decided adversely, individually or in the aggregate, will have a material adverse effect on our financial condition, cash flows or results of operations. For a description of our legal proceedings, see Item I, “Financial Statements – Note 7 – Commitments and Contingencies” in the Condensed Consolidated Financial Statements included in Part I of this Quarterly Report.

 

Item 1A. Risk Factors

 

In addition to the other information set forth in this Quarterly Report, you should carefully consider the risk factors and other cautionary statements described under the heading “Item 1A. Risk Factors” included in our Annual Report and the risk factors and other cautionary statements contained in our other SEC filings, which could materially affect our businesses, financial condition or future results.

 

Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in our Annual Report.

 

Item 4. Mine Safety Disclosures

 

No response required.

 

Item 5. Other Information

 

No response required.

 

21

 

Item 6. Exhibits

 

3.1   Certificate of Incorporation (filed as Exhibit 3.1 to the Company’s Registration Statement on Form S-1 filed on August 9, 2011 (file number 333-176154))
     
3.2   Bylaws (filed as Exhibit 3.2 to the Company’s Registration Statement on Form S-1 filed on August 9, 2011 (file number 333-176154))
     
3.3   Certificate of Designation of Rights, Preferences and Limitations of the Series A Convertible Voting Preferred Stock (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on December 4, 2019 (file number 000-176154)) 
     
3.4   Certificate of Designation of Rights, Preferences and Limitations of the Series B Redeemable Convertible Preferred Stock (filed as Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on January 6, 2021 (file number 000-55019))
     
4.1   2020 Form of Generation Hemp Warrant (filed as Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed on December 15, 2020 (file number 333-176154))
     
4.1   Form of Warrant (filed as Exhibit 4.1 to the Company’s Current Report on Form 8-K filed on January 6, 2021 (file number 000-55019))
     
10.1   Biomass Tolling Agreement, dated July 11, 2021, between GENH Halcyon Acquisition, LLC and GenCanna Acquisition Corp. (filed as Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 14, 2021 (file number 000-55019).)
     
10.2   Unsecured Promissory Note, dated August 11, 2021, with Gary C. Evans as Holder and Generation Hemp, Inc. as Borrower. (filed as Exhibit 10.2 to the Company’s Quarterly Report for the period ended June 30, 2021 filed on August 13, 2021)
     
10.3   Biomass Services Agreement, dated August 11, 2021, between GENH Halcyon Acquisition, LLC and KushCo Holdings, Inc. (filed as Exhibit 10.3 to the Company’s Quarterly Report for the period ended June 30, 2021 filed on August 13, 2021)
     
10.4   Amended and Restated Promissory Note, dated September 9, 2021, between Generation Hemp, Inc. and Gary C. Evans, filed as Exhibit 10.1 to the Company’s Current Report filed on Form 8-K on September 10, 2021.
     
10.5   Amended and Restated Promissory Note, dated September 28, 2021, between Generation Hemp, Inc. and Gary C. Evans, filed as Exhibit 10.1 to the Company’s Current Report filed on Form 8-K on September 29, 2021.
     
10.6   Amended and Restated Promissory Note, dated October 22, 2021, between Generation Hemp, Inc. and Gary C. Evans, filed as Exhibit 10.1 to the Company’s Current Report filed on Form 8-K on October 28, 2021.
     
10.7   Letter Agreement, dated November 11, 2021, with Coventry Asset Management, Ltd amending that certain Secured Promissory Note Issued by Halcyon Thruput, LLC, dated December 30, 2020.
     
10.8   Amended and Restated Subordinated Promissory Note, dated November 11, 2021, between Generation Hemp, Inc. and Gary C. Evans.
     
10.9   Amended and Restated Promissory Note, dated November 1, 2021 between Generation Hemp, Inc. and Gary C. Evans.
     
31.1   Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1**   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
     
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Schema Document
101.CAL   Inline XBRL Calculation Linkbase Document
101.DEF   Inline XBRL Definition Linkbase Document
101.LAB   Inline XBRL Label Linkbase Document
101.PRE   Inline XBRL Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

 

  * Exhibit filed herewith.

 

  ** Furnished herewith. Pursuant to SEC Release No. 33-8212, this certification will be treated as “accompanying” this Quarterly Report on Form 10-Q and not “filed” as part of such report for purposes of Section 18 of the Exchange Act or otherwise subject to the liability under Section 18 of the Exchange Act, and this certification will not be deemed to be incorporated by reference into any filing under the Securities Act, except to the extent that the registrant specifically incorporates it by reference.

 

 

22

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  GENERATION HEMP, INC.
     
November 15, 2021 By: Gary C. Evans
    Gary C. Evans
    Chairman and Chief Executive Officer

 

 

23

 

 

NYSE May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock. Contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price. false --12-31 Q3 0001527102 0001527102 2021-01-01 2021-09-30 0001527102 2021-11-15 0001527102 2021-09-30 0001527102 2020-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-12-31 0001527102 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001527102 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001527102 2021-07-01 2021-09-30 0001527102 2020-07-01 2020-09-30 0001527102 2020-01-01 2020-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2019-12-31 0001527102 us-gaap:PreferredStockMember 2019-12-31 0001527102 us-gaap:CommonStockMember 2019-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001527102 us-gaap:RetainedEarningsMember 2019-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2019-12-31 0001527102 2019-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-01-01 2020-03-31 0001527102 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001527102 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001527102 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001527102 2020-01-01 2020-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-03-31 0001527102 us-gaap:PreferredStockMember 2020-03-31 0001527102 us-gaap:CommonStockMember 2020-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001527102 us-gaap:RetainedEarningsMember 2020-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-03-31 0001527102 2020-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-04-01 2020-06-30 0001527102 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001527102 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001527102 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001527102 2020-04-01 2020-06-30 0001527102 us-gaap:PreferredStockMember 2020-06-30 0001527102 us-gaap:CommonStockMember 2020-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001527102 us-gaap:RetainedEarningsMember 2020-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-06-30 0001527102 2020-06-30 0001527102 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-09-30 0001527102 us-gaap:PreferredStockMember 2020-09-30 0001527102 us-gaap:CommonStockMember 2020-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001527102 us-gaap:RetainedEarningsMember 2020-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-09-30 0001527102 2020-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-12-31 0001527102 us-gaap:PreferredStockMember 2020-12-31 0001527102 us-gaap:CommonStockMember 2020-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001527102 us-gaap:RetainedEarningsMember 2020-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001527102 2021-01-01 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-03-31 0001527102 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001527102 2021-04-01 2021-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-06-30 0001527102 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-09-30 0001527102 2019-11-02 2019-11-27 0001527102 2021-01-05 2021-01-11 0001527102 genh:CustomerOneMember 2021-07-01 2021-09-30 0001527102 genh:CustomerOneMember 2021-01-01 2021-09-30 0001527102 genh:HalcyonMember 2021-01-11 2021-01-11 0001527102 genh:HalcyonMember 2021-01-11 0001527102 2021-01-11 0001527102 2021-03-03 0001527102 genh:AcquisitionsMember 2021-09-30 0001527102 2021-02-25 2021-03-09 0001527102 genh:ConventryAssetManagementLTDMember 2020-12-30 0001527102 genh:ConventryAssetManagementLTDMember 2021-06-01 2021-06-30 0001527102 us-gaap:SubsequentEventMember 2021-10-01 0001527102 us-gaap:SubsequentEventMember 2021-10-01 2021-10-31 0001527102 us-gaap:SubsequentEventMember 2021-11-01 2021-11-30 0001527102 genh:ConventryAssetManagementLTDMember 2021-09-30 0001527102 genh:AccreditedInvestorMember 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteMember 2020-12-02 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteMember 2021-04-30 0001527102 genh:SubordinatedPromissoryNoteMember 2021-01-01 2021-09-30 0001527102 us-gaap:SubsequentEventMember 2022-12-30 0001527102 genh:SeniorSecuredPromissoryNoteMember 2021-09-30 0001527102 genh:SeniorSecuredPromissoryNoteMember 2020-12-31 0001527102 genh:ConvertiblePromissoryNoteMember 2021-09-30 0001527102 genh:ConvertiblePromissoryNoteMember 2020-12-31 0001527102 genh:SubordinatedPromissoryNoteMember 2021-09-30 0001527102 genh:SubordinatedPromissoryNoteMember 2020-12-31 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2021-09-30 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2020-12-31 0001527102 genh:SubordinatedPromissoryNoteToInvestorMember 2021-09-30 0001527102 genh:SubordinatedPromissoryNoteToInvestorMember 2020-12-31 0001527102 2021-10-31 2021-10-31 0001527102 2021-11-15 2021-11-15 0001527102 srt:ScenarioForecastMember 2023-08-01 2023-08-01 0001527102 srt:ScenarioForecastMember 2021-01-01 2021-12-21 0001527102 srt:ScenarioForecastMember 2022-01-01 2022-12-31 0001527102 srt:ScenarioForecastMember 2023-01-01 2023-12-31 0001527102 2020-04-29 0001527102 2020-01-01 2020-12-31 0001527102 genh:OzCapitalLLCMember 2021-01-01 2021-09-30 0001527102 genh:OzCapitalLLCMember 2021-07-01 2021-09-30 0001527102 2019-01-01 2019-12-31 0001527102 genh:GrandTraverseHoldingsLLCMember 2018-01-01 2018-12-31 0001527102 genh:GrandTraverseHoldingsLLCMember 2019-04-01 2019-04-12 0001527102 2019-04-01 2019-04-12 0001527102 genh:JohnGallegosMember genh:GrandTraverseHoldingsLLCMember 2019-04-01 2019-04-12 0001527102 2020-12-01 2020-12-23 0001527102 genh:DecemberTwoThousedTwoZeroIssuanceOfSeriesBPreferredStockUnitsMember 2021-09-30 0001527102 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001527102 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHRMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHRMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHROneMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHROneMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0001527102 genh:FebruaryTwoThousandTwentyMember genh:CommonStockUnitsMember 2021-09-30 0001527102 genh:FebruaryTwoThousandTwentyMember genh:CommonStockUnitsMember 2021-01-01 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2021-01-01 2021-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember us-gaap:CommonStockMember 2021-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001527102 genh:TwoThousandTwentyOnePlanMember 2021-01-01 2021-09-30 0001527102 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001527102 2021-04-06 0001527102 us-gaap:SubsequentEventMember 2021-10-31 0001527102 2021-10-01 2021-10-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:USD utr:sqft
EX-10.7 2 f10q0921ex10-7_generation.htm LETTER AGREEMENT, DATED NOVEMBER 11, 2021, WITH COVENTRY ASSET MANAGEMENT, LTD AMENDING THAT CERTAIN SECURED PROMISSORY NOTE ISSUED BY HALCYON THRUPUT, LLC, DATED DECEMBER 30, 2020

Exhibit 10.7

 

Generation Hemp, Inc.

8533 Midway Road

Dallas, Texas 75209

 

Coventry Asset Management, Ltd.

2048 Coventry Ct.

Keller, Texas 76262

 

Re: In reference to that certain Secured Promissory Note Issued by Halcyon Thruput, LLC, dated December 30, 2020 (the “Note”).

 

Coventry Assert Management, Ltd.:

 

To Coventry Asset Management, Ltd. (“Coventry”), this letter agreement (the “Agreement”) is being issued by Generation Hemp, Inc. (the “Company”) to amend certain terms and conditions of the Note referenced above. All terms used herein shall have the meanings ascribed to such terms in the Note.

 

All principal payments shall be suspended until the Maturity Date of the Note. The Maturity Date of the Note shall be amended to reflect that it is December 31, 2021; provided however that if the Company successfully completes a public equity offering equal to or in excess of $10,000,000 (the “Offering”) prior to such date, then the Company will pay all outstanding principal and interest payments due under the Note within five business days of the closing of such offering. In addition, if the Company does not complete and close a public equity offering prior to December 31, 2021, the Maturity Date shall be extended to January 31, 2022.

 

In consideration of such modifications to the Note, the Company agrees to issue to Coventry 20,000 shares of the Company’s common stock. These shares will be unregistered restricted securities and shall be subject to the restrictions placed on such shares through both Blue-Sky Laws of the applicable states and the rules and regulations of the United States Securities and Exchange Commission and applicable laws and regulatory authorities.

 

Additionally, during a period of fourteen days following the execution of this letter agreement modifying the Note, Coventry has the exclusive option to elect to convert $250,000 of the outstanding principal balance under the Note into shares of the Company’s common stock at an exercise price of $0.60 per share.

 

Except as modified by this Agreement, all other terms of the Note shall remain in full force and effect.

 

Generation Hemp, Inc.

 

/S/ Gary C. Evans  
Gary C. Evans, Chairman and  
Chief Executive Officer  

 

  Agreed and Accepted by Coventry Asset Management, Ltd. on November 11, 2021
     
  /S/ Gen Fukunaga
  By: Gen Fukunaga, Managing Partner

 

EX-10.8 3 f10q0921ex10-8_generation.htm AMENDED AND RESTATED SUBORDINATED PROMISSORY NOTE, DATED NOVEMBER 11, 2021, BETWEEN GENERATION HEMP, INC. AND GARY C. EVANS

Exhibit 10.8

 

AMENDED AND RESTATED SUBORDINATED PROMISSORY NOTE

 

Dated November 11, 2021

 

Principal Amount $525,967.36

 

FOR VALUE, Generation Hemp, Inc., a Delaware corporation (“Borrower”), whose mailing address is P.O. Box 540308, Dallas, Texas 75354, promises and agrees to pay to the order of Gary C. Evans, a Texas resident (“Lender”), whose address is 8533 Midway Road, Dallas, Texas 75209, or at such other location as the holder of this Amended and Restated Subordinated Promissory Note (the “Note”), originally issued on November 20, 2020 (the “Original Note”), may designate by written notice to Borrower, the sum of five hundred twenty-five thousand nine hundred sixty-seven dollars and thirty-six cents ($525,967.36) in the lawful currency of the United States with interest at a rate of 10 % per annum, but in no event higher than the Highest Lawful Rate (as hereinafter defined). This Note amends and restates the Original Note and all amendments, allonges and modifications thereto, in its collective entirety.

 

“Highest Lawful Rate” means the maximum nonusurious rate of interest permitted by applicable federal or Texas law from time to time.

 

Interest on this Note shall be computed for the actual number of days elapsed and on the basis of a year consisting of 365 days, and a month consisting of 30 days, unless the Highest Lawful Rate would thereby be exceeded, in which event, to the extent necessary to avoid exceeding the Highest Lawful Rate, interest shall be computed on the basis of the actual number of days elapsed in the applicable calendar year in which accrued. It is understood that interest will begin to accrue on the date of each principal amount advanced as outlined on Exhibit “A.”

 

The principal amount of this Note and all accrued, unpaid interest thereon is due and payable in full on the 31st day of December, 2021 (the “Payment Date”). This Note may be prepaid in whole or in part at any time prior to the payment date stated in the preceding sentence without penalty as to principal, and any partial payments shall be applied to the principal due on this Note in inverse order of maturity with interest being adjusted accordingly.

 

If one of the following events occurs, Maker shall be in default (“Default”) and this Note shall, at Lender’s option, become immediately due and payable without demand or notice:

 

(i) the failure of Borrower to pay the principal and any accrued interest in full on or before the Payment Date;

 

(ii) the filing of bankruptcy proceedings involving the Borrower as a debtor;

 

(iii) the making of a general assignment for the benefit of the Borrower’s creditors; or the uncured breach by Borrower under any of the security documents executed in conformity with this Note, which remains uncured following any applicable cure period.

 

If any payment date falls on a Saturday, Sunday, or a federal holiday, then payment will be due on the next business day and such extension of time shall in such case be included in the computation or payment of interest hereunder. All past due principal and interest on this Note shall bear interest at the Highest Lawful Rate.

 

 

 

To the extent that waiver of notice is permitted by applicable law, the Borrower and any and all co-makers, endorsers, guarantors, and sureties jointly and severally waive notice (including, but not limited to, notice of intent to accelerate and notice of acceleration), demand, presentment for payment, protest and the filing of suit for the purpose of fixing liability and consent that the time of payment hereof may be extended and re-extended from time to time without notice to them or any of them, and each agree that his, her, or its liability on or with respect to this Note shall not be affected by any release of or change in any security at any time existing or by any failure to perfect or to maintain perfection of any lien on or security interest in any such security.

 

This Note has been executed and delivered in Dallas, Dallas County, Texas, and shall be governed by and construed in accordance with the laws of the State of Texas and the United States of America from time to time in effect without regard to the choice of law provisions thereof, and shall be enforceable in Dallas County, Texas.

 

Regardless of any provision contained in this Note, the Payee shall never be deemed to have contracted for or be entitled to receive, collect or apply as interest on the Note, any amount in excess of the maximum rate of interest permitted to be charged by applicable law and, in the event Payee ever receives, collects or applies as interest any such excess, such amount which would be excessive interest shall be applied to the reduction of the unpaid principal balance of this Note; and, if the principal balance of this Note is paid in full, any remaining excess shall forthwith be paid to Maker. In determining whether or not the interest paid or payable under any specific contingency exceeds the highest lawful rate, Maker and Payee shall, to the maximum extent permitted under applicable law, (i) exclude voluntary prepayments and the effect thereof, and (ii) spread the total amount of interest throughout the entire contemplated term of this Note so that the interest rate is uniform throughout such term.

 

This Promissory Note is intended to be an obligation of Borrower and, by the execution of this Promissory Note, Borrower agrees that Borrower shall not be entitled to sell, transfer, assign, or convey in any manner whatsoever, this Promissory Note and Borrower shall remain obligated under this Promissory Note until the obligation set forth herein is paid in full.

 

If this Note is placed in the hands of any attorney for collection, or if it is collected through any legal proceedings at law or in equity or in bankruptcy, receivership or other court proceedings, Maker joint and severally agrees to pay all costs of collection, including, but not limited court costs and reasonable attorney’s fees.

 

IN WITNESS WHEREOF, the undersigned Borrower has duly executed this Note effective as of the date first written above.

 

  By: /s/ Chad Burkhardt
  Name:   Chad Burkhardt
  Title: Vice President and General Counsel

 

 

 

 

EX-10.9 4 f10q0921ex10-9_generation.htm AMENDED AND RESTATED PROMISSORY NOTE, DATED NOVEMBER 1, 2021 BETWEEN GENERATION HEMP, INC. AND GARY C. EVANS

Exhibit 10.9

 

AMENDED AND RESTATED PROMISSORY NOTE

 

$685,000.00 November 11, 2021

 

For value received, GENERATION HEMP, INC., a Delaware corporation (the “Borrower”), promises to pay to GARY C. EVANS, an individual, or his assigns (the “Holder”), the principal sum of $685,000 (U.S. Dollars), together with all accrued and unpaid interest thereon as set forth below. It is expressly understood that the commitment to provide the first principal sum of $100,000 was agreed to on July 20, 2021 and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to such amount. It is expressly understood that the commitment to provide the second principal sum of $100,000.00 was agreed to on August 3, 2021 and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to such amount. It is expressly understood that the commitment to provide the third principal sum of $100,000.00 was agreed to on August 30, 2021 and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to such amount. It is expressly understood that the commitment to provide the fourth principal sum of $50,000.00 was agreed to on September 9, 2021 and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to such amount. It is expressly understood that the commitment to provide the fifth principal sum of $270,000.00 was agreed to on September 28, 2021 and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to such amount. It is expressly understood that the commitment to provide the sixth principal sum of $15,000.00 was agreed to on October 22, 2021 and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to such amount. It is expressly understood that the commitment to provide the sixth principal sum of $50,000.00 was agreed to on November 11, 2021 and all provisions of this unsecured promissory note shall be deemed effective as of such date and all financial obligations shall accrue from such date with respect to such amount. All payments of principal and interest hereunder shall be made by check or wire transfer pursuant to wire transfer instructions that may be provided by the Holder to the Borrower from time to time.

 

1.Payments; Conversion. The Borrower shall make the principal payment on January 1, 2022 to the Holder, together with accrued and unpaid interest hereunder. Notwithstanding to the contrary, all outstanding principal and all accrued and unpaid interest hereunder shall be due and payable in full at that time. In addition, the Holder shall have the option to convert the then outstanding balance of principal and interest under this Note into restricted shares of the Borrower’s Common Stock at a conversion price equal to $0.50 per share of Common Stock.

 

2.Interest Rate. Simple interest on the unpaid principal balance of this Note shall accrue at the lesser of ten percent (10%) per annum and the highest rate permitted by law. If an Event of Default (as defined below) shall occur under this Note, interest shall immediately commence accruing at a default rate of twelve percent (12%) per annum.

 

PROMISSORY NOTE – Page 1

 

 

 

3.Default. The occurrence of any of the following events of default (each, an “Event of Default”) shall, at the option of the Holder thereof, make all principal and interest (to the extend accrued) then remaining unpaid hereon and all other amounts payable hereunder immediately due and payable, upon written demand, without presentment, or grace period, all of which hereby are expressly waived, except as set forth below:

 

(a)Failure to Pay Principal or Interest. The Borrower fails to pay any installment of principal or interest due under this Note when due and such failure continues for a period of five (5) days after written notice.

 

(b)Receiver or Trustee. The Borrower shall make an assignment for the benefit of creditors, or applies for or consents to the appointment of a receiver or trustee for it or for a substantial part of its property or business; or such a receiver of trustee shall otherwise be appointed without the consent of the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

 

(c)Bankruptcy. Bankruptcy, insolvency, reorganization, or liquidation proceedings or other proceedings or relief under any bankruptcy law or any law, or the issuance of any notice in relation to such event, for the relief of debtors shall be instituted by or against the Borrower, which shall constitute an automatic Event of Default and shall result in all remaining unpaid principal and interest due hereon immediately due and payable without the written demand from the Holder.

 

4.Termination. Upon payment of all cash amounts due to the Holder as provided in this Note, the Borrower will forever be released from all of its payment obligations and liabilities under this Note and the Holder agrees to promptly return to the Borrower the Note marked “paid in full”. This Note may be prepaid, in whole or in part, without the prior consent of the Holder.

 

5.Miscellaneous

 

(a)Successors and Assigns. This Note shall be binding upon successors and assigns of the Borrower, and shall inure to the benefit of the successors and permitted assigns of the Holder.

 

(b)Severability. The unenforceability or invalidity of any provision or provisions of this Note shall not render any other provision or provisions herein contained unenforceable or invalid.

 

PROMISSORY NOTE – Page 2

 

 

 

(c)Notice. Any notice or communication required to be given hereunder may be delivered by hand or deposited with an overnight courier (with overnight delivery instructions), if to the Borrower, to the address of the Borrower’s corporate headquarters, and if to the Holder, to the last address of the Holder set forth in the Borrower’s books and records. Notice shall be deemed given and received on the date sent if sent by personal delivery; and one (1) day after the date sent if sent by overnight courier.

 

(d)Entire Agreement. This Note contains the entire and complete understanding between the parties concerning its subject matter and all representations, agreements, arrangements, and understandings between or among the parties, whether oral or written, have been fully merged herein and are superseded thereby, except for representations, agreements, and understandings between or among the parties made pursuant to the Purchase Agreement and any other agreements entered into in connection therewith and herewith. The Note may be modified only by a writing signed by both parties.

 

(e)Governing Law; Attorneys’ Fees. This Note shall be governed by and construed in accordance with the laws of the State of Texas, without giving effect to its principles regarding conflicts of law. Upon default, the breaching party agrees to pay to the non-breaching party reasonable attorneys’ fees, plus all other reasonable expenses, incurred by the non-breaching party in exercising any of the non-breaching party’s rights and remedies.

 

(f)Jurisdiction. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of the State of Texas, Dallas County, and to the jurisdiction of the United States District Court for the State of Texas, for the purpose of any suit, action, or other proceeding arising out of or based upon this Note; (b) agree not to commence any suit, action, or other proceeding arising out of or based upon this Note except in the state courts of the State of Texas, Dallas County, or the United States District Court for the State of Texas; and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action, or proceeding, any claim that it is not subject personally to the jurisdiction of the above named courts, that its property is exempt or immune from attachment or execution, that the suit, action, or proceeding is brought in an inconvenient forum, that the venue of the suit, action, or proceeding is improper or that this Note or the subject matter hereof may not be enforced in or by such court.

 

(g)FINAL AGREEMENT. THIS NOTE AND ALL OTHER INSTRUMENTS, DOCUMENTS, AND AGREEMENTS EXECUTED AND DELIVERED BY THE BORROWER IN CONNECTION WITH THE INDEBTEDNESS EVIDENCED BY THIS NOTE EMBOTY THE FINAL, ENTIRE AGREEMENT OF THE BORROWER AND THE HOLDER WITH RESPECT TO THE INDEBTEDNESS EVIDENCED BY THIS NOTE AND SUPERSEDE ANY AND ALL PRIOR COMMITMENTS, AGREEMENTS, REPRESENTATIONS, AND UNDERSTANDINGS, WHETHER WRITTEN OR ORAL, RELATING TO THE INDEBTEDNESS EVIDENCED BYT HIS NOTE AND MAY NOT BE CONTRADICTED OR VARIED BY EVIDENCE OF PRIOR, CONTEMPORANEOUS OR SUBSEQUENT ORAL AGREEMENTS OR DISCUSSIONS OF THE BORROWER AND THE HOLDER. THERE ARE NO ORAL AGREEMENTS BETWEEN THE BORROWER AND THE HOLDER.

 

(h)Subordination. By its acceptance hereof, the Holder agrees that the indebtedness evidenced by this Note, including the principal of and interest thereon, shall be subordinate to and subject in right of payment, to the extent hereinafter set forth, to the prior payment in full of all principal, interest, and any other sums then due on all existing or future Senior Indebtedness of the Borrower. The term “Senior Indebtedness” shall mean secured and unsecured indebtedness of the Borrower, or with respect to which the Borrower is a guarantor, for money borrowed by the Borrower from any financial institution or other sources prior to the date of this unsecured promissory note.

 

Signature Page Follows

 

PROMISSORY NOTE – Page 3 

 

 

 

IN WITNESS WHEREOF, the Borrower has executed this Note as of the date set forth above.

 

  GENERATION HEMP, INC.,
  a Colorado Corporation
     
  By: /s/ Chad Burkhardt
    Chad Burkhardt
    Vice President & General Counsel

 

PROMISSORY NOTE – Page 4

 

 

EX-31.1 5 f10q0921ex31-1_generation.htm CERTIFICATION

Exhibit 31.1

 

CERTIFICATION PURSUANT TO SECTION 302

OF THE SARBANES-OXLEY ACT OF 2002 

 

I, Gary C. Evans, certify that:

 

1)I have reviewed this Quarterly Report of Generation Hemp, Inc. on Form 10-Q;

 

2)Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3)Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Registrant as of, and for, the periods presented in this report;

 

4)I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))  for the Registrant and have;

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure the material information relating to the Registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the Registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation.

 

(d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

 

5)I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Registrant's auditors and the audit committee of the Registrant's board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Registrant's ability to record, process summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the Registrant's internal controls over financial reporting.

 

DATE: November 15, 2021 By: /s/ Gary C. Evans
   

Gary C. Evans
Chairman
Chief Executive Officer
(Principal Executive Officer and
Principal Accounting and Financial Officer)

 

 

EX-32.1 6 f10q0921ex32-1_generation.htm CERTIFICATION

Exhibit 32.1

 

CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT 0F 2002

  

In connection with the Quarterly Report of Generation Hemp, Inc. (the Company") on Form 10-Q for the period ended herein as filed with the Securities and Exchange Commission (the "Report"), I. Gary C. Evans, Chairman and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. ss.1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

 

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)The information contained in the Report fully presents, in all material respects, the financial condition and results of operations or the Company.

 

DATE: November 15, 2021 By: /s/ Gary C. Evans
   

Gary C. Evans
Chairman
Chief Executive Officer
(Principal Executive Officer and
Principal Accounting and Financial Officer)

 

 

EX-101.SCH 7 genh-20210930.xsd XBRL SCHEMA FILE 001 - Statement - Unaudited Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) link:presentationLink link:definitionLink link:calculationLink 003 - Statement - Unaudited Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 004 - Statement - Unaudited Condensed Consolidated Statements of Equity link:presentationLink link:definitionLink link:calculationLink 005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 006 - Disclosure - Business link:presentationLink link:definitionLink link:calculationLink 007 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 008 - Disclosure - Acquisition link:presentationLink link:definitionLink link:calculationLink 009 - Disclosure - Discontinued Operations link:presentationLink link:definitionLink link:calculationLink 010 - Disclosure - Notes Payable – Related Parties link:presentationLink link:definitionLink link:calculationLink 011 - Disclosure - Other Indebtedness link:presentationLink link:definitionLink link:calculationLink 012 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 013 - Disclosure - Equity link:presentationLink link:definitionLink link:calculationLink 014 - Disclosure - Stock-Based Compensation link:presentationLink link:definitionLink link:calculationLink 015 - Disclosure - Income Taxes link:presentationLink link:definitionLink link:calculationLink 016 - Disclosure - Supplemental Cash Flow Information link:presentationLink link:definitionLink link:calculationLink 017 - Disclosure - Earnings (Loss) Per Share link:presentationLink link:definitionLink link:calculationLink 018 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 019 - Disclosure - Accounting Policies, by Policy (Policies) link:presentationLink link:definitionLink link:calculationLink 020 - Disclosure - Acquisition (Tables) link:presentationLink link:definitionLink link:calculationLink 021 - Disclosure - Discontinued Operations (Tables) link:presentationLink link:definitionLink link:calculationLink 022 - Disclosure - Notes Payable – Related Parties (Tables) link:presentationLink link:definitionLink link:calculationLink 023 - Disclosure - Other Indebtedness (Tables) link:presentationLink link:definitionLink link:calculationLink 024 - Disclosure - Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 025 - Disclosure - Supplemental Cash Flow Information (Tables) link:presentationLink link:definitionLink link:calculationLink 026 - Disclosure - Earnings (Loss) Per Share (Tables) link:presentationLink link:definitionLink link:calculationLink 027 - Disclosure - Business (Details) link:presentationLink link:definitionLink link:calculationLink 028 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 029 - Disclosure - Acquisition (Details) link:presentationLink link:definitionLink link:calculationLink 030 - Disclosure - Acquisition (Details) - Schedule of amortizable tangible and intangible assets link:presentationLink link:definitionLink link:calculationLink 031 - Disclosure - Acquisition (Details) - Schedule of pro forma consolidated results of operations link:presentationLink link:definitionLink link:calculationLink 032 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities link:presentationLink link:definitionLink link:calculationLink 033 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations link:presentationLink link:definitionLink link:calculationLink 034 - Disclosure - Notes Payable – Related Parties (Details) link:presentationLink link:definitionLink link:calculationLink 035 - Disclosure - Notes Payable – Related Parties (Details) - Schedule of notes payable related parties link:presentationLink link:definitionLink link:calculationLink 036 - Disclosure - Other Indebtedness (Details) link:presentationLink link:definitionLink link:calculationLink 037 - Disclosure - Other Indebtedness (Details) - Schedule of other indebtedness link:presentationLink link:definitionLink link:calculationLink 038 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:definitionLink link:calculationLink 039 - Disclosure - Equity (Details) link:presentationLink link:definitionLink link:calculationLink 040 - Disclosure - Equity (Details) - Schedule of warrants outstanding link:presentationLink link:definitionLink link:calculationLink 041 - Disclosure - Equity (Details) - Schedule of outstanding stock warrants activity link:presentationLink link:definitionLink link:calculationLink 042 - Disclosure - Stock-Based Compensation (Details) link:presentationLink link:definitionLink link:calculationLink 043 - Disclosure - Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information link:presentationLink link:definitionLink link:calculationLink 044 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share link:presentationLink link:definitionLink link:calculationLink 045 - Disclosure - Subsequent Events (Details) link:presentationLink link:definitionLink link:calculationLink 000 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 8 genh-20210930_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 genh-20210930_def.xml XBRL DEFINITION FILE EX-101.LAB 10 genh-20210930_lab.xml XBRL LABEL FILE EX-101.PRE 11 genh-20210930_pre.xml XBRL PRESENTATION FILE XML 12 f10q0921_generation_htm.xml IDEA: XBRL DOCUMENT 0001527102 2021-01-01 2021-09-30 0001527102 2021-11-15 0001527102 2021-09-30 0001527102 2020-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-12-31 0001527102 us-gaap:SeriesAPreferredStockMember 2021-09-30 0001527102 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001527102 2021-07-01 2021-09-30 0001527102 2020-07-01 2020-09-30 0001527102 2020-01-01 2020-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2019-12-31 0001527102 us-gaap:PreferredStockMember 2019-12-31 0001527102 us-gaap:CommonStockMember 2019-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001527102 us-gaap:RetainedEarningsMember 2019-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2019-12-31 0001527102 2019-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-01-01 2020-03-31 0001527102 us-gaap:PreferredStockMember 2020-01-01 2020-03-31 0001527102 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001527102 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-03-31 0001527102 2020-01-01 2020-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-03-31 0001527102 us-gaap:PreferredStockMember 2020-03-31 0001527102 us-gaap:CommonStockMember 2020-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001527102 us-gaap:RetainedEarningsMember 2020-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-03-31 0001527102 2020-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-04-01 2020-06-30 0001527102 us-gaap:PreferredStockMember 2020-04-01 2020-06-30 0001527102 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001527102 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-04-01 2020-06-30 0001527102 2020-04-01 2020-06-30 0001527102 us-gaap:PreferredStockMember 2020-06-30 0001527102 us-gaap:CommonStockMember 2020-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001527102 us-gaap:RetainedEarningsMember 2020-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-06-30 0001527102 2020-06-30 0001527102 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-07-01 2020-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-09-30 0001527102 us-gaap:PreferredStockMember 2020-09-30 0001527102 us-gaap:CommonStockMember 2020-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001527102 us-gaap:RetainedEarningsMember 2020-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2020-09-30 0001527102 2020-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2020-12-31 0001527102 us-gaap:PreferredStockMember 2020-12-31 0001527102 us-gaap:CommonStockMember 2020-12-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001527102 us-gaap:RetainedEarningsMember 2020-12-31 0001527102 us-gaap:NoncontrollingInterestMember 2020-12-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-03-31 0001527102 2021-01-01 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-03-31 0001527102 us-gaap:PreferredStockMember 2021-03-31 0001527102 us-gaap:CommonStockMember 2021-03-31 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001527102 us-gaap:RetainedEarningsMember 2021-03-31 0001527102 us-gaap:NoncontrollingInterestMember 2021-03-31 0001527102 2021-03-31 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-04-01 2021-06-30 0001527102 2021-04-01 2021-06-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-06-30 0001527102 us-gaap:PreferredStockMember 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-06-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001527102 us-gaap:RetainedEarningsMember 2021-06-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-06-30 0001527102 2021-06-30 0001527102 us-gaap:CommonStockMember 2021-07-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:PreferredStockMember 2021-07-01 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-07-01 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-07-01 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-07-01 2021-09-30 0001527102 genh:SeriesBRedeemablePreferredStockMember 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-09-30 0001527102 us-gaap:AdditionalPaidInCapitalMember 2021-09-30 0001527102 us-gaap:RetainedEarningsMember 2021-09-30 0001527102 us-gaap:NoncontrollingInterestMember 2021-09-30 0001527102 2019-11-02 2019-11-27 0001527102 2021-01-05 2021-01-11 0001527102 genh:CustomerOneMember 2021-07-01 2021-09-30 0001527102 genh:CustomerOneMember 2021-01-01 2021-09-30 0001527102 genh:HalcyonMember 2021-01-11 2021-01-11 0001527102 genh:HalcyonMember 2021-01-11 0001527102 2021-01-11 0001527102 2021-03-03 0001527102 genh:AcquisitionsMember 2021-09-30 0001527102 2021-02-25 2021-03-09 0001527102 genh:ConventryAssetManagementLTDMember 2020-12-30 0001527102 genh:ConventryAssetManagementLTDMember 2021-06-01 2021-06-30 0001527102 us-gaap:SubsequentEventMember 2021-10-01 0001527102 us-gaap:SubsequentEventMember 2021-10-01 2021-10-31 0001527102 us-gaap:SubsequentEventMember 2021-11-01 2021-11-30 0001527102 genh:ConventryAssetManagementLTDMember 2021-09-30 0001527102 genh:AccreditedInvestorMember 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteMember 2020-12-02 2020-12-30 0001527102 genh:SubordinatedPromissoryNoteMember 2021-04-30 0001527102 genh:SubordinatedPromissoryNoteMember 2021-01-01 2021-09-30 0001527102 us-gaap:SubsequentEventMember 2022-12-30 0001527102 genh:SeniorSecuredPromissoryNoteMember 2021-09-30 0001527102 genh:SeniorSecuredPromissoryNoteMember 2020-12-31 0001527102 genh:ConvertiblePromissoryNoteMember 2021-09-30 0001527102 genh:ConvertiblePromissoryNoteMember 2020-12-31 0001527102 genh:SubordinatedPromissoryNoteMember 2021-09-30 0001527102 genh:SubordinatedPromissoryNoteMember 2020-12-31 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2021-09-30 0001527102 genh:SecuredPromissoryNoteToCoventryAssetManagementLtdMember 2020-12-31 0001527102 genh:SubordinatedPromissoryNoteToInvestorMember 2021-09-30 0001527102 genh:SubordinatedPromissoryNoteToInvestorMember 2020-12-31 0001527102 2021-10-31 2021-10-31 0001527102 2021-11-15 2021-11-15 0001527102 srt:ScenarioForecastMember 2023-08-01 2023-08-01 0001527102 srt:ScenarioForecastMember 2021-01-01 2021-12-21 0001527102 srt:ScenarioForecastMember 2022-01-01 2022-12-31 0001527102 srt:ScenarioForecastMember 2023-01-01 2023-12-31 0001527102 2020-04-29 0001527102 2020-01-01 2020-12-31 0001527102 genh:OzCapitalLLCMember 2021-01-01 2021-09-30 0001527102 genh:OzCapitalLLCMember 2021-07-01 2021-09-30 0001527102 2019-01-01 2019-12-31 0001527102 genh:GrandTraverseHoldingsLLCMember 2018-01-01 2018-12-31 0001527102 genh:GrandTraverseHoldingsLLCMember 2019-04-01 2019-04-12 0001527102 2019-04-01 2019-04-12 0001527102 genh:JohnGallegosMember genh:GrandTraverseHoldingsLLCMember 2019-04-01 2019-04-12 0001527102 2020-12-01 2020-12-23 0001527102 genh:DecemberTwoThousedTwoZeroIssuanceOfSeriesBPreferredStockUnitsMember 2021-09-30 0001527102 us-gaap:SeriesBPreferredStockMember 2021-09-30 0001527102 us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-09-30 0001527102 us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHRMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHRMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHROneMember us-gaap:SeriesCPreferredStockMember 2021-09-30 0001527102 genh:IssuedUponExchangeOfEHROneMember us-gaap:SeriesCPreferredStockMember 2021-01-01 2021-09-30 0001527102 genh:FebruaryTwoThousandTwentyMember genh:CommonStockUnitsMember 2021-09-30 0001527102 genh:FebruaryTwoThousandTwentyMember genh:CommonStockUnitsMember 2021-01-01 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember us-gaap:SeriesBPreferredStockMember 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember us-gaap:SeriesBPreferredStockMember 2021-01-01 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2021-09-30 0001527102 genh:DecemberTwoThousandTwentyMember genh:SubordinatedNoteToInvestorMember 2021-01-01 2021-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember us-gaap:CommonStockMember 2021-09-30 0001527102 genh:MarchTwoThousandTwentyOneMember us-gaap:CommonStockMember 2021-01-01 2021-09-30 0001527102 genh:TwoThousandTwentyOnePlanMember 2021-01-01 2021-09-30 0001527102 us-gaap:RestrictedStockMember 2021-01-01 2021-03-31 0001527102 2021-04-06 0001527102 us-gaap:SubsequentEventMember 2021-10-31 0001527102 2021-10-01 2021-10-31 shares iso4217:USD iso4217:USD shares pure iso4217:USD utr:sqft 10-Q true 2021-09-30 2021 false 000-55019 GENERATION HEMP, INC. DE 26-3119496 8533 Midway Road Dallas TX 75209 (469) 209-6154 Common Stock, no par value GENH Yes Yes Non-accelerated Filer true false false 111486996 134165 2776425 127665 14232 276062 2776425 3012316 1222430 417135 102938 2595181 1119492 286839 2474136 509701 407000 23077 6548919 3918994 1061873 1053542 375521 337588 167482 448271 98749 2360000 3336592 516359 619461 50000 137068 140068 4717052 5985522 188090 25200 158498 144149 5063640 6154871 10000 10000 300 300 118 118 135 135 591558 729058 0.00001 0.00001 1 1 6500000 6500000 6328948 6328948 4975503 0.00001 200000000 111070329 111070329 1111 100000000 17380317 17380317 6083480 23776409 4436018 -22644284 -18220705 1133236 -2725704 -239515 -239231 893721 -2964935 6548919 3918994 487088 535053 15000 22500 60000 67500 502088 22500 595053 67500 279621 549881 315729 16038 1006804 54961 6856 16115 99880 1128298 108728 2763529 883565 1723648 131622 4336329 1038406 -1221560 -109122 -3741276 -970906 -25424 -1 -1826 -11770 14736 155505 68475 651807 204875 155505 66649 614613 219610 -1377065 -175771 -4355889 -1190516 -1630 -7989 -11349 -5457 -1378695 -183760 -4367238 -1195973 -1137 -4904 -284 -44266 -1377558 -178856 -4366954 -1151707 -0.03 -0.01 -0.11 -0.07 -0.03 -0.01 -0.11 -0.07 -0.03 -0.01 -0.11 -0.07 -0.03 -0.01 -0.11 -0.07 6328948 4975503 17130317 6029328 3426946 -16722036 -184551 -2474810 250000 54152 45848 100000 -712566 -30075 -742641 6328948 4975503 17380317 6083480 3472794 -17434602 -214626 -3117451 -260285 -9287 -269572 6328948 4975503 17380317 6083480 3472794 -17694887 -223913 -3387023 -178856 -4904 -183760 6328948 4975503 17380317 6083480 3472794 -17873743 -228817 -3570783 135 729058 6328948 4975503 17380317 6083480 4436018 -18220705 -239231 -2964935 6250000 2500000 2500000 800000 136707 263293 400000 8428976 4771669 -1804669 2967000 618660 217769 217769 1000000 1942500 1942500 500000 42250 42250 20250 20250 -1836882 3668 -1833214 135 729058 6328948 4975503 34977953 15694375 2894642 -20077837 -235563 3251120 38750 38750 -17 -137500 20250 20250 -1152514 -2815 -1155329 118 591558 6328948 4975503 34977953 15733125 2894642 -21250601 -238378 2114291 125000 117500 117500 20000 18000 18000 -15868273 15868273 38750 38750 -6328948 -4975503 75947376 759 4974744 16125 16125 -1377558 -1137 -1378695 118 591558 111070329 1111 23776409 -22644284 -239515 893721 -4367238 -1195973 11349 5457 -4355889 -1190516 1006804 54961 380282 119750 117500 -25424 -539 11770 -14736 52195 14232 176969 466533 -2658205 -653747 31716 -2658205 -622031 77716 -1525470 34847 -1568339 -1568339 150000 350000 100000 137500 -16500 2967000 995614 25200 620000 340000 1100000 103102 11740 1584284 603460 1584284 603460 -2642260 -18571 2776425 101337 134165 82766 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>1. Business</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Generation Hemp, Inc. (the “Company”), formerly known as Home Treasure Finders, Inc. (“HTF”), was incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated on July 28, 2008 in the State of Colorado. On November 27, 2019, HTF purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger (the “Transaction”). Upon closing of the Transaction, HTF changed its name to Generation Hemp, Inc.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">On January 11, 2021, we completed the acquisition of certain assets of Halcyon Thruput, LLC (“Halcyon”). With this acquisition, we commenced providing post-harvest and midstream services to growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot leased facility located in Hopkinsville, Kentucky. Additionally, the Company offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. In August 2021, the Company launched its small animal bedding consumer goods product line (“Rowdy Rooster”) made from the hemp hurd byproduct that is produced from its hemp processing operations.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to an unaffiliated hemp seed company.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">As of September 30, 2021, EHR held an approximate 8% working interest in an oil &amp; gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil &amp; gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Our management team has been and continues to actively review acquisition candidates involved in the hemp industry that operate within a number of vertical businesses, predominantly within the midstream sector that are attractive to us and are within the hemp supply chain.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Liquidity – </i>The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">In the nine months ended September 30, 2021, the Company used $2.7 million of cash for its operating activities. At September 30, 2021, the Company’s current liabilities, including financing obligations due within one year, totaled $4.7 million as compared with its current assets of $276 thousand. Cash payments under several financing obligations were initially due in September and October of 2021. As disclosed in Notes 5 and 6 below, these were subsequently amended to extend these payments by one to six months.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Impact of COVID-19 Pandemic on Our Business – </i>Our business, results of operations and financial condition have been adversely affected by the COVID-19 pandemic, beginning in mid-March 2020. The COVID-19 pandemic and measures taken to contain it have subjected our business, results of operations, financial condition, stock price and liquidity to a number of material risks and uncertainties, all of which may continue or may worsen.</span></p> 0.94 48000 EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented. 2700000 4700000 276000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>2. Summary of Significant Accounting Policies</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Basis of Presentation</i> – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Revenue Recognition</i> – Post-harvest and midstream services revenue is typically determined based on volumes processed at agreed-upon contractual prices and is recognized when performance obligations under the terms of a contract with our customers are satisfied. This occurs when control of the product is transferred to our customers upon completion of our processing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Rental revenue is recognized based on the contractual cash rental payments for the period. Oil &amp; gas revenue is recognized for discontinued operations based on delivered quantities in the amount of the consideration to which the Company is entitled.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Stock-based Compensation – </i>We account for employee stock-based compensation using the fair value method. Compensation cost for equity incentive awards is based on the fair value of the equity instrument generally on the date of grant and is recognized over the requisite service period. Forfeitures are recognized as they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Fair Value Measurement</i> – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and notes payable. The fair values of these instruments approximate their carrying amounts at each reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The Company’s non-financial assets measured at fair value on non-recurring basis include impairment measurements of oil and gas properties and warrants issued as part of financing transactions. These are considered Level 3 measurements as they involve significant unobservable inputs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Major Customer and Concentration of Credit Risk</i> – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2021 or December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During the three and nine months ended September 30, 2021, one customer accounted for approximately 99% and 90% of our post-harvest and midstream services revenue, respectively. Amounts outstanding from this customer represented 99% of total accounts receivable at September 30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2021 or December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Recent Accounting Pronouncements – </i>In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>. ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company elected to early adopt ASU 2020-06 in 2021. Adoption of this new guidance had no impact on its financial statements at the date of adoption but is applicable to newly issued instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Basis of Presentation</i> – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Revenue Recognition</i> – Post-harvest and midstream services revenue is typically determined based on volumes processed at agreed-upon contractual prices and is recognized when performance obligations under the terms of a contract with our customers are satisfied. This occurs when control of the product is transferred to our customers upon completion of our processing.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Rental revenue is recognized based on the contractual cash rental payments for the period. Oil &amp; gas revenue is recognized for discontinued operations based on delivered quantities in the amount of the consideration to which the Company is entitled.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Stock-based Compensation – </i>We account for employee stock-based compensation using the fair value method. Compensation cost for equity incentive awards is based on the fair value of the equity instrument generally on the date of grant and is recognized over the requisite service period. Forfeitures are recognized as they occur.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Fair Value Measurement</i> – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and notes payable. The fair values of these instruments approximate their carrying amounts at each reporting date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The Company’s non-financial assets measured at fair value on non-recurring basis include impairment measurements of oil and gas properties and warrants issued as part of financing transactions. These are considered Level 3 measurements as they involve significant unobservable inputs.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Major Customer and Concentration of Credit Risk</i> – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2021 or December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">During the three and nine months ended September 30, 2021, one customer accounted for approximately 99% and 90% of our post-harvest and midstream services revenue, respectively. Amounts outstanding from this customer represented 99% of total accounts receivable at September 30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2021 or December 31, 2020.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 0.99 0.90 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Recent Accounting Pronouncements – </i>In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-06, <i>Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity</i>. ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company elected to early adopt ASU 2020-06 in 2021. Adoption of this new guidance had no impact on its financial statements at the date of adoption but is applicable to newly issued instruments.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>3. Acquisition</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">On January 11, 2021, the Company completed the acquisition of certain assets of Halcyon pursuant to the Asset Purchase Agreement dated March 7, 2020, as amended on January 11, 2021. The purchase consideration totaled approximately $6.1 million consisting of 6,250,000 shares of Company common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year), $1.75 million in cash, a promissory note for $850,000 issued by the Company’s subsidiary, GenH Halcyon Acquisition, LLC, and guaranteed by Gary C. Evans, CEO of the Company, and assumption of approximately $1.0 million of new indebtedness of Halcyon. The Company was granted an option to purchase the real estate occupied by Halcyon for $993,000. This option is exercisable at any time before its expiration on January 11, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The acquisition was accounted for as a business combination where the Company is the acquirer and the acquisition method of accounting was applied in accordance with GAAP. Accordingly, the aggregate value of the consideration we paid to complete the acquisition was allocated to the assets acquired based upon their estimated fair values on the acquisition date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The following table summarizes the purchase price allocation for the assets acquired. This allocation is preliminary. In the third quarter of 2021, we made adjustments to the previously recognized amounts for inventory, intangibles, goodwill and the real estate purchase option based on the preliminary results of a valuation study. The final allocation of the purchase price will be determined at a later date and is dependent on a number of factors, including the final evaluation of the fair value of tangible and identifiable intangible assets acquired. Final adjustments, including increases and decreases to depreciation and amortization resulting from the allocation of the purchase price to amortizable tangible and intangible assets, may be material.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: 0; padding-left: 0">Accounts receivable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,470</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0">Other working capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">224,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0">Property and equipment, other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,712,170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0">Intangibles:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Non-competition agreements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,691</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,052</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0">Other assets - Purchase option on real estate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">407,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">509,701</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0; padding-left: 0.125in">Assets acquired</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,095,614</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Intangible assets consist of customer relationships and non-compete agreements, each having definite-lives. These intangible assets are being amortized over the estimated useful life on an accelerated basis reflecting the anticipated future cash flows of the Company post acquisition of Halcyon.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The results of operations for the acquired Halcyon assets have been included in the Company’s consolidated financial statements since the January 11, 2021 acquisition date.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Concurrent with the closing of the asset acquisition, the Company entered into term employment agreements with two executives to serve as vice presidents of the Company for a term of at least two years. The term employment agreements each provide for the issuance of 250,000 shares of restricted common stock of the Company as a signing bonus. Such shares are subject to restrictions on the trading or transfer of such common stock.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">Further, the term employment agreements each provide for the payment by the executives of liquidated damages if the employee terminates his employment without good reason during the initial term, other than due to the employee’s death or disability. Such liquidated damages total $600,000 if such termination occurs on or prior to January 11, 2022 or $375,000 if such termination occurs after January 11, 2022 and prior to January 11, 2023.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">On March 3, 2021, the Company repaid the outstanding principal and interest balance on the $850,000 promissory note issued in connection with the acquisition.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Supplemental Pro Forma Information</i> – The supplemental pro forma financial information presented below is for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the acquisition of certain assets of Halcyon had been completed on the date indicated, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that management believes are reasonable under the circumstances.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the acquisition had occurred on January 1, 2020, to give effect to certain events that management believes to be directly attributable to the acquisition. These pro forma adjustments primarily include:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an increase to depreciation and amortization expense that would have been recognized due to acquired tangible and intangible assets; and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="font-family: Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 48px"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">an adjustment to interest expense to reflect the reduced borrowings due to the repayment of Halcyon’s historical debt in conjunction with the acquisition;</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The supplemental pro forma financial information for the periods presented is as follows:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: 0; padding-left: 0">Revenue, continuing operations</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">502,088</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">974,434</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">596,291</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,106,440</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0">Income (loss) from continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,377,065</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,424,786</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,528,788</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Earnings (loss) per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td></tr> </table> 6100000 6250000 2500000 0.4 1750000 850000 the Company, and assumption of approximately $1.0 million of new indebtedness of Halcyon. The Company was granted an option to purchase the real estate occupied by Halcyon for $993,000. This option is exercisable at any time before its expiration on January 11, 2022. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 88%; text-align: left; text-indent: 0; padding-left: 0">Accounts receivable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">75,470</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0">Other working capital</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">224,530</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0">Property and equipment, other</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,712,170</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0">Intangibles:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Non-competition agreements</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,691</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Customer relationships</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,052</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0">Other assets - Purchase option on real estate</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">407,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-bottom: 1.5pt; text-indent: 0; padding-left: 0">Goodwill</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">509,701</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0; padding-left: 0.125in">Assets acquired</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">6,095,614</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p> 75470 224530 1712170 64691 3102052 407000 509701 6095614 250000 the employee terminates his employment without good reason during the initial term, other than due to the employee’s death or disability. Such liquidated damages total $600,000 if such termination occurs on or prior to January 11, 2022 or $375,000 if such termination occurs after January 11, 2022 and prior to January 11, 2023. 850000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: 0; padding-left: 0">Revenue, continuing operations</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">502,088</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">974,434</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">596,291</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,106,440</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0">Income (loss) from continuing operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,377,065</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,631</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(4,424,786</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,528,788</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Earnings (loss) per common share:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Basic and diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.09</td><td style="text-align: left">)</td></tr> </table> 502088 974434 596291 1106440 -1377065 59631 -4424786 -1528788 -0.03 0 -0.11 -0.09 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>4. Discontinued Operations</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">In connection with the Transaction, management determined to fully divest of EHR’s oil and gas activities. As such, these activities are presented as discontinued operations for each of the periods presented.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The following is a summary of the carrying amounts of major classes of assets and liabilities of the discontinued operations to assets and liabilities held for sale:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0">Assets -</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; width: 76%; text-align: left; padding-left: 0">Oil and natural gas properties held for sale, at cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Accumulated DD&amp;A</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-bottom: 4pt; padding-left: 0">Total assets of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-left: 0">Accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">32,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,117</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Asset retirement obligations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,834</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Revenue payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Current liabilities of discontinued operations held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140,068</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Asset retirement obligations -</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0.125in">Long-term liabilities of discontinued operations held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">158,498</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">144,149</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-bottom: 4pt; padding-left: 0">Total liabilities of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">295,566</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">284,217</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">The following is a summary of the major classes of line items constituting loss on discontinued operations shown in the consolidated statements of operations:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0">Revenue -</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: 0; padding-left: 0.125in">Oil and gas sales</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,036</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">93,248</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">93,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Costs and Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Lease operating expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,919</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Depreciation, depletion &amp; amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,942</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0.125in">Accretion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,851</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,883</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,868</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0.125in">Gain on disposal of oil &amp; gas property interests</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"> </div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,008</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.25in">Total costs and expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,770</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Interest expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,917</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 4pt; padding-left: 0">Loss from discontinued operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,630</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,989</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,349</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,457</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0">Assets -</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; width: 76%; text-align: left; padding-left: 0">Oil and natural gas properties held for sale, at cost</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,874,849</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Accumulated DD&amp;A</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,874,849</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-bottom: 4pt; padding-left: 0">Total assets of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-151">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-152">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-left: 0">Accrued liabilities</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">32,583</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">31,117</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Asset retirement obligations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,368</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,834</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Revenue payable</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">52,117</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Current liabilities of discontinued operations held for sale</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">137,068</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140,068</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Asset retirement obligations -</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0.125in">Long-term liabilities of discontinued operations held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">158,498</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">144,149</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-bottom: 4pt; padding-left: 0">Total liabilities of discontinued operations held for sale</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">295,566</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">284,217</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 1874849 1874849 1874849 1874849 32583 31117 52368 56834 52117 52117 137068 140068 158498 144149 295566 284217 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the three months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0">Revenue -</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%; text-align: left; text-indent: 0; padding-left: 0.125in">Oil and gas sales</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">55,140</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">13,036</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">93,248</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">93,361</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Costs and Expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Lease operating expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">53,919</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,762</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,714</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,099</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0; padding-left: 0.125in">Depreciation, depletion &amp; amortization</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-153">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-154">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,942</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0.125in">Accretion</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,851</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,263</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,883</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,868</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: 0; padding-left: 0.125in">Gain on disposal of oil &amp; gas property interests</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-155">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-156"> </div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24,008</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0; padding-left: 0.25in">Total costs and expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">56,770</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,025</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">104,597</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,901</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Interest expense</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-157">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-158">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">22,917</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 4pt; padding-left: 0">Loss from discontinued operations</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,630</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(7,989</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(11,349</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(5,457</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> </table> 55140 13036 93248 93361 53919 16762 94714 77099 9942 2851 4263 9883 12868 -24008 56770 21025 104597 75901 22917 -1630 -7989 -11349 -5457 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><b>5. Notes Payable – Related Parties</b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif">Notes payable – related parties consisted of the following:</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; padding-bottom: 1.5pt; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; width: 76%; text-align: left; padding-left: 0">Senior Secured Promissory Note</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-left: 0">Convertible Promissory Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,874</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Subordinated Promissory Note to CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-left: 0">Convertible Promissory Note to CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Secured Promissory Note to Coventry Asset Management, LTD.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Subordinated Promissory Note to Investor</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,360,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,698,874</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Less debt discounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(362,282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0; padding-left: 0.125in">Total Notes Payable – Related Parties</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,360,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,336,592</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Senior Secured Promissory Note – </i>On March 9, 2021, the total principal, interest and accrued fees under the Senior Secured Promissory Note was contributed to the Company and exchanged into 1,000,000 common shares.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Convertible Promissory Note – </i>On March 9, 2021, the convertible promissory note issued in October 2019, together with accrued interest thereon, was converted into 618,660 common shares under the terms of the note.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Subordinated Promissory Note to CEO – </i>Our CEO made advances to the Company during 2020 under a subordinated promissory note due September 30, 2021. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $28,508 at September 30, 2021 and $22,393 at December 31, 2020. This note was amended to a new maturity date of January 31, 2022.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Convertible Promissory Note to CEO</i> – In the third quarter of 2021, our CEO made advances totaling $620,000 to the Company under a convertible promissory note. The convertible note matures on January 1, 2022, bears interest at 10%. The principal and interest due on the convertible note may be converted, at the option of the holder, into restricted shares of the Company’s common stock at a conversion price equal to $0.50 per share. Accrued interest on this subordinated promissory note totaled $5,047 at September 30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"><i>Secured Promissory Note and Warrants to Coventry Asset Management, LTD. – </i>On December 30, 2020, the Company received proceeds from issuance of a secured promissory note in principal amount of $1,000,000 to Coventry Asset Management, LTD. The promissory note is secured by the property acquired in the acquisition of certain assets of Halcyon. The unpaid balance of the secured promissory note bears interest at a rate of 10% per annum and initially matured on June 30, 2021. Effective June 30, 2021, the promissory note was extended to a new maturity date of December 31, 2021. The Company agreed to issue 20,000 restricted common shares as a first extension fee, make a payment of $50,000 of accrued interest and a principal payment of $250,000 on October 1, 2021. The accrued interest and principal payment were not made but were subsequently amended. As amended in November 2021, the promissory note’s required payments and maturity date were extended to January 31, 2022. If before December 31, 2021 the Company raises new equity capital of $10 million or more, then the full amount outstanding under the promissory note is due within five days. Additionally, the holder of the promissory note was given an option exercisable in November 2021 to convert $250,000 of the outstanding principal balance into shares of the Company’s common stock at an exercise price of $0.60 per share. The Company agreed to issue 20,000 restricted common shares as a second extension fee. Accrued interest on this secured note totaled $75,069 at September 30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif">The holder of the secured promissory note received a warrant to purchase 1,000,000 shares of common stock exercisable at an exercise price of $0.352 per share upon origination of the promissory note in 2020. This warrant was subsequently exercised in the first quarter of 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><i>Subordinated Promissory Note and Warrants to Investor</i> – On December 30, 2020, the Company issued a subordinated promissory note in principal amount of $500,000 to an accredited investor. The unpaid balance of the Subordinated Note bears interest at a rate of 10% per annum. The Company made a principal payment of $250,000 in April 2021. The subordinated note principal together with accrued and unpaid interest was due September 30, 2021 but was subsequently extended. As amended, payments of $125,000 each are due on January 31, 2022 and March 31, 2022 together with accrued interest thereon. If at any time prior to the note’s maturity the Company raises new equity capital of $12.5 million or more, then the full amount outstanding under the note is due within five days. Accrued interest on this subordinated promissory note totaled $18,733 at September 30, 2021.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">The holder of the subordinated note received a warrant to purchase 500,000 shares of common stock exercisable until December 30, 2022 at an exercise price of $0.352 per share.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">September 30,</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; padding-bottom: 1.5pt; text-indent: 0"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0; text-indent: 0"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; width: 76%; text-align: left; padding-left: 0">Senior Secured Promissory Note</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-159">-</div></td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,500,000</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-left: 0">Convertible Promissory Note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-160">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,874</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Subordinated Promissory Note to CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-left: 0">Convertible Promissory Note to CEO</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">620,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-left: 0">Secured Promissory Note to Coventry Asset Management, LTD.</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,000,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Subordinated Promissory Note to Investor</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">500,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,360,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,698,874</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: 0; text-align: left; padding-bottom: 1.5pt; padding-left: 0">Less debt discounts</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(362,282</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0; padding-left: 0"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: 0; padding-left: 0.125in">Total Notes Payable – Related Parties</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,360,000</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3,336,592</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 1500000 208874 490000 490000 620000 1000000 1000000 250000 500000 2360000 3698874 -362282 2360000 3336592 1000000 618660 2021-09-30 0.10 28508 22393 620000 0.10 0.5 5047 1000000 0.10 20000 50000 250000 10000000 $250,000 0.6 20000 75069 1000000 0.352 500000 0.10 250000 2021-09-30 125000 due on January 31, 2022 and March 31, 2022 12.5 18733 500000 0.352 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>6. Other Indebtedness</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; ">Other indebtedness consisted of the following:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">September 30,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left; text-indent: -0.125in">Mortgage Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">516,359</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">619,461</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Paycheck Protection Program Loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">516,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,661</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(516,359</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(619,461</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Total Other Indebtedness - Long-Term</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,200</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Mortgage Payable and Operating Lease<b>—</b></i>The Company is obligated under a mortgage payable, dated September 15, 2014 and as amended October 1, 2019, secured by its warehouse property located in Denver, Colorado. The note provided for a 25-year amortization period and an initial interest rate of 9% annually. As amended, the note matured on January 15, 2021 but was extended under terms of the amendment to July 15, 2021 after payment by the Company of an extension fee of 1% of the then outstanding principal. The rate during this extension period was 11% annually.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In July 2021, the mortgage payable was amended to a new maturity date of October 15, 2021. The Company made a $100,000 principal payment and paid an extension fee of $6,000 in July 2021 for this amendment. The rate during the extension period was increased to 12% annually and the new monthly payment is $5,279.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2021, the mortgage payable was amended to a new maturity date of January 15, 2022. The Company will pay an extension fee of $1,000 each month beginning November 15, 2021. The new monthly payment of the note is $5,500 including interest at an effective rate of approximately 13%.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">The Company leases the Denver warehouse property to a tenant under an operating lease which was renewed with a new tenant and extended to August 1, 2023 for a monthly rent of $7,500. The lease requires a true-up with the tenant for property taxes and insurance paid by the Company and requires the tenant to maintain the interior and exterior of the warehouse (except for the roof). The lease provides for a rent abatement in the first and last month of the contracted extension. Minimum future rents for the remainder of 2021 are $22,500, for 2022 are $90,000 and for 2023 are $52,500.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Paycheck Protection Program Loan –</i> Congress created the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) to provide forgivable loans to eligible small businesses facing economic hardship to retain U.S. employees on their payroll during the Coronavirus Disease 2019 (“COVID-19”) pandemic.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">PPP loan recipients may be eligible to have their loans forgiven if the funds were used for eligible expenses over the eight-week coverage period commencing when the loan was originally disbursed. The amount of forgiveness may be reduced if the percentage of eligible expenses attributed to nonpayroll expenses exceeds 25% of the loan, if employee headcount decreases, or compensation decreases by more than 25% for each employee making less than $100,000 per year, unless the reduced headcount or compensation levels are restored.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">On April 29, 2020, we received disbursement of an approved PPP loan in the amount of $25,200. The Company received notice from the SBA that the PPP Loan principal and interest thereon was fully forgiven on April 20, 2021.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">September 30,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">December 31,</td><td style="vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; width: 76%; text-align: left; text-indent: -0.125in">Mortgage Payable</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">516,359</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">619,461</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Paycheck Protection Program Loan</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-161">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">25,200</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Total</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">516,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">644,661</td><td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Less current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(516,359</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(619,461</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Total Other Indebtedness - Long-Term</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><div style="-sec-ix-hidden: hidden-fact-162">-</div></td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">25,200</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; "> </p> 516359 619461 25200 516359 644661 516359 619461 25200 The Company is obligated under a mortgage payable, dated September 15, 2014 and as amended October 1, 2019, secured by its warehouse property located in Denver, Colorado. The note provided for a 25-year amortization period and an initial interest rate of 9% annually. As amended, the note matured on January 15, 2021 but was extended under terms of the amendment to July 15, 2021 after payment by the Company of an extension fee of 1% of the then outstanding principal. The rate during this extension period was 11% annually.In July 2021, the mortgage payable was amended to a new maturity date of October 15, 2021. The Company made a $100,000 principal payment and paid an extension fee of $6,000 in July 2021 for this amendment. The rate during the extension period was increased to 12% annually and the new monthly payment is $5,279.  2022-01-15 1000 5500 0.13 7500 22500 90000 52500 0.25 0.25 100000 25200 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>7. <span>Commitments and Contingencies</span></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Leases – </i>The Company assumed Halcyon’s lease of office space in Fort Worth, Texas for managerial offices. This lease requires monthly payments of $2,000 and is month-to-month. Lease expense for this facility totaled $6,000 and $16,000 in the three and nine months ended September 30, 2021, respectively.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">The Company leases its operating facility in Kentucky from Oz Capital, LLC, a related party, under a lease expiring May 31, 2024. The lease provides for monthly payments of $10,249. Oz Capital, LLC is responsible for all taxes and maintenance under the lease. Lease expense for this facility totaled $30,747 and $88,604 in the three and nine months ended September 30, 2021, respectively. A right-of-use asset and lease liability is recorded for this lease.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">The right-of-use asset represent the right to use the underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. A right-of-use asset and lease liabilities were recognized at the commencement date based on the present value of lease payments over the lease term. As the lease does not provide an implicit rate, the Company used its estimated incremental borrowing rate of 10% in determining the present value of the lease payments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Pending Insurance Claim – </i>In 2019, drying equipment that Halcyon purchased from a third party was being placed into service when a fire loss subsequently occurred and destroyed the equipment causing significant business interruption. The cost of this drying equipment totaled $1.1 million. In 2020, Halcyon received, as partial payment, insurance proceeds of $595,000 from its insurance carrier. The Company has made a formal claim against the insurance carrier and is pursuing all available options to recover the unpaid amounts.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Litigation – </i>From time to time, we are subject to various litigation and other claims in the normal course of business. Below is a discussion of specific matters. We cannot predict the ultimate outcome of these matters.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="text-decoration:underline">JDONE, LLC v. Grand Traverse Holdings, LLC and John Gallegos, Denver District Court Case No. 2019CV33723</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">JDONE, LLC (“JDONE”) is a wholly owned subsidiary of the Company and landlord of a commercial warehouse building that was leased to Grand Traverse Holdings, LLC on December 31, 2018 for a term of 61 months, with a personal guaranty from Defendant, John Gallegos. On April 12, 2019, Grand Traverse presented JDONE with an alleged forged, signed copy of the draft early termination amendment that JDONE had previously rejected. JDONE has suffered damages due to Defendant’s alleged misconduct of approximately $823,504 plus interest and attorney’s fees exceeding $300,000. A court ordered mediation was held in May 2020 without success. All material defendant motions have been denied by the court. The case is set for jury trial in January 2022. We believe that Grand Traverse Holdings, LLC and John Gallegos are jointly liable for the asserted damages which exceed $1 million and continue to vigorously pursue our claims.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><span style="text-decoration:underline">KBSIII Tower at Lake Carolyn, LLC and Prime US-Tower at Lake Carolyn, LLC (collectively – “KBSIII”) vs. Energy Hunter Resources, Inc.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">Plaintiff/Counterdefendant KBSIII was seeking lost rent on office space for periods after EHR vacated office premises located in Las Colinas, Texas. EHR filed a counter suit alleging specific damages due to uninhabitable premises of the office space due to the intolerable conduct of other tenants located on the same floor. On December 23, 2020, the trial court entered a summary judgment against EHR for $230,712. The judgment provides for post-judgment interest at a rate of 5% per annum until paid and further provides for additional amounts owed should EHR pursue unsuccessful appeals to higher courts. At September 30, 2021, the Company had accrued $252,583 for this judgment, which is exclusively an EHR obligation.</p> 2000 6000 16000 2024-05-31 10249 30747 88604 0.10 1100000 595000 P61M 823504 300000 1000000 230712 0.05 252583 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>8. Equity</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Change of Corporate Domicile</i> – On August 21, 2021, the Company changed its domicile from the State of Colorado to the State of Delaware. The change of domicile had no effect on the number of outstanding securities of the Company. The Company is authorized for 200 million shares of capital stock, par value $0.00001 per share and 20 million shares of preferred stock, par value $0.00001 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Series A Preferred Stock <b>– </b></i>On September 8, 2021, holders of the Company’s Series A Preferred Stock elected to convert such shares into shares of the Company’s common stock. As a result, 6,328,948 shares of Series A Preferred Stock were converted into 75,947,376 shares of common stock, with each share of Series A Preferred Stock converting into 12 shares of restricted common stock pursuant to the applicable Certificate of Designations. The Series A Preferred Stock was originally issued in connection with the Company’s merger transaction completed in December 2019.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Series B Preferred Stock Units – </i>On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">The sale of the preferred stock units for $10,000 each resulted in aggregate gross proceeds of approximately $1.35 million, before deducting estimated offering expenses payable by the Company. Substantially all of the proceeds raised in the offering were used to fund the acquisition of assets of Halcyon, expenses related thereto and for general corporate purposes.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">Each share of Series B Preferred Stock is initially convertible into 25,000 shares of common stock, subject to adjustment. Holders of Series B Preferred Stock are entitled to receive dividends of 6.00% per annum based on the stated value equal to $10,000 per share. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the related certificate of designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of its common stock, (e) enter into any agreement with respect to any of the foregoing, or (f) pay cash dividends or distributions on any equity securities of the Company other than pursuant to the terms of the outstanding Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">Beginning the later of June 30, 2021 or the effectiveness of any registration statement registering the underlying common shares, all or any portion of the Series B Preferred Stock may be converted, at their holder’s option, into 25,000 shares of common stock, as adjusted for any stock dividends, splits, combinations or similar events.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">At any time after the occurrence of a “Qualifying Event,” the Company, upon 5-day written notice, shall have the right to cause each share of Series B Preferred Stock (and all accrued in-kind dividends with respect thereto) to be converted into common stock. For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00. In each instance, a conversion may not be made unless the Company has filed an amendment to its Articles of Incorporation effecting an increase in its authorized common stock so that the Company has a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">The Series B Preferred Stock may be redeemed by the Company for its stated value, plus accrued and unpaid dividends, at any time. Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">In May, June and October of 2021, the three holders of the Series B Preferred Stock, including the Company’s chief executive officer, entered into transactions in which they accepted the mandatory redemption payment required pursuant to the Series B Preferred Stock certificate of designation in a number of Series B Units to effectively waive the redemption requirement. All other terms of the Series B Units remain unchanged and the holders’ ownership interest in the Series B Preferred Units remains the same as it was before such transactions.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Common Stock – </i>At September 30, 2021, the Company had 111,070,329 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>February 2020 Issuance of Common Stock Units – </i>In February 2020, the Company issued 250,000 common units for $100,000. Each unit consisted of one share of common stock and a warrant for purchase of one common share for $0.40 per share. The warrant expires March 1, 2022 and contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price. Proceeds of this issuance were used for general corporate purposes.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; ">The common stock issued in the exchange was valued using the trading price of the common stock on February 20, 2020. The warrants were valued at $45,848 using a binomial lattice valuation model using inputs as of the exchange date. Our expected volatility assumption was based on the historical volatility of the Company’s common stock (252%). The expected life assumption was based on the expiration date of the warrant (two years). The risk-free interest rate for the expected term of the warrant was based on the U.S. Treasury yield curve in effect at the time of measurement (1.39%). The warrants are classified within equity in the consolidated balance sheets. Under GAAP, the anti-dilution provisions will be accounted for if and when these provisions are triggered.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; "> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Acquisition of Certain Assets of Halcyon </i>– the Company issued 6,250,000 shares of common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year) in the acquisition. Refer to Note 3.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>2021 First Quarter Issuances of Common Stock Units</i> – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.  </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Warrant Exercises </i>– In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuances for Exchange or Conversion of Debt </i>– The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt. Refer to Note 5.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance to Vendor for Services </i>– In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed. </span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance for Extension of Secured Note </i>– The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021. Refer to Note 5.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Issuance for Conversion of Series A Preferred Stock </i>– As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; "> <tr style="vertical-align: top"> <td style="width: 0.5in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Stock-based Compensation</i> – The Company issued 500,000 restricted common shares as incentive compensation to two executives who joined the Company in the first quarter of 2021.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "><i>Common Stock Warrants Outstanding – </i>Following is a summary of warrants outstanding:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i> </i></p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"># of Warrants</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">Exercise Price<br/> (each)</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">Expiration Date</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">Method of Exercise</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued upon exchange of EHR Series C Preferred Stock <sup>(1)</sup></span></p></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,065,340</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.352</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="text-align: center; width: 14%; padding-left: 0pt">November 27, 2021</td><td style="width: 1%"> </td> <td style="width: 14%; text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued upon exchange of EHR Series C Preferred Stock <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,244,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">November 27, 2021</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cashless</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in February 2020 with common stock units <sup>(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">March 1, 2022</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in December 2020 with Series B preferred units <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">December 30, 2022</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in December 2020 with subordinated note to investor <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">December 30, 2022</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in Q1 2021 with common stock units <sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,600,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt">Jan-Feb, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Total warrants outstanding at September 30, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16,159,656</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt; padding-left: 0pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt; padding-left: 0pt"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i> </i></p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-indent: -0.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price.</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in">Following is a summary of outstanding stock warrants activity for the periods presented:</p><p style="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%">Warrants as of January 1, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">14,488,632</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Warrants as of September 30, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">14,738,632</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Warrants as of January 1, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,988,632</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,428,976</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Warrants as of September 30, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16,159,656</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> The Company is authorized for 200 million shares of capital stock, par value $0.00001 per share and 20 million shares of preferred stock, par value $0.00001 per share. 6328948 75947376 50000 0.352 10000 1350000 25000 0.06 10000 25000 For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00. Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021. At September 30, 2021, the Company had 111,070,329 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:   ● February 2020 Issuance of Common Stock Units – In February 2020, the Company issued 250,000 common units for $100,000. Each unit consisted of one share of common stock and a warrant for purchase of one common share for $0.40 per share. The warrant expires March 1, 2022 and contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price. Proceeds of this issuance were used for general corporate purposes.  The common stock issued in the exchange was valued using the trading price of the common stock on February 20, 2020. The warrants were valued at $45,848 using a binomial lattice valuation model using inputs as of the exchange date. Our expected volatility assumption was based on the historical volatility of the Company’s common stock (252%). The expected life assumption was based on the expiration date of the warrant (two years). The risk-free interest rate for the expected term of the warrant was based on the U.S. Treasury yield curve in effect at the time of measurement (1.39%). The warrants are classified within equity in the consolidated balance sheets. Under GAAP, the anti-dilution provisions will be accounted for if and when these provisions are triggered.    ● Acquisition of Certain Assets of Halcyon – the Company issued 6,250,000 shares of common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year) in the acquisition. Refer to Note 3.     ● 2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.       ● Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants.     ● Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt. Refer to Note 5.     ● Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.     ● Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021. Refer to Note 5.     ● Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.   ●Stock-based Compensation – The Company issued 500,000 restricted common shares as incentive compensation to two executives who joined the Company in the first quarter of 2021. <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap"># of Warrants</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">Exercise Price<br/> (each)</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">Expiration Date</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td style="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center; white-space: nowrap">Method of Exercise</td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td style="text-align: center"> </td><td> </td> <td style="text-align: center"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left; text-indent: -0.125in; padding-left: 0.125in"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued upon exchange of EHR Series C Preferred Stock <sup>(1)</sup></span></p></td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">1,065,340</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">0.352</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="text-align: center; width: 14%; padding-left: 0pt">November 27, 2021</td><td style="width: 1%"> </td> <td style="width: 14%; text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued upon exchange of EHR Series C Preferred Stock <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">7,244,316</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">November 27, 2021</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cashless</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in February 2020 with common stock units <sup>(2)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">250,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.400</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">March 1, 2022</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in December 2020 with Series B preferred units <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">December 30, 2022</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in December 2020 with subordinated note to investor <sup>(1)</sup></span></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">0.352</td><td style="text-align: left"> </td><td> </td> <td style="text-align: center; padding-left: 0pt">December 30, 2022</td><td> </td> <td style="text-align: center; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Issued in Q1 2021 with common stock units <sup>(1)</sup></span></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,600,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">0.500</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt">Jan-Feb, 2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="text-align: center; padding-bottom: 1.5pt; padding-left: 0pt">Cash</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 4pt; text-indent: -0.125in; padding-left: 0.25in">Total warrants outstanding at September 30, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16,159,656</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt; text-align: right"> </td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt; padding-left: 0pt"> </td><td style="padding-bottom: 4pt"> </td> <td style="text-align: center; padding-bottom: 4pt; padding-left: 0pt"> </td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i> </i></p> 1065340 0.352 November 27, 2021 Cash 7244316 0.352 November 27, 2021 Cashless 250000 0.4 March 1, 2022 Cash 5500000 0.352 December 30, 2022 Cash 500000 0.352 December 30, 2022 Cash 1600000 0.5 Jan-Feb, 2023 Cash 16159656 0.0001 1 25000 <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%">Warrants as of January 1, 2020</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">14,488,632</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Issued</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">250,000</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Warrants as of September 30, 2020</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">14,738,632</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Warrants as of January 1, 2021</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,988,632</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Issued</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,600,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt">Exercised</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,428,976</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt">Warrants as of September 30, 2021</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">16,159,656</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table> 14488632 250000 14738632 22988632 1600000 -8428976 16159656 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>9. Stock-Based Compensation</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">We award restricted stock or stock options as incentive compensation to employees. Generally, these awards include vesting periods of up to three years from the date of grant.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">The 2021 Omnibus Incentive Plan (“2021 Plan”) was adopted by our Board on July 1, 2021. The 2021 Plan provides for the initial reservation of 15 million shares of common stock for issuance, and provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 15 million. The number of shares of common stock available for issuance under the 2021 Plan constituted approximately 13.1% of the Company’s fully diluted common shares outstanding as of the date of Board approval, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis. On the one-year anniversary date of the 2021 Plan, the number of shares of common stock reserved for issuance thereunder shall automatically increase to 20% of the fully diluted common shares outstanding, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; ">In the first quarter of 2021, the Company issued 500,000 restricted shares valued at $158,500 as incentive compensation to two executives who joined the Company. Compensation expense related to these awards totaled $38,750 and $119,750 for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, there was $38,750 of total unrecognized compensation cost related to unvested awards to be recognized over a weighted-average period of three months.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">On April 6, 2021, the Company announced that Chad Burkhardt has joined the Company as its Vice President and General Counsel, effective April 1, 2021. In addition to his annual salary, the Company agreed to make a future grant to Mr. Burkhardt of $750,000 worth of options for the purchase of our common stock at an exercise price equal to the fair market value of the Company’s common stock on the date of grant. Such options will vest annually in equal installments over a three-year period from his date of hire.</p> 15000000 15000000 0.131 0.20 500000 158500 38750 119750 38750 750000 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>10. Income Taxes</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. An income tax benefit for the three and nine months ended September 30, 2021 or 2020 was not recognized because tax losses incurred were fully offset by a valuation allowance against deferred tax assets. There were no uncertain tax positions as of September 30, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>11. Supplemental Cash Flow Information</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">For the nine months ended <br/> September 30,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; vertical-align: bottom; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Cash paid for interest</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,812</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash paid for taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">            -</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">                 -</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Noncash investing and financing activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 9pt">Acquisition of certain assets of Halcyon Thruput, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0.25in">- issuance of common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.25in">- issuance of subordinated note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">850,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0.25in">- assumption of Halcyon bank note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">995,614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 9pt">Series B preferred stock dividend payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 9pt">Issuance of common stock units previously subscribed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 9pt">Issuances of common shares for exchange or conversion of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,160,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="vertical-align: bottom; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">For the nine months ended <br/> September 30,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; vertical-align: bottom; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left">Cash paid for interest</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">127,812</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><div style="-sec-ix-hidden: hidden-fact-163">-</div></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Cash paid for taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-164">            -</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-165">                 -</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left">Noncash investing and financing activities:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 9pt">Acquisition of certain assets of Halcyon Thruput, LLC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: 0.25in">- issuance of common shares</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,500,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-166">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 0.25in">- issuance of subordinated note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">850,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-167">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 0.25in">- assumption of Halcyon bank note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">995,614</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-168">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 9pt">Series B preferred stock dividend payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,137</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-169">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="text-align: left; text-indent: 9pt">Issuance of common stock units previously subscribed</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-170">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: 9pt">Issuances of common shares for exchange or conversion of debt</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,160,269</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-171">-</div></td><td style="text-align: left"> </td></tr> </table> 127812 2500000 850000 995614 39137 50000 2160269 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>12. Earnings (Loss) per Share</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The following is the computation of earnings (loss) per basic and diluted share:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">For the three months ended<br/> September 30,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">For the nine months ended<br/> September 30,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">Amounts attributable to Generation Hemp:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; width: 52%; text-align: left; text-indent: -0.125in">Loss from continuing operations attributable to common stockholders</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,376,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(171,367</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,356,315</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,146,592</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,528</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,489</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,639</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,115</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Less: preferred stock dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Net loss attributable to common stockholders</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,393,683</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(178,856</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,423,579</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,151,707</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Weighted average shares used to compute basic EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,109,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,380,317</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,693,679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,500,308</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Dilutive effect of convertible note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Dilutive effect of preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,913,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,947,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,641,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,947,376</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Dilutive effect of common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,042,419</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,126,327</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Weighted average shares used to compute diluted EPS</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">123,065,873</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">93,327,693</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">122,461,090</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">93,447,684</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Earnings (loss) per share:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in">Loss from continuing operations</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.375in; width: 52%; text-indent: -0.125in">Basic</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.03</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.01</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.11</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.07</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.375in; text-indent: -0.125in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.07</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">(Loss) income from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.375in; text-indent: -0.125in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.375in; text-indent: -0.125in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in">Earnings (loss) per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.375in; text-indent: -0.125in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.07</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.375in; text-indent: -0.125in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.07</td><td style="text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The computation of diluted earnings per common share excludes the assumed conversion of the Series B Preferred Stock and outstanding convertible notes and exercise of common stock warrants in periods when we report a loss. The dilutive effect of the assumed exercise of outstanding warrants was calculated using the treasury stock method.</p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">For the three months ended<br/> September 30,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="vertical-align: bottom; font-weight: bold; padding-bottom: 1.5pt; white-space: nowrap; text-align: center"> </td> <td colspan="6" style="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; white-space: nowrap">For the nine months ended<br/> September 30,</td><td style="vertical-align: bottom; padding-bottom: 1.5pt; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; padding-left: 0.125in; vertical-align: bottom; white-space: nowrap; text-align: center; text-indent: -0.125in"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2021</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center; white-space: nowrap">2020</td><td style="padding-bottom: 1.5pt; vertical-align: bottom; font-weight: bold; white-space: nowrap; text-align: center"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">Amounts attributable to Generation Hemp:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-left: 0.125in; text-indent: -0.125in">Numerator</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; width: 52%; text-align: left; text-indent: -0.125in">Loss from continuing operations attributable to common stockholders</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,376,030</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(171,367</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,356,315</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(1,146,592</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Loss from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,528</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,489</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(10,639</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(5,115</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Less: preferred stock dividends</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(16,125</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-172">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(56,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-173">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Net loss attributable to common stockholders</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,393,683</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(178,856</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(4,423,579</td><td style="padding-bottom: 4pt; text-align: left">)</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">(1,151,707</td><td style="padding-bottom: 4pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-indent: -0.125in">Denominator</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Weighted average shares used to compute basic EPS</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">54,109,797</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,380,317</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,693,679</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,500,308</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Dilutive effect of convertible note</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-174">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-175">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-176">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-177">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">Dilutive effect of preferred stock</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">59,913,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,947,376</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">72,641,084</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">75,947,376</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt; text-indent: -0.125in">Dilutive effect of common stock warrants</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">9,042,419</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-178">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">11,126,327</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><div style="-sec-ix-hidden: hidden-fact-179">-</div></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; padding-bottom: 4pt; text-indent: -0.125in">Weighted average shares used to compute diluted EPS</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">123,065,873</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">93,327,693</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">122,461,090</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left"> </td><td style="border-bottom: Black 4pt double; text-align: right">93,447,684</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.125in; text-align: left; text-indent: -0.125in"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.125in; text-indent: -0.125in">Earnings (loss) per share:</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in">Loss from continuing operations</td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.375in; width: 52%; text-indent: -0.125in">Basic</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.03</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.01</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.11</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(0.07</td><td style="width: 1%; text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.375in; text-indent: -0.125in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.07</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.25in; text-align: left; text-indent: -0.125in">(Loss) income from discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.375in; text-indent: -0.125in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-180">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-181">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-182">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-183">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.375in; text-indent: -0.125in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-184">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-185">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-186">-</div></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-187">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.25in; text-indent: -0.125in">Earnings (loss) per share</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 0.375in; text-indent: -0.125in">Basic</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.07</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; "> <td style="padding-left: 0.375in; text-indent: -0.125in">Diluted</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.03</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.01</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.11</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">(0.07</td><td style="text-align: left">)</td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> -1376030 -171367 -4356315 -1146592 -1528 -7489 -10639 -5115 -16125 -56625 -1393683 -178856 -4423579 -1151707 54109797 17380317 38693679 17500308 59913657 75947376 72641084 75947376 9042419 11126327 123065873 93327693 122461090 93447684 -0.03 -0.01 -0.11 -0.07 -0.03 -0.01 -0.11 -0.07 -0.03 -0.01 -0.11 -0.07 -0.03 -0.01 -0.11 -0.07 <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>13. Subsequent Events</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2021, the Company issued 416,667 common stock units to an accredited investor for total proceeds of $250,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of one share of common stock for $0.60 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As disclosed in Note 5 above, (i) we amended the subordinated note to our CEO in the amount of $490,000 to a new maturity date of January 31, 2022, (ii) we amended the secured promissory note to Coventry Asset Management, LTD. to a new maturity date of January 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed and granted the holder a limited option to convert part of the principal to common stock and (iii) we amended the subordinated promissory note with an investor to a new maturity date of March 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">In October 2021, our CEO made advances totaling $15,000 to the Company. The existing convertible promissory note was amended and restated to a new balance of $635,000. The interest rate of 10% per annum and maturity date of January 1, 2022 were unchanged.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">As disclosed in Note 6 above, the mortgage payable was amended to a new maturity date of January 15, 2022.</p> 416667 250000 0.6 As disclosed in Note 5 above, (i) we amended the subordinated note to our CEO in the amount of $490,000 to a new maturity date of January 31, 2022, (ii) we amended the secured promissory note to Coventry Asset Management, LTD. to a new maturity date of January 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed and granted the holder a limited option to convert part of the principal to common stock and (iii) we amended the subordinated promissory note with an investor to a new maturity date of March 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed.  15000 635000 0.10 2022-01-01 NYSE false --12-31 Q3 0001527102 May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock. Contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price. XML 13 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information - shares
9 Months Ended
Sep. 30, 2021
Nov. 15, 2021
Document Information Line Items    
Entity Registrant Name GENERATION HEMP, INC.  
Trading Symbol GENH  
Document Type 10-Q  
Current Fiscal Year End Date --12-31  
Entity Common Stock, Shares Outstanding   111,486,996
Amendment Flag false  
Entity Central Index Key 0001527102  
Entity Current Reporting Status Yes  
Entity Filer Category Non-accelerated Filer  
Document Period End Date Sep. 30, 2021  
Document Fiscal Year Focus 2021  
Document Fiscal Period Focus Q3  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Document Quarterly Report true  
Document Transition Report false  
Entity File Number 000-55019  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 26-3119496  
Entity Address, Address Line One 8533 Midway Road  
Entity Address, City or Town Dallas  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 75209  
City Area Code (469)  
Local Phone Number 209-6154  
Title of 12(b) Security Common Stock, no par value  
Security Exchange Name NYSE  
Entity Interactive Data Current Yes  
XML 14 R2.htm IDEA: XBRL DOCUMENT v3.21.2
Unaudited Condensed Consolidated Balance Sheets - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Current Assets    
Cash $ 134,165 $ 2,776,425
Accounts receivable 127,665
Prepaid expenses 14,232
Total Current Assets 276,062 2,776,425
Property and Equipment    
Property and equipment 3,012,316 1,222,430
Accumulated depreciation (417,135) (102,938)
Total Property and Equipment, Net 2,595,181 1,119,492
Operating lease right-of-use asset 286,839
Intangible assets, net 2,474,136
Goodwill 509,701  
Other assets 407,000 23,077
Total Assets 6,548,919 3,918,994
Current Liabilities    
Accounts payable 1,061,873 1,053,542
Accrued liabilities 375,521 337,588
Payables to related parties 167,482 448,271
Operating lease liability - related party 98,749
Notes payable – related parties 2,360,000 3,336,592
Other indebtedness - current 516,359 619,461
Common stock issuable 50,000
Current liabilities of discontinued operations held for sale 137,068 140,068
Total Current Liabilities 4,717,052 5,985,522
Operating lease liability - related party, net of current portion 188,090
Other indebtedness - long-term 25,200
Long-term liabilities of discontinued operations held for sale 158,498 144,149
Total Liabilities 5,063,640 6,154,871
Commitments and Contingencies
Series B redeemable preferred stock, no par value, $10,000 stated value, 300 shares authorized, 118 and 135 shares issued and outstanding at September 30, 2021 and December 31, 2020 591,558 729,058
Equity (Deficit)    
Series A preferred stock, $0.00001 par value; $1.00 stated value; 6,500,000 shares authorized, none and 6,328,948 shares issued and outstanding at September 30, 2021 and December 31, 2020 4,975,503
Common stock, $0.00001 par value; 200,000,000 shares authorized, 111,070,329 shares issued and outstanding at September 30, 2021 1,111
Common stock, no par value; 100,000,000 shares authorized, 17,380,317 shares issued and outstanding at December 31, 2020 6,083,480
Additional paid-in capital 23,776,409 4,436,018
Accumulated deficit (22,644,284) (18,220,705)
Generation Hemp equity 1,133,236 (2,725,704)
Noncontrolling interest (239,515) (239,231)
Total Equity (Deficit) 893,721 (2,964,935)
Total Liabilities and Equity (Deficit) $ 6,548,919 $ 3,918,994
XML 15 R3.htm IDEA: XBRL DOCUMENT v3.21.2
Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Common stock, par value (in Dollars per share) $ 0.00001  
Common stock, shares authorized 200,000,000 100,000,000
Common stock, shares issued 111,070,329 17,380,317
Common stock, shares outstanding 111,070,329 17,380,317
Series B Redeemable Preferred Stock    
Preferred stock par value (in Dollars per share)
Preferred stock, Stated Value (in Dollars) $ 10,000 $ 10,000
Preferred stock, shares authorized 300 300
Preferred stock, shares issued 118 135
Preferred stock, shares outstanding 118 135
Series A Preferred Stock    
Preferred stock par value (in Dollars per share) $ 0.00001 $ 0.00001
Preferred stock, shares authorized 6,500,000 6,500,000
Preferred stock, shares issued 6,328,948
Preferred stock, shares outstanding 6,328,948
Preferred stock, stated value (in Dollars per share) $ 1 $ 1
XML 16 R4.htm IDEA: XBRL DOCUMENT v3.21.2
Unaudited Condensed Consolidated Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue        
Post-harvest and midstream services $ 487,088 $ 535,053  
Rental 15,000 22,500 60,000 $ 67,500
Total revenue 502,088 22,500 595,053 67,500
Costs and Expenses        
Cost of revenue (exclusive of items shown separately below) 279,621 549,881  
Depreciation and amortization 315,729 16,038 1,006,804 54,961
Merger and acquisition costs   6,856 16,115 99,880
General and administrative 1,128,298 108,728 2,763,529 883,565
Total costs and expenses 1,723,648 131,622 4,336,329 1,038,406
Operating loss (1,221,560) (109,122) (3,741,276) (970,906)
Other expense (income)        
Interest and other income     (25,424) (1)
Change in fair value of marketable security   (1,826) (11,770) 14,736
Interest expense 155,505 68,475 651,807 204,875
Total other expense 155,505 66,649 614,613 219,610
Loss from continuing operations (1,377,065) (175,771) (4,355,889) (1,190,516)
Loss from discontinued operations (1,630) (7,989) (11,349) (5,457)
Net loss (1,378,695) (183,760) (4,367,238) (1,195,973)
Less: net loss attributable to noncontrolling interests (1,137) (4,904) (284) (44,266)
Net loss attributable to Generation Hemp $ (1,377,558) $ (178,856) $ (4,366,954) $ (1,151,707)
Loss from continuing operations        
Basic (in Dollars per share) $ (0.03) $ (0.01) $ (0.11) $ (0.07)
Diluted (in Dollars per share) (0.03) (0.01) (0.11) (0.07)
Loss from discontinued operations        
Basic (in Dollars per share)
Diluted (in Dollars per share)
Earnings (loss) per share        
Basic (in Dollars per share) (0.03) (0.01) (0.11) (0.07)
Diluted (in Dollars per share) $ (0.03) $ (0.01) $ (0.11) $ (0.07)
XML 17 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Unaudited Condensed Consolidated Statements of Equity - USD ($)
Total
Series B Redeemable Preferred Stock
Series A Preferred Stock
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Noncontrolling Interest
Balance at Dec. 31, 2019 $ (2,474,810) $ 4,975,503 $ 6,029,328 $ 3,426,946 $ (16,722,036) $ (184,551)
Balance (in Shares) at Dec. 31, 2019   6,328,948 17,130,317      
Issuances of common stock units 100,000 $ 54,152 45,848
Issuances of common stock units (in Shares)   250,000      
Net loss (742,641) (712,566) (30,075)
Balance at Mar. 31, 2020 (3,117,451) $ 4,975,503 $ 6,083,480 3,472,794 (17,434,602) (214,626)
Balance (in Shares) at Mar. 31, 2020   6,328,948 17,380,317      
Balance at Dec. 31, 2019 (2,474,810) $ 4,975,503 $ 6,029,328 3,426,946 (16,722,036) (184,551)
Balance (in Shares) at Dec. 31, 2019   6,328,948 17,130,317      
Net loss (1,195,973)            
Balance at Sep. 30, 2020 (3,570,783) $ 4,975,503 $ 6,083,480 3,472,794 (17,873,743) (228,817)
Balance (in Shares) at Sep. 30, 2020   6,328,948 17,380,317      
Balance at Mar. 31, 2020 (3,117,451) $ 4,975,503 $ 6,083,480 3,472,794 (17,434,602) (214,626)
Balance (in Shares) at Mar. 31, 2020   6,328,948 17,380,317      
Net loss (269,572) (260,285) (9,287)
Balance at Jun. 30, 2020 (3,387,023)   $ 4,975,503 $ 6,083,480 3,472,794 (17,694,887) (223,913)
Balance (in Shares) at Jun. 30, 2020     6,328,948 17,380,317      
Net loss (183,760)         (178,856) (4,904)
Balance at Sep. 30, 2020 (3,570,783) $ 4,975,503 $ 6,083,480 3,472,794 (17,873,743) (228,817)
Balance (in Shares) at Sep. 30, 2020   6,328,948 17,380,317      
Balance at Dec. 31, 2020 (2,964,935) $ 729,058 $ 4,975,503 $ 6,083,480 4,436,018 (18,220,705) (239,231)
Balance (in Shares) at Dec. 31, 2020   135 6,328,948 17,380,317      
Acquisition of Certain Assets of Halcyon Thruput, LLC 2,500,000 $ 2,500,000
Acquisition of Certain Assets of Halcyon Thruput, LLC (in Shares)   6,250,000      
Issuances of common stock units 400,000 $ 136,707 263,293
Issuances of common stock units (in Shares)   800,000      
Warrant exercises 2,967,000 $ 4,771,669 (1,804,669)
Warrant exercises (in Shares)   8,428,976      
Issuance of common shares for Convertible Promissory Note 217,769 $ 217,769
Issuance of common shares for Convertible Promissory Note (in Shares)   618,660      
Issuance of common shares for Senior Secured Promissory Note 1,942,500 $ 1,942,500
Issuance of common shares for Senior Secured Promissory Note (in Shares)   1,000,000      
Stock-based compensation 42,250 $ 42,250
Stock-based compensation (in Shares)   500,000      
Series B preferred stock dividend (20,250) (20,250)
Net loss (1,833,214) (1,836,882) 3,668
Balance at Mar. 31, 2021 3,251,120 $ 729,058 $ 4,975,503 $ 15,694,375 2,894,642 (20,077,837) (235,563)
Balance (in Shares) at Mar. 31, 2021   135 6,328,948 34,977,953      
Balance at Dec. 31, 2020 (2,964,935) $ 729,058 $ 4,975,503 $ 6,083,480 4,436,018 (18,220,705) (239,231)
Balance (in Shares) at Dec. 31, 2020   135 6,328,948 17,380,317      
Net loss (4,367,238)            
Balance at Sep. 30, 2021 893,721 $ 591,558   $ 1,111 23,776,409 (22,644,284) (239,515)
Balance (in Shares) at Sep. 30, 2021   118   111,070,329      
Balance at Mar. 31, 2021 3,251,120 $ 729,058 $ 4,975,503 $ 15,694,375 2,894,642 (20,077,837) (235,563)
Balance (in Shares) at Mar. 31, 2021   135 6,328,948 34,977,953      
Stock-based compensation 38,750 $ 38,750
Stock-based compensation (in Shares)        
Series B preferred stock redemption $ (137,500)
Series B preferred stock redemption (in Shares)   (17)          
Series B preferred stock dividend (20,250) (20,250)
Net loss (1,155,329) (1,152,514) (2,815)
Balance at Jun. 30, 2021 2,114,291 $ 591,558 $ 4,975,503 $ 15,733,125 2,894,642 (21,250,601) (238,378)
Balance (in Shares) at Jun. 30, 2021   118 6,328,948 34,977,953      
Stock-based compensation 38,750       38,750    
Series B preferred stock dividend (16,125)         (16,125)  
Common shares issued to vendor for services 117,500     $ 117,500      
Common shares issued to vendor for services (in Shares)       125,000      
Issuance of common shares for extension of secured note 18,000 $ 18,000
Issuance of common shares for extension of secured note (in Shares)   20,000      
Change in common stock par value due to change in corporate domicile       $ (15,868,273) 15,868,273    
Conversion of Series A preferred stock     $ (4,975,503) $ 759 4,974,744    
Conversion of Series A preferred stock (in Shares)     (6,328,948) 75,947,376      
Net loss (1,378,695)         (1,377,558) (1,137)
Balance at Sep. 30, 2021 $ 893,721 $ 591,558   $ 1,111 $ 23,776,409 $ (22,644,284) $ (239,515)
Balance (in Shares) at Sep. 30, 2021   118   111,070,329      
XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash Flows From Operating Activities    
Net loss $ (4,367,238) $ (1,195,973)
Loss from discontinued operations (11,349) (5,457)
Net loss from continuing operations (4,355,889) (1,190,516)
Adjustments to reconcile net loss from continuing operations to net cash from operating activities:    
Depreciation expense 1,006,804 54,961
Amortization of debt discount 380,282
Stock-based compensation 119,750
Common shares issued to vendor for services 117,500
Other income - PPP Loan forgiveness (25,424)
Loss on disposal of property and equipment 539
Change in fair value of marketable securities (11,770) 14,736
Changes in operating assets and liabilities:    
Accounts receivable (52,195)
Prepaid expenses (14,232)
Accounts payable and accrued liabilities 176,969 466,533
Net cash from operating activities – continuing operations (2,658,205) (653,747)
Net cash from operating activities – discontinued operations 31,716
Net cash from operating activities (2,658,205) (622,031)
Cash Flows From Investing Activities    
Capital expenditures (77,716)
Acquisition of certain assets of Halcyon Thruput, LLC, net of acquired cash of $224,530 (1,525,470)
Proceeds from sale of investment in common stock 34,847
Net cash from investing activities – continuing operations (1,568,339)
Net cash from investing activities – discontinued operations
Net cash from investing activities (1,568,339)
Cash Flows From Financing Activities    
Proceeds for common stock issuable 150,000
Issuance of common stock units 350,000 100,000
Redemptions of Series B preferred stock (137,500)
Series B preferred stock dividends paid (16,500)
Proceeds from warrant exercises 2,967,000
Repayment of Halcyon bank note (995,614)
Proceeds from SBA PPP Loan 25,200
Proceeds from subordinated notes 620,000 340,000
Repayment of subordinated notes (1,100,000)
Payment of mortgage payable (103,102) (11,740)
Net cash from financing activities – continuing operations 1,584,284 603,460
Net cash from financing activities – discontinued operations
Net cash from financing activities 1,584,284 603,460
Net change in cash (2,642,260) (18,571)
Cash, beginning of period 2,776,425 101,337
Cash, end of period $ 134,165 $ 82,766
XML 19 R7.htm IDEA: XBRL DOCUMENT v3.21.2
Business
9 Months Ended
Sep. 30, 2021
Business [Abstract]  
Business

1. Business

 

Generation Hemp, Inc. (the “Company”), formerly known as Home Treasure Finders, Inc. (“HTF”), was incorporated on August 21, 2021 in the State of Delaware. The Company was originally incorporated on July 28, 2008 in the State of Colorado. On November 27, 2019, HTF purchased approximately 94% of the common stock of Energy Hunter Resources, Inc. (“EHR”) in a series of transactions accounted for as a reverse merger (the “Transaction”). Upon closing of the Transaction, HTF changed its name to Generation Hemp, Inc.

 

On January 11, 2021, we completed the acquisition of certain assets of Halcyon Thruput, LLC (“Halcyon”). With this acquisition, we commenced providing post-harvest and midstream services to growers by drying, processing, cleaning and stripping harvested hemp directly from the field and wetbaled at our 48,000 square foot leased facility located in Hopkinsville, Kentucky. Additionally, the Company offers safe storage services for processed hemp, which enables farmers to maximize strategic market timing. In August 2021, the Company launched its small animal bedding consumer goods product line (“Rowdy Rooster”) made from the hemp hurd byproduct that is produced from its hemp processing operations.

 

We also generate revenue from rental of our “Cannabis Zoned” (Hemp) warehouse property located in Denver, Colorado currently leased to an unaffiliated hemp seed company.

 

As of September 30, 2021, EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.

 

Our management team has been and continues to actively review acquisition candidates involved in the hemp industry that operate within a number of vertical businesses, predominantly within the midstream sector that are attractive to us and are within the hemp supply chain.

 

Liquidity – The Company is dependent upon obtaining additional funding to continue ongoing operations and to pursue its strategy and execute its acquisition plans.

 

In the nine months ended September 30, 2021, the Company used $2.7 million of cash for its operating activities. At September 30, 2021, the Company’s current liabilities, including financing obligations due within one year, totaled $4.7 million as compared with its current assets of $276 thousand. Cash payments under several financing obligations were initially due in September and October of 2021. As disclosed in Notes 5 and 6 below, these were subsequently amended to extend these payments by one to six months.

 

The Company will continue to pursue additional capital raising opportunities in order to fund future acquisitions and meet its obligations as they become due. In the event financing cannot be obtained, the Company may not be able to satisfy these plans and obligations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Impact of COVID-19 Pandemic on Our Business – Our business, results of operations and financial condition have been adversely affected by the COVID-19 pandemic, beginning in mid-March 2020. The COVID-19 pandemic and measures taken to contain it have subjected our business, results of operations, financial condition, stock price and liquidity to a number of material risks and uncertainties, all of which may continue or may worsen.

XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

 

Basis of Presentation – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.

 

Revenue Recognition – Post-harvest and midstream services revenue is typically determined based on volumes processed at agreed-upon contractual prices and is recognized when performance obligations under the terms of a contract with our customers are satisfied. This occurs when control of the product is transferred to our customers upon completion of our processing.

 

Rental revenue is recognized based on the contractual cash rental payments for the period. Oil & gas revenue is recognized for discontinued operations based on delivered quantities in the amount of the consideration to which the Company is entitled.

 

Stock-based Compensation – We account for employee stock-based compensation using the fair value method. Compensation cost for equity incentive awards is based on the fair value of the equity instrument generally on the date of grant and is recognized over the requisite service period. Forfeitures are recognized as they occur.

 

Fair Value Measurement – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and notes payable. The fair values of these instruments approximate their carrying amounts at each reporting date.

 

The Company’s non-financial assets measured at fair value on non-recurring basis include impairment measurements of oil and gas properties and warrants issued as part of financing transactions. These are considered Level 3 measurements as they involve significant unobservable inputs.

 

Major Customer and Concentration of Credit Risk – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2021 or December 31, 2020.

 

During the three and nine months ended September 30, 2021, one customer accounted for approximately 99% and 90% of our post-harvest and midstream services revenue, respectively. Amounts outstanding from this customer represented 99% of total accounts receivable at September 30, 2021.

 

Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2021 or December 31, 2020.

 

Recent Accounting Pronouncements – In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company elected to early adopt ASU 2020-06 in 2021. Adoption of this new guidance had no impact on its financial statements at the date of adoption but is applicable to newly issued instruments.

 

There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.

XML 21 R9.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisition
9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Acquisition

3. Acquisition

 

On January 11, 2021, the Company completed the acquisition of certain assets of Halcyon pursuant to the Asset Purchase Agreement dated March 7, 2020, as amended on January 11, 2021. The purchase consideration totaled approximately $6.1 million consisting of 6,250,000 shares of Company common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year), $1.75 million in cash, a promissory note for $850,000 issued by the Company’s subsidiary, GenH Halcyon Acquisition, LLC, and guaranteed by Gary C. Evans, CEO of the Company, and assumption of approximately $1.0 million of new indebtedness of Halcyon. The Company was granted an option to purchase the real estate occupied by Halcyon for $993,000. This option is exercisable at any time before its expiration on January 11, 2022.

 

The acquisition was accounted for as a business combination where the Company is the acquirer and the acquisition method of accounting was applied in accordance with GAAP. Accordingly, the aggregate value of the consideration we paid to complete the acquisition was allocated to the assets acquired based upon their estimated fair values on the acquisition date.

 

The following table summarizes the purchase price allocation for the assets acquired. This allocation is preliminary. In the third quarter of 2021, we made adjustments to the previously recognized amounts for inventory, intangibles, goodwill and the real estate purchase option based on the preliminary results of a valuation study. The final allocation of the purchase price will be determined at a later date and is dependent on a number of factors, including the final evaluation of the fair value of tangible and identifiable intangible assets acquired. Final adjustments, including increases and decreases to depreciation and amortization resulting from the allocation of the purchase price to amortizable tangible and intangible assets, may be material.

 

Accounts receivable  $75,470 
Other working capital   224,530 
Property and equipment, other   1,712,170 
Intangibles:     
Non-competition agreements   64,691 
Customer relationships   3,102,052 
Other assets - Purchase option on real estate   407,000 
Goodwill   509,701 
Assets acquired  $6,095,614 

 

Intangible assets consist of customer relationships and non-compete agreements, each having definite-lives. These intangible assets are being amortized over the estimated useful life on an accelerated basis reflecting the anticipated future cash flows of the Company post acquisition of Halcyon.

 

The results of operations for the acquired Halcyon assets have been included in the Company’s consolidated financial statements since the January 11, 2021 acquisition date.

 

Concurrent with the closing of the asset acquisition, the Company entered into term employment agreements with two executives to serve as vice presidents of the Company for a term of at least two years. The term employment agreements each provide for the issuance of 250,000 shares of restricted common stock of the Company as a signing bonus. Such shares are subject to restrictions on the trading or transfer of such common stock.

 

Further, the term employment agreements each provide for the payment by the executives of liquidated damages if the employee terminates his employment without good reason during the initial term, other than due to the employee’s death or disability. Such liquidated damages total $600,000 if such termination occurs on or prior to January 11, 2022 or $375,000 if such termination occurs after January 11, 2022 and prior to January 11, 2023.

 

On March 3, 2021, the Company repaid the outstanding principal and interest balance on the $850,000 promissory note issued in connection with the acquisition.

 

Supplemental Pro Forma Information – The supplemental pro forma financial information presented below is for illustrative purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the acquisition of certain assets of Halcyon had been completed on the date indicated, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions that management believes are reasonable under the circumstances.

 

The supplemental pro forma financial information reflects pro forma adjustments to present the combined pro forma results of operations as if the acquisition had occurred on January 1, 2020, to give effect to certain events that management believes to be directly attributable to the acquisition. These pro forma adjustments primarily include:

 

  an increase to depreciation and amortization expense that would have been recognized due to acquired tangible and intangible assets; and

 

  an adjustment to interest expense to reflect the reduced borrowings due to the repayment of Halcyon’s historical debt in conjunction with the acquisition;

 

The supplemental pro forma financial information for the periods presented is as follows:

 

   For the three months ended September 30,   For the nine months ended September 30, 
   2021   2020   2021   2020 
Revenue, continuing operations  $502,088   $974,434   $596,291   $1,106,440 
Income (loss) from continuing operations   (1,377,065)   59,631    (4,424,786)   (1,528,788)
Earnings (loss) per common share:                    
Basic and diluted  $(0.03)  $0.00   $(0.11)  $(0.09)
XML 22 R10.htm IDEA: XBRL DOCUMENT v3.21.2
Discontinued Operations
9 Months Ended
Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Discontinued Operations

4. Discontinued Operations

 

In connection with the Transaction, management determined to fully divest of EHR’s oil and gas activities. As such, these activities are presented as discontinued operations for each of the periods presented.

 

The following is a summary of the carrying amounts of major classes of assets and liabilities of the discontinued operations to assets and liabilities held for sale:

 

   September 30,   December 31, 
   2021   2020 
Assets -        
Oil and natural gas properties held for sale, at cost  $1,874,849   $1,874,849 
Accumulated DD&A   (1,874,849)   (1,874,849)
Total assets of discontinued operations held for sale  $
-
   $
-
 
           
Liabilities          
Accrued liabilities  $32,583   $31,117 
Asset retirement obligations   52,368    56,834 
Revenue payable   52,117    52,117 
Current liabilities of discontinued operations held for sale   137,068    140,068 
           
Asset retirement obligations -          
Long-term liabilities of discontinued operations held for sale   158,498    144,149 
Total liabilities of discontinued operations held for sale  $295,566   $284,217 

 

The following is a summary of the major classes of line items constituting loss on discontinued operations shown in the consolidated statements of operations:

 

   For the three months ended September 30,   For the nine months ended September 30, 
   2021   2020   2021   2020 
Revenue -                
Oil and gas sales  $55,140   $13,036   $93,248   $93,361 
                     
Costs and Expenses                    
Lease operating expense   53,919    16,762    94,714    77,099 
Depreciation, depletion & amortization   
-
    -    
-
    9,942 
Accretion   2,851    4,263    9,883    12,868 
Gain on disposal of oil & gas property interests   
-
    -    
 
    (24,008)
Total costs and expenses   56,770    21,025    104,597    75,901 
                     
Interest expense   
-
    -    
-
    22,917 
                     
Loss from discontinued operations  $(1,630)  $(7,989)  $(11,349)  $(5,457)
XML 23 R11.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable – Related Parties
9 Months Ended
Sep. 30, 2021
Note Payable Related Party [Abstract]  
Notes Payable – Related Parties

5. Notes Payable – Related Parties

 

Notes payable – related parties consisted of the following:

 

   September 30,   December 31, 
   2021   2020 
         
Senior Secured Promissory Note  $
-
   $1,500,000 
Convertible Promissory Note   
-
    208,874 
Subordinated Promissory Note to CEO   490,000    490,000 
Convertible Promissory Note to CEO   620,000    - 
Secured Promissory Note to Coventry Asset Management, LTD.   1,000,000    1,000,000 
Subordinated Promissory Note to Investor   250,000    500,000 
           
Total   2,360,000    3,698,874 
Less debt discounts   -    (362,282)
           
Total Notes Payable – Related Parties  $2,360,000   $3,336,592 

 

Senior Secured Promissory Note – On March 9, 2021, the total principal, interest and accrued fees under the Senior Secured Promissory Note was contributed to the Company and exchanged into 1,000,000 common shares.

 

Convertible Promissory Note – On March 9, 2021, the convertible promissory note issued in October 2019, together with accrued interest thereon, was converted into 618,660 common shares under the terms of the note.

 

Subordinated Promissory Note to CEO – Our CEO made advances to the Company during 2020 under a subordinated promissory note due September 30, 2021. The note bears interest at 10% per annum. Accrued interest on this subordinated promissory note totaled $28,508 at September 30, 2021 and $22,393 at December 31, 2020. This note was amended to a new maturity date of January 31, 2022.

 

Convertible Promissory Note to CEO – In the third quarter of 2021, our CEO made advances totaling $620,000 to the Company under a convertible promissory note. The convertible note matures on January 1, 2022, bears interest at 10%. The principal and interest due on the convertible note may be converted, at the option of the holder, into restricted shares of the Company’s common stock at a conversion price equal to $0.50 per share. Accrued interest on this subordinated promissory note totaled $5,047 at September 30, 2021.

 

Secured Promissory Note and Warrants to Coventry Asset Management, LTD. – On December 30, 2020, the Company received proceeds from issuance of a secured promissory note in principal amount of $1,000,000 to Coventry Asset Management, LTD. The promissory note is secured by the property acquired in the acquisition of certain assets of Halcyon. The unpaid balance of the secured promissory note bears interest at a rate of 10% per annum and initially matured on June 30, 2021. Effective June 30, 2021, the promissory note was extended to a new maturity date of December 31, 2021. The Company agreed to issue 20,000 restricted common shares as a first extension fee, make a payment of $50,000 of accrued interest and a principal payment of $250,000 on October 1, 2021. The accrued interest and principal payment were not made but were subsequently amended. As amended in November 2021, the promissory note’s required payments and maturity date were extended to January 31, 2022. If before December 31, 2021 the Company raises new equity capital of $10 million or more, then the full amount outstanding under the promissory note is due within five days. Additionally, the holder of the promissory note was given an option exercisable in November 2021 to convert $250,000 of the outstanding principal balance into shares of the Company’s common stock at an exercise price of $0.60 per share. The Company agreed to issue 20,000 restricted common shares as a second extension fee. Accrued interest on this secured note totaled $75,069 at September 30, 2021.

 

The holder of the secured promissory note received a warrant to purchase 1,000,000 shares of common stock exercisable at an exercise price of $0.352 per share upon origination of the promissory note in 2020. This warrant was subsequently exercised in the first quarter of 2021.

 

Subordinated Promissory Note and Warrants to Investor – On December 30, 2020, the Company issued a subordinated promissory note in principal amount of $500,000 to an accredited investor. The unpaid balance of the Subordinated Note bears interest at a rate of 10% per annum. The Company made a principal payment of $250,000 in April 2021. The subordinated note principal together with accrued and unpaid interest was due September 30, 2021 but was subsequently extended. As amended, payments of $125,000 each are due on January 31, 2022 and March 31, 2022 together with accrued interest thereon. If at any time prior to the note’s maturity the Company raises new equity capital of $12.5 million or more, then the full amount outstanding under the note is due within five days. Accrued interest on this subordinated promissory note totaled $18,733 at September 30, 2021.

 

The holder of the subordinated note received a warrant to purchase 500,000 shares of common stock exercisable until December 30, 2022 at an exercise price of $0.352 per share.

XML 24 R12.htm IDEA: XBRL DOCUMENT v3.21.2
Other Indebtedness
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Other Indebtedness

6. Other Indebtedness

 

Other indebtedness consisted of the following:

 

   September 30,   December 31, 
   2021   2020 
         
Mortgage Payable  $516,359   $619,461 
Paycheck Protection Program Loan   
-
    25,200 
           
Total   516,359    644,661 
Less current portion   (516,359)   (619,461)
Total Other Indebtedness - Long-Term  $
-
   $25,200 

 

Mortgage Payable and Operating LeaseThe Company is obligated under a mortgage payable, dated September 15, 2014 and as amended October 1, 2019, secured by its warehouse property located in Denver, Colorado. The note provided for a 25-year amortization period and an initial interest rate of 9% annually. As amended, the note matured on January 15, 2021 but was extended under terms of the amendment to July 15, 2021 after payment by the Company of an extension fee of 1% of the then outstanding principal. The rate during this extension period was 11% annually.

 

In July 2021, the mortgage payable was amended to a new maturity date of October 15, 2021. The Company made a $100,000 principal payment and paid an extension fee of $6,000 in July 2021 for this amendment. The rate during the extension period was increased to 12% annually and the new monthly payment is $5,279.

 

In October 2021, the mortgage payable was amended to a new maturity date of January 15, 2022. The Company will pay an extension fee of $1,000 each month beginning November 15, 2021. The new monthly payment of the note is $5,500 including interest at an effective rate of approximately 13%.

 

The Company leases the Denver warehouse property to a tenant under an operating lease which was renewed with a new tenant and extended to August 1, 2023 for a monthly rent of $7,500. The lease requires a true-up with the tenant for property taxes and insurance paid by the Company and requires the tenant to maintain the interior and exterior of the warehouse (except for the roof). The lease provides for a rent abatement in the first and last month of the contracted extension. Minimum future rents for the remainder of 2021 are $22,500, for 2022 are $90,000 and for 2023 are $52,500.

 

Paycheck Protection Program Loan – Congress created the Paycheck Protection Program (“PPP”) under the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) to provide forgivable loans to eligible small businesses facing economic hardship to retain U.S. employees on their payroll during the Coronavirus Disease 2019 (“COVID-19”) pandemic.

 

PPP loan recipients may be eligible to have their loans forgiven if the funds were used for eligible expenses over the eight-week coverage period commencing when the loan was originally disbursed. The amount of forgiveness may be reduced if the percentage of eligible expenses attributed to nonpayroll expenses exceeds 25% of the loan, if employee headcount decreases, or compensation decreases by more than 25% for each employee making less than $100,000 per year, unless the reduced headcount or compensation levels are restored.

 

On April 29, 2020, we received disbursement of an approved PPP loan in the amount of $25,200. The Company received notice from the SBA that the PPP Loan principal and interest thereon was fully forgiven on April 20, 2021.

XML 25 R13.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies

7. Commitments and Contingencies

 

Leases – The Company assumed Halcyon’s lease of office space in Fort Worth, Texas for managerial offices. This lease requires monthly payments of $2,000 and is month-to-month. Lease expense for this facility totaled $6,000 and $16,000 in the three and nine months ended September 30, 2021, respectively.

 

The Company leases its operating facility in Kentucky from Oz Capital, LLC, a related party, under a lease expiring May 31, 2024. The lease provides for monthly payments of $10,249. Oz Capital, LLC is responsible for all taxes and maintenance under the lease. Lease expense for this facility totaled $30,747 and $88,604 in the three and nine months ended September 30, 2021, respectively. A right-of-use asset and lease liability is recorded for this lease.

 

The right-of-use asset represent the right to use the underlying asset for the lease term, and lease liabilities represent the obligation to make lease payments arising from the lease. A right-of-use asset and lease liabilities were recognized at the commencement date based on the present value of lease payments over the lease term. As the lease does not provide an implicit rate, the Company used its estimated incremental borrowing rate of 10% in determining the present value of the lease payments.

 

Pending Insurance Claim – In 2019, drying equipment that Halcyon purchased from a third party was being placed into service when a fire loss subsequently occurred and destroyed the equipment causing significant business interruption. The cost of this drying equipment totaled $1.1 million. In 2020, Halcyon received, as partial payment, insurance proceeds of $595,000 from its insurance carrier. The Company has made a formal claim against the insurance carrier and is pursuing all available options to recover the unpaid amounts.

 

Litigation – From time to time, we are subject to various litigation and other claims in the normal course of business. Below is a discussion of specific matters. We cannot predict the ultimate outcome of these matters.

 

JDONE, LLC v. Grand Traverse Holdings, LLC and John Gallegos, Denver District Court Case No. 2019CV33723

 

JDONE, LLC (“JDONE”) is a wholly owned subsidiary of the Company and landlord of a commercial warehouse building that was leased to Grand Traverse Holdings, LLC on December 31, 2018 for a term of 61 months, with a personal guaranty from Defendant, John Gallegos. On April 12, 2019, Grand Traverse presented JDONE with an alleged forged, signed copy of the draft early termination amendment that JDONE had previously rejected. JDONE has suffered damages due to Defendant’s alleged misconduct of approximately $823,504 plus interest and attorney’s fees exceeding $300,000. A court ordered mediation was held in May 2020 without success. All material defendant motions have been denied by the court. The case is set for jury trial in January 2022. We believe that Grand Traverse Holdings, LLC and John Gallegos are jointly liable for the asserted damages which exceed $1 million and continue to vigorously pursue our claims.

 

KBSIII Tower at Lake Carolyn, LLC and Prime US-Tower at Lake Carolyn, LLC (collectively – “KBSIII”) vs. Energy Hunter Resources, Inc.

 

Plaintiff/Counterdefendant KBSIII was seeking lost rent on office space for periods after EHR vacated office premises located in Las Colinas, Texas. EHR filed a counter suit alleging specific damages due to uninhabitable premises of the office space due to the intolerable conduct of other tenants located on the same floor. On December 23, 2020, the trial court entered a summary judgment against EHR for $230,712. The judgment provides for post-judgment interest at a rate of 5% per annum until paid and further provides for additional amounts owed should EHR pursue unsuccessful appeals to higher courts. At September 30, 2021, the Company had accrued $252,583 for this judgment, which is exclusively an EHR obligation.

XML 26 R14.htm IDEA: XBRL DOCUMENT v3.21.2
Equity
9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Equity

8. Equity

 

Change of Corporate Domicile – On August 21, 2021, the Company changed its domicile from the State of Colorado to the State of Delaware. The change of domicile had no effect on the number of outstanding securities of the Company. The Company is authorized for 200 million shares of capital stock, par value $0.00001 per share and 20 million shares of preferred stock, par value $0.00001 per share.

 

Series A Preferred Stock – On September 8, 2021, holders of the Company’s Series A Preferred Stock elected to convert such shares into shares of the Company’s common stock. As a result, 6,328,948 shares of Series A Preferred Stock were converted into 75,947,376 shares of common stock, with each share of Series A Preferred Stock converting into 12 shares of restricted common stock pursuant to the applicable Certificate of Designations. The Series A Preferred Stock was originally issued in connection with the Company’s merger transaction completed in December 2019.

 

Series B Preferred Stock Units – On December 30, 2020, the Company sold to certain accredited investors, including Gary C. Evans, our Chief Executive Officer, an aggregate of 135 preferred stock units comprised of (i) one share of Series B Redeemable Convertible Preferred Stock, no par value, and (ii) one warrant exercisable for 50,000 shares of common stock of the Company until December 30, 2022 at an exercise price of $0.352 per share.

 

The sale of the preferred stock units for $10,000 each resulted in aggregate gross proceeds of approximately $1.35 million, before deducting estimated offering expenses payable by the Company. Substantially all of the proceeds raised in the offering were used to fund the acquisition of assets of Halcyon, expenses related thereto and for general corporate purposes.

 

Each share of Series B Preferred Stock is initially convertible into 25,000 shares of common stock, subject to adjustment. Holders of Series B Preferred Stock are entitled to receive dividends of 6.00% per annum based on the stated value equal to $10,000 per share. Except as otherwise required by law, the Series B Preferred Stock does not have voting rights. However, as long as any shares of Series B Preferred Stock are outstanding, the Company will not, without the affirmative vote of the holders of a majority of the then outstanding shares of the Series B Preferred Stock, (a) alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock, (b) alter or amend the related certificate of designation, (c) amend its certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock, (d) repay, repurchase or offer to repay, repurchase or otherwise acquire more than a de minimis number of shares of its common stock, (e) enter into any agreement with respect to any of the foregoing, or (f) pay cash dividends or distributions on any equity securities of the Company other than pursuant to the terms of the outstanding Series B Preferred Stock. The Series B Preferred Stock does not have a preference upon any liquidation, dissolution or winding-up of the Company.

 

Beginning the later of June 30, 2021 or the effectiveness of any registration statement registering the underlying common shares, all or any portion of the Series B Preferred Stock may be converted, at their holder’s option, into 25,000 shares of common stock, as adjusted for any stock dividends, splits, combinations or similar events.

 

At any time after the occurrence of a “Qualifying Event,” the Company, upon 5-day written notice, shall have the right to cause each share of Series B Preferred Stock (and all accrued in-kind dividends with respect thereto) to be converted into common stock. For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00. In each instance, a conversion may not be made unless the Company has filed an amendment to its Articles of Incorporation effecting an increase in its authorized common stock so that the Company has a sufficient number of authorized and unissued shares of common stock so as to permit the conversion of all outstanding shares.

 

The Series B Preferred Stock may be redeemed by the Company for its stated value, plus accrued and unpaid dividends, at any time. Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021.

 

In May, June and October of 2021, the three holders of the Series B Preferred Stock, including the Company’s chief executive officer, entered into transactions in which they accepted the mandatory redemption payment required pursuant to the Series B Preferred Stock certificate of designation in a number of Series B Units to effectively waive the redemption requirement. All other terms of the Series B Units remain unchanged and the holders’ ownership interest in the Series B Preferred Units remains the same as it was before such transactions.

 

Common Stock – At September 30, 2021, the Company had 111,070,329 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:

 

  February 2020 Issuance of Common Stock Units – In February 2020, the Company issued 250,000 common units for $100,000. Each unit consisted of one share of common stock and a warrant for purchase of one common share for $0.40 per share. The warrant expires March 1, 2022 and contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price. Proceeds of this issuance were used for general corporate purposes.

 

The common stock issued in the exchange was valued using the trading price of the common stock on February 20, 2020. The warrants were valued at $45,848 using a binomial lattice valuation model using inputs as of the exchange date. Our expected volatility assumption was based on the historical volatility of the Company’s common stock (252%). The expected life assumption was based on the expiration date of the warrant (two years). The risk-free interest rate for the expected term of the warrant was based on the U.S. Treasury yield curve in effect at the time of measurement (1.39%). The warrants are classified within equity in the consolidated balance sheets. Under GAAP, the anti-dilution provisions will be accounted for if and when these provisions are triggered.

 

  Acquisition of Certain Assets of Halcyon – the Company issued 6,250,000 shares of common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year) in the acquisition. Refer to Note 3.

 

  2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.  

 

  Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants.

 

  Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt. Refer to Note 5.

 

  Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.

 

  Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021. Refer to Note 5.

 

  Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.

 

  Stock-based Compensation – The Company issued 500,000 restricted common shares as incentive compensation to two executives who joined the Company in the first quarter of 2021.

 

Common Stock Warrants Outstanding – Following is a summary of warrants outstanding:

 

   # of Warrants   Exercise Price
(each)
   Expiration Date  Method of Exercise
               

Issued upon exchange of EHR Series C Preferred Stock (1)

   1,065,340   $0.352   November 27, 2021  Cash
Issued upon exchange of EHR Series C Preferred Stock (1)   7,244,316   $0.352   November 27, 2021  Cashless
Issued in February 2020 with common stock units (2)   250,000   $0.400   March 1, 2022  Cash
Issued in December 2020 with Series B preferred units (1)   5,500,000   $0.352   December 30, 2022  Cash
Issued in December 2020 with subordinated note to investor (1)   500,000   $0.352   December 30, 2022  Cash
Issued in Q1 2021 with common stock units (1)   1,600,000   $0.500   Jan-Feb, 2023  Cash
Total warrants outstanding at September 30, 2021   16,159,656            

 

(1) May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.

 

(2) Contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price.

 

Following is a summary of outstanding stock warrants activity for the periods presented:

 

Warrants as of January 1, 2020   14,488,632 
Issued   250,000 
Warrants as of September 30, 2020   14,738,632 
      
Warrants as of January 1, 2021   22,988,632 
Issued   1,600,000 
Exercised   (8,428,976)
Warrants as of September 30, 2021   16,159,656 
XML 27 R15.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation
9 Months Ended
Sep. 30, 2021
Share-based Payment Arrangement [Abstract]  
Stock-Based Compensation

9. Stock-Based Compensation

 

We award restricted stock or stock options as incentive compensation to employees. Generally, these awards include vesting periods of up to three years from the date of grant.

 

The 2021 Omnibus Incentive Plan (“2021 Plan”) was adopted by our Board on July 1, 2021. The 2021 Plan provides for the initial reservation of 15 million shares of common stock for issuance, and provides that the maximum number of shares that may be issued pursuant to the exercise of ISOs is 15 million. The number of shares of common stock available for issuance under the 2021 Plan constituted approximately 13.1% of the Company’s fully diluted common shares outstanding as of the date of Board approval, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis. On the one-year anniversary date of the 2021 Plan, the number of shares of common stock reserved for issuance thereunder shall automatically increase to 20% of the fully diluted common shares outstanding, including shares issuable upon the conversion of preferred shares, as calculated on an as-converted basis.

 

In the first quarter of 2021, the Company issued 500,000 restricted shares valued at $158,500 as incentive compensation to two executives who joined the Company. Compensation expense related to these awards totaled $38,750 and $119,750 for the three and nine months ended September 30, 2021, respectively. As of September 30, 2021, there was $38,750 of total unrecognized compensation cost related to unvested awards to be recognized over a weighted-average period of three months.

 

On April 6, 2021, the Company announced that Chad Burkhardt has joined the Company as its Vice President and General Counsel, effective April 1, 2021. In addition to his annual salary, the Company agreed to make a future grant to Mr. Burkhardt of $750,000 worth of options for the purchase of our common stock at an exercise price equal to the fair market value of the Company’s common stock on the date of grant. Such options will vest annually in equal installments over a three-year period from his date of hire.

XML 28 R16.htm IDEA: XBRL DOCUMENT v3.21.2
Income Taxes
9 Months Ended
Sep. 30, 2021
Income Taxes [Abstract]  
Income Taxes

10. Income Taxes

 

Income tax provisions for interim quarterly periods are generally based on an estimated annual effective income tax rate calculated separately from the effect of significant, infrequent or unusual items related specifically to interim periods. An income tax benefit for the three and nine months ended September 30, 2021 or 2020 was not recognized because tax losses incurred were fully offset by a valuation allowance against deferred tax assets. There were no uncertain tax positions as of September 30, 2021.

XML 29 R17.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental Cash Flow Information
9 Months Ended
Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]  
Supplemental Cash Flow Information

11. Supplemental Cash Flow Information

 

   For the nine months ended
September 30,
 
   2021   2020 
         
Cash paid for interest  $127,812   $
-
 
Cash paid for taxes   
            -
    
                 -
 
           
Noncash investing and financing activities:          
Acquisition of certain assets of Halcyon Thruput, LLC          
- issuance of common shares   2,500,000    
-
 
- issuance of subordinated note   850,000    
-
 
- assumption of Halcyon bank note   995,614    
-
 
Series B preferred stock dividend payable   39,137    
-
 
Issuance of common stock units previously subscribed   50,000    
-
 
Issuances of common shares for exchange or conversion of debt   2,160,269    
-
 
XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Loss) Per Share
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Earnings (Loss) per Share

12. Earnings (Loss) per Share

 

The following is the computation of earnings (loss) per basic and diluted share:

 

   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2021   2020   2021   2020 
Amounts attributable to Generation Hemp:                
Numerator                
Loss from continuing operations attributable to common stockholders  $(1,376,030)  $(171,367)  $(4,356,315)  $(1,146,592)
Loss from discontinued operations   (1,528)   (7,489)   (10,639)   (5,115)
Less: preferred stock dividends   (16,125)   
-
    (56,625)   
-
 
Net loss attributable to common stockholders  $(1,393,683)  $(178,856)  $(4,423,579)  $(1,151,707)
                     
Denominator                    
Weighted average shares used to compute basic EPS   54,109,797    17,380,317    38,693,679    17,500,308 
Dilutive effect of convertible note   
-
    
-
    
-
    
-
 
Dilutive effect of preferred stock   59,913,657    75,947,376    72,641,084    75,947,376 
Dilutive effect of common stock warrants   9,042,419    
-
    11,126,327    
-
 
Weighted average shares used to compute diluted EPS   123,065,873    93,327,693    122,461,090    93,447,684 
                     
Earnings (loss) per share:                
Loss from continuing operations                
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)
(Loss) income from discontinued operations                    
Basic  $
-
   $
-
   $
-
   $
-
 
Diluted  $
-
   $
-
   $
-
   $
-
 
Earnings (loss) per share                    
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)

 

The computation of diluted earnings per common share excludes the assumed conversion of the Series B Preferred Stock and outstanding convertible notes and exercise of common stock warrants in periods when we report a loss. The dilutive effect of the assumed exercise of outstanding warrants was calculated using the treasury stock method.

XML 31 R19.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events
9 Months Ended
Sep. 30, 2021
Subsequent Events [Abstract]  
Subsequent Events

13. Subsequent Events

 

In October 2021, the Company issued 416,667 common stock units to an accredited investor for total proceeds of $250,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of one share of common stock for $0.60 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance.

 

As disclosed in Note 5 above, (i) we amended the subordinated note to our CEO in the amount of $490,000 to a new maturity date of January 31, 2022, (ii) we amended the secured promissory note to Coventry Asset Management, LTD. to a new maturity date of January 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed and granted the holder a limited option to convert part of the principal to common stock and (iii) we amended the subordinated promissory note with an investor to a new maturity date of March 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed.

 

In October 2021, our CEO made advances totaling $15,000 to the Company. The existing convertible promissory note was amended and restated to a new balance of $635,000. The interest rate of 10% per annum and maturity date of January 1, 2022 were unchanged.

 

As disclosed in Note 6 above, the mortgage payable was amended to a new maturity date of January 15, 2022.

XML 32 R20.htm IDEA: XBRL DOCUMENT v3.21.2
Accounting Policies, by Policy (Policies)
9 Months Ended
Sep. 30, 2021
Accounting Policies [Abstract]  
Basis of Presentation

Basis of Presentation – These interim financial statements are unaudited and have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain disclosures have been condensed or omitted from these financial statements. Accordingly, they do not include all the information and notes required by accounting principles generally accepted in the United States of America (“GAAP”) for complete consolidated financial statements, and should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.

 

In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary to fairly present the financial position as of, and the results of operations for, all periods presented. In preparing the accompanying financial statements, management has made certain estimates and assumptions that affect reported amounts in the condensed consolidated financial statements and disclosures of contingencies. Actual results may differ from those estimates. The results for interim periods are not necessarily indicative of annual results. Certain reclassifications have been made to the prior period’s consolidated financial statements and related footnotes to conform them to the current period presentation. Intercompany balances and transactions between consolidated entities are eliminated.

 

Revenue Recognition

Revenue Recognition – Post-harvest and midstream services revenue is typically determined based on volumes processed at agreed-upon contractual prices and is recognized when performance obligations under the terms of a contract with our customers are satisfied. This occurs when control of the product is transferred to our customers upon completion of our processing.

 

Rental revenue is recognized based on the contractual cash rental payments for the period. Oil & gas revenue is recognized for discontinued operations based on delivered quantities in the amount of the consideration to which the Company is entitled.

 

Stock-based Compensation

Stock-based Compensation – We account for employee stock-based compensation using the fair value method. Compensation cost for equity incentive awards is based on the fair value of the equity instrument generally on the date of grant and is recognized over the requisite service period. Forfeitures are recognized as they occur.

 

Fair Value Measurement

Fair Value Measurement – Our financial assets and liabilities consist of cash, accounts receivable, accounts payable and notes payable. The fair values of these instruments approximate their carrying amounts at each reporting date.

 

The Company’s non-financial assets measured at fair value on non-recurring basis include impairment measurements of oil and gas properties and warrants issued as part of financing transactions. These are considered Level 3 measurements as they involve significant unobservable inputs.

 

Major Customer and Concentration of Credit Risk

Major Customer and Concentration of Credit Risk – We estimate an allowance for doubtful accounts based on an analysis of specific customers, taking into consideration the age of past due accounts and an assessment of the customer’s ability to pay. An allowance for doubtful accounts was not needed as of September 30, 2021 or December 31, 2020.

 

During the three and nine months ended September 30, 2021, one customer accounted for approximately 99% and 90% of our post-harvest and midstream services revenue, respectively. Amounts outstanding from this customer represented 99% of total accounts receivable at September 30, 2021.

 

Our rental revenue is derived from a single lessee on a commercial warehouse owned by the Company. There were no amounts due from this customer at September 30, 2021 or December 31, 2020.

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements – In August 2020, the Financial Accounting Standards Board issued Accounting Standards Update (“ASU”) No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. ASU 2020-06 simplifies the accounting for convertible instruments by reducing the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models results in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. ASU 2020-06 also amends the guidance for the derivatives scope exception for contracts in an entity’s own equity to reduce form-over-substance-based accounting conclusions. The Company elected to early adopt ASU 2020-06 in 2021. Adoption of this new guidance had no impact on its financial statements at the date of adoption but is applicable to newly issued instruments.

 

There are no other new accounting pronouncements that are expected to have a material impact on the consolidated financial statements.

XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisition (Tables)
9 Months Ended
Sep. 30, 2021
Business Combinations [Abstract]  
Schedule of amortizable tangible and intangible assets
Accounts receivable  $75,470 
Other working capital   224,530 
Property and equipment, other   1,712,170 
Intangibles:     
Non-competition agreements   64,691 
Customer relationships   3,102,052 
Other assets - Purchase option on real estate   407,000 
Goodwill   509,701 
Assets acquired  $6,095,614 

 

Schedule of pro forma consolidated results of operations
   For the three months ended September 30,   For the nine months ended September 30, 
   2021   2020   2021   2020 
Revenue, continuing operations  $502,088   $974,434   $596,291   $1,106,440 
Income (loss) from continuing operations   (1,377,065)   59,631    (4,424,786)   (1,528,788)
Earnings (loss) per common share:                    
Basic and diluted  $(0.03)  $0.00   $(0.11)  $(0.09)
XML 34 R22.htm IDEA: XBRL DOCUMENT v3.21.2
Discontinued Operations (Tables)
9 Months Ended
Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of discontinued operations to assets and liabilities
   September 30,   December 31, 
   2021   2020 
Assets -        
Oil and natural gas properties held for sale, at cost  $1,874,849   $1,874,849 
Accumulated DD&A   (1,874,849)   (1,874,849)
Total assets of discontinued operations held for sale  $
-
   $
-
 
           
Liabilities          
Accrued liabilities  $32,583   $31,117 
Asset retirement obligations   52,368    56,834 
Revenue payable   52,117    52,117 
Current liabilities of discontinued operations held for sale   137,068    140,068 
           
Asset retirement obligations -          
Long-term liabilities of discontinued operations held for sale   158,498    144,149 
Total liabilities of discontinued operations held for sale  $295,566   $284,217 

 

Schedule of discontinued operations shown in the consolidated statements of operations
   For the three months ended September 30,   For the nine months ended September 30, 
   2021   2020   2021   2020 
Revenue -                
Oil and gas sales  $55,140   $13,036   $93,248   $93,361 
                     
Costs and Expenses                    
Lease operating expense   53,919    16,762    94,714    77,099 
Depreciation, depletion & amortization   
-
    -    
-
    9,942 
Accretion   2,851    4,263    9,883    12,868 
Gain on disposal of oil & gas property interests   
-
    -    
 
    (24,008)
Total costs and expenses   56,770    21,025    104,597    75,901 
                     
Interest expense   
-
    -    
-
    22,917 
                     
Loss from discontinued operations  $(1,630)  $(7,989)  $(11,349)  $(5,457)
XML 35 R23.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable – Related Parties (Tables)
9 Months Ended
Sep. 30, 2021
Note Payable Related Party [Abstract]  
Schedule of notes payable related parties
   September 30,   December 31, 
   2021   2020 
         
Senior Secured Promissory Note  $
-
   $1,500,000 
Convertible Promissory Note   
-
    208,874 
Subordinated Promissory Note to CEO   490,000    490,000 
Convertible Promissory Note to CEO   620,000    - 
Secured Promissory Note to Coventry Asset Management, LTD.   1,000,000    1,000,000 
Subordinated Promissory Note to Investor   250,000    500,000 
           
Total   2,360,000    3,698,874 
Less debt discounts   -    (362,282)
           
Total Notes Payable – Related Parties  $2,360,000   $3,336,592 

 

XML 36 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Other Indebtedness (Tables)
9 Months Ended
Sep. 30, 2021
Debt Disclosure [Abstract]  
Schedule of other indebtedness
   September 30,   December 31, 
   2021   2020 
         
Mortgage Payable  $516,359   $619,461 
Paycheck Protection Program Loan   
-
    25,200 
           
Total   516,359    644,661 
Less current portion   (516,359)   (619,461)
Total Other Indebtedness - Long-Term  $
-
   $25,200 

 

XML 37 R25.htm IDEA: XBRL DOCUMENT v3.21.2
Equity (Tables)
9 Months Ended
Sep. 30, 2021
Stockholders' Equity Note [Abstract]  
Schedule of warrants outstanding
   # of Warrants   Exercise Price
(each)
   Expiration Date  Method of Exercise
               

Issued upon exchange of EHR Series C Preferred Stock (1)

   1,065,340   $0.352   November 27, 2021  Cash
Issued upon exchange of EHR Series C Preferred Stock (1)   7,244,316   $0.352   November 27, 2021  Cashless
Issued in February 2020 with common stock units (2)   250,000   $0.400   March 1, 2022  Cash
Issued in December 2020 with Series B preferred units (1)   5,500,000   $0.352   December 30, 2022  Cash
Issued in December 2020 with subordinated note to investor (1)   500,000   $0.352   December 30, 2022  Cash
Issued in Q1 2021 with common stock units (1)   1,600,000   $0.500   Jan-Feb, 2023  Cash
Total warrants outstanding at September 30, 2021   16,159,656            

 

Schedule of outstanding stock warrants activity
Warrants as of January 1, 2020   14,488,632 
Issued   250,000 
Warrants as of September 30, 2020   14,738,632 
      
Warrants as of January 1, 2021   22,988,632 
Issued   1,600,000 
Exercised   (8,428,976)
Warrants as of September 30, 2021   16,159,656 
XML 38 R26.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental Cash Flow Information (Tables)
9 Months Ended
Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]  
Schedule of supplemental cash flow information
   For the nine months ended
September 30,
 
   2021   2020 
         
Cash paid for interest  $127,812   $
-
 
Cash paid for taxes   
            -
    
                 -
 
           
Noncash investing and financing activities:          
Acquisition of certain assets of Halcyon Thruput, LLC          
- issuance of common shares   2,500,000    
-
 
- issuance of subordinated note   850,000    
-
 
- assumption of Halcyon bank note   995,614    
-
 
Series B preferred stock dividend payable   39,137    
-
 
Issuance of common stock units previously subscribed   50,000    
-
 
Issuances of common shares for exchange or conversion of debt   2,160,269    
-
 
XML 39 R27.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Loss) Per Share (Tables)
9 Months Ended
Sep. 30, 2021
Earnings Per Share [Abstract]  
Schedule of earnings (loss) per basic and diluted share
   For the three months ended
September 30,
   For the nine months ended
September 30,
 
   2021   2020   2021   2020 
Amounts attributable to Generation Hemp:                
Numerator                
Loss from continuing operations attributable to common stockholders  $(1,376,030)  $(171,367)  $(4,356,315)  $(1,146,592)
Loss from discontinued operations   (1,528)   (7,489)   (10,639)   (5,115)
Less: preferred stock dividends   (16,125)   
-
    (56,625)   
-
 
Net loss attributable to common stockholders  $(1,393,683)  $(178,856)  $(4,423,579)  $(1,151,707)
                     
Denominator                    
Weighted average shares used to compute basic EPS   54,109,797    17,380,317    38,693,679    17,500,308 
Dilutive effect of convertible note   
-
    
-
    
-
    
-
 
Dilutive effect of preferred stock   59,913,657    75,947,376    72,641,084    75,947,376 
Dilutive effect of common stock warrants   9,042,419    
-
    11,126,327    
-
 
Weighted average shares used to compute diluted EPS   123,065,873    93,327,693    122,461,090    93,447,684 
                     
Earnings (loss) per share:                
Loss from continuing operations                
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)
(Loss) income from discontinued operations                    
Basic  $
-
   $
-
   $
-
   $
-
 
Diluted  $
-
   $
-
   $
-
   $
-
 
Earnings (loss) per share                    
Basic  $(0.03)  $(0.01)  $(0.11)  $(0.07)
Diluted  $(0.03)  $(0.01)  $(0.11)  $(0.07)

 

XML 40 R28.htm IDEA: XBRL DOCUMENT v3.21.2
Business (Details)
$ in Thousands
1 Months Ended 9 Months Ended
Jan. 11, 2021
$ / ft²
Nov. 27, 2019
Sep. 30, 2021
USD ($)
Accounting Policies [Abstract]      
Owns approximately percentage   94.00%  
Square Foot Facility (in Dollars per Square Foot) | $ / ft² 48,000    
Description of business, description     EHR held an approximate 8% working interest in an oil & gas property located in Cochran County, Texas within the Slaughter-Levelland Field of the San Andres formation in the Northwest Shelf of West Texas. EHR’s oil & gas activities are currently held for sale and are presented in these consolidated financial statements as discontinued operations for each of the periods presented.
Cash for operating activities     $ 2,700
Financing obligations     4,700
Current Assets     $ 276
XML 41 R29.htm IDEA: XBRL DOCUMENT v3.21.2
Summary of Significant Accounting Policies (Details)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2021
One Customer [Member]    
Summary of Significant Accounting Policies (Details) [Line Items]    
Service revenue percentage 99.00% 90.00%
XML 42 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisition (Details) - USD ($)
9 Months Ended
Jan. 11, 2021
Sep. 30, 2021
Mar. 03, 2021
Dec. 31, 2020
Acquisition (Details) [Line Items]        
Company common stock (in Shares)   111,070,329   17,380,317
Per share value (in Dollars per share)   $ 0.00001    
Promissory note     $ 850,000  
Issuance of restricted common stock (in Shares) 250,000      
Employee terminates, description   the employee terminates his employment without good reason during the initial term, other than due to the employee’s death or disability. Such liquidated damages total $600,000 if such termination occurs on or prior to January 11, 2022 or $375,000 if such termination occurs after January 11, 2022 and prior to January 11, 2023.    
Halcyon [Member]        
Acquisition (Details) [Line Items]        
Consideration value $ 6,100,000      
Company common stock (in Shares) 6,250,000      
Common stock, value $ 2,500,000      
Per share value (in Dollars per share) $ 0.4      
Cash $ 1,750,000      
Promissory note $ 850,000      
Real estate occupied, description the Company, and assumption of approximately $1.0 million of new indebtedness of Halcyon. The Company was granted an option to purchase the real estate occupied by Halcyon for $993,000. This option is exercisable at any time before its expiration on January 11, 2022.      
XML 43 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisition (Details) - Schedule of amortizable tangible and intangible assets - Acquisitions [Member]
Sep. 30, 2021
USD ($)
Indefinite-lived Intangible Assets [Line Items]  
Accounts receivable $ 75,470
Other working capital 224,530
Property and equipment, other 1,712,170
Intangibles:  
Non-competition agreements 64,691
Customer relationships 3,102,052
Other assets - Purchase option on real estate 407,000
Goodwill 509,701
Assets acquired $ 6,095,614
XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Acquisition (Details) - Schedule of pro forma consolidated results of operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Schedule of pro forma consolidated results of operations [Abstract]        
Revenue, continuing operations $ 502,088 $ 974,434 $ 596,291 $ 1,106,440
Income (loss) from continuing operations $ (1,377,065) $ 59,631 $ (4,424,786) $ (1,528,788)
Earnings (loss) per common share:        
Basic and diluted (in Dollars per share) $ (0.03) $ 0 $ (0.11) $ (0.09)
XML 45 R33.htm IDEA: XBRL DOCUMENT v3.21.2
Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Schedule of discontinued operations to assets and liabilities [Abstract]    
Oil and natural gas properties held for sale, at cost $ 1,874,849 $ 1,874,849
Accumulated DD&A (1,874,849) (1,874,849)
Total assets of discontinued operations held for sale
Accrued liabilities 32,583 31,117
Asset retirement obligations 52,368 56,834
Revenue payable 52,117 52,117
Current liabilities of discontinued operations held for sale 137,068 140,068
Asset retirement obligations -    
Long-term liabilities of discontinued operations held for sale 158,498 144,149
Total liabilities of discontinued operations held for sale $ 295,566 $ 284,217
XML 46 R34.htm IDEA: XBRL DOCUMENT v3.21.2
Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue -        
Oil and gas sales $ 55,140 $ 13,036 $ 93,248 $ 93,361
Costs and Expenses        
Lease operating expense 53,919 16,762 94,714 77,099
Depreciation, depletion & amortization   9,942
Accretion 2,851 4,263 9,883 12,868
Gain on disposal of oil & gas property interests   (24,008)
Total costs and expenses 56,770 21,025 104,597 75,901
Interest expense   22,917
Loss from discontinued operations $ (1,630) $ (7,989) $ (11,349) $ (5,457)
XML 47 R35.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable – Related Parties (Details) - USD ($)
1 Months Ended 9 Months Ended
Nov. 30, 2021
Oct. 31, 2021
Jun. 30, 2021
Mar. 09, 2021
Dec. 30, 2020
Sep. 30, 2021
Dec. 30, 2022
Oct. 01, 2021
Apr. 30, 2021
Dec. 31, 2020
Notes Payable – Related Parties (Details) [Line Items]                    
Exchange of common shares (in Shares)       1,000,000            
Converted into common shares (in Shares)       618,660            
Subordinated Promissory note due date           Sep. 30, 2021        
Interest rate           10.00%        
Accrued interest           $ 28,508        
Accrued interest           5,047       $ 22,393
Convertible debt           $ 620,000        
Bears interest           10.00%        
Conversion price (in Dollars per share)           $ 0.5        
New equity capital           $ 10,000,000        
Exercise price per share (in Dollars per share)           $ 0.6        
Restricted common shares (in Shares)           20,000        
Warrant to purchase of common stock (in Shares)           1,000,000        
Exercise price (in Dollars per share)           $ 0.352        
Amended, payments           $ 125,000        
Maturity date           due on January 31, 2022 and March 31, 2022        
Equity capital amount           $ 12.5        
Accrued interest           $ 18,733        
Subsequent Event [Member]                    
Notes Payable – Related Parties (Details) [Line Items]                    
Accrued interest               $ 250,000    
Extension fee (in Shares)               20,000    
Accrued interest   $ 50,000                
Option exercisable $250,000                  
Exercise price per share (in Dollars per share)             $ 0.352      
Warrant to purchase of common stock (in Shares)             500,000      
Subordinated Promissory Note [Member]                    
Notes Payable – Related Parties (Details) [Line Items]                    
Interest rate         10.00%          
Principal amount                 $ 250,000  
Accrued and unpaid interest due date           Sep. 30, 2021        
Conventry Asset Management, LTD. [Member]                    
Notes Payable – Related Parties (Details) [Line Items]                    
Interest rate     10.00%              
Principal amount         $ 1,000,000 $ 75,069        
Accredited Investor [Member]                    
Notes Payable – Related Parties (Details) [Line Items]                    
Principal amount         $ 500,000          
XML 48 R36.htm IDEA: XBRL DOCUMENT v3.21.2
Notes Payable – Related Parties (Details) - Schedule of notes payable related parties - USD ($)
9 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Notes Payable – Related Parties (Details) - Schedule of notes payable related parties [Line Items]    
Total $ 2,360,000 $ 3,698,874
Less debt discounts   (362,282)
Total Notes Payable – Related Parties 2,360,000 3,336,592
Convertible Promissory Note to CEO 620,000  
Senior Secured Promissory Note [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable related parties [Line Items]    
Total 1,500,000
Convertible Promissory Note [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable related parties [Line Items]    
Total 208,874
Subordinated Promissory Note to CEO [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable related parties [Line Items]    
Total 490,000 490,000
Secured Promissory Note to Coventry Asset Management, LTD. [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable related parties [Line Items]    
Total 1,000,000 1,000,000
Subordinated Promissory Note to Investor [Member]    
Notes Payable – Related Parties (Details) - Schedule of notes payable related parties [Line Items]    
Total $ 250,000 $ 500,000
XML 49 R37.htm IDEA: XBRL DOCUMENT v3.21.2
Other Indebtedness (Details) - USD ($)
9 Months Ended 12 Months Ended
Aug. 01, 2023
Nov. 15, 2021
Oct. 31, 2021
Sep. 30, 2021
Dec. 31, 2023
Dec. 31, 2022
Dec. 21, 2021
Apr. 29, 2020
Other Indebtedness (Details) [Line Items]                
Mortgage payable, description       The Company is obligated under a mortgage payable, dated September 15, 2014 and as amended October 1, 2019, secured by its warehouse property located in Denver, Colorado. The note provided for a 25-year amortization period and an initial interest rate of 9% annually. As amended, the note matured on January 15, 2021 but was extended under terms of the amendment to July 15, 2021 after payment by the Company of an extension fee of 1% of the then outstanding principal. The rate during this extension period was 11% annually.In July 2021, the mortgage payable was amended to a new maturity date of October 15, 2021. The Company made a $100,000 principal payment and paid an extension fee of $6,000 in July 2021 for this amendment. The rate during the extension period was increased to 12% annually and the new monthly payment is $5,279.         
Maturity date     Jan. 15, 2022          
Extension fee   $ 1,000            
Interest expenses       $ 5,500        
Interest rate       13.00%        
Nonpayroll expenses       25.00%        
Compensation decreases percentage       25.00%        
Compensation levels amount       $ 100,000        
PPP loan amount               $ 25,200
Forecast [Member]                
Other Indebtedness (Details) [Line Items]                
Lease and rental expense $ 7,500              
Minimum future rents             $ 22,500  
Minimum future rents twelve months           $ 90,000    
Minimum future rents two years         $ 52,500      
XML 50 R38.htm IDEA: XBRL DOCUMENT v3.21.2
Other Indebtedness (Details) - Schedule of other indebtedness - USD ($)
9 Months Ended 12 Months Ended
Sep. 30, 2021
Dec. 31, 2020
Schedule of other indebtedness [Abstract]    
Mortgage Payable $ 516,359 $ 619,461
Paycheck Protection Program Loan 25,200
Total 516,359 644,661
Less current portion (516,359) (619,461)
Total Other Indebtedness - Long-Term $ 25,200
XML 51 R39.htm IDEA: XBRL DOCUMENT v3.21.2
Commitments and Contingencies (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 12, 2019
Dec. 23, 2020
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Commitments and Contingencies (Details) [Line Items]              
Lease monthly payments       $ 2,000      
Lease expense     $ 6,000 $ 16,000      
Incremental borrowing rate       10.00%      
Cost of drying equipment total           $ 1,100,000  
Insurance proceeds         $ 595,000    
Fees Exceeding $ 300,000            
Amount of summary judgment   $ 230,712          
Litigation settlement interest percentage   5.00%          
Legal fees       $ 252,583      
Oz Capital, LLC [Member]              
Commitments and Contingencies (Details) [Line Items]              
Lease monthly payments       10,249      
Lease expense     $ 30,747 $ 88,604      
Lease expiration date       May 31, 2024      
Grand Traverse Holdings, LLC [Member]              
Commitments and Contingencies (Details) [Line Items]              
Lease term             61 months
Interest and attorney fees 823,504            
Grand Traverse Holdings, LLC [Member] | John Gallegos [Member]              
Commitments and Contingencies (Details) [Line Items]              
Liable for the asserted damages $ 1,000,000            
XML 52 R40.htm IDEA: XBRL DOCUMENT v3.21.2
Equity (Details)
9 Months Ended
Sep. 30, 2021
USD ($)
$ / shares
shares
Equity (Details) [Line Items]  
Preferred stock description The Company is authorized for 200 million shares of capital stock, par value $0.00001 per share and 20 million shares of preferred stock, par value $0.00001 per share.
Exercisable warrants common stock shares (in Dollars per share) | $ / shares $ 0.352
Sale of preferred stock units (in Dollars) | $ $ 10,000
Aggregate gross proceeds (in Dollars) | $ $ 1,350,000
Common stock shares Issued 25,000
Equity description For purposes of this automatic conversion of the Series B Preferred Stock, a “Qualifying Event” shall have occurred if (A) (1) the rolling five-trading day volume-weighted average trading price of shares of the common stock exceeds $1.00, and (2) there shall be an effective registration statement under the Securities Act of 1933, as amended covering all of the shares of common stock which would be issuable upon conversion of all of the outstanding shares of Series B Preferred Stock or (B) the Company closes a firm commitment underwriting of the common stock on a Form S-1 Registration Statement with aggregate gross proceeds of at least $5,000,000 at a price per share equal to or greater than $1.00.
Warrant per share (in Dollars per share) | $ / shares $ 0.0001
Weighted average price exceed (in Dollars per share) | $ / shares $ 1
Shares of Common stock 25,000
December 2020 Issuance of Series B Preferred Stock Units [Member]  
Equity (Details) [Line Items]  
Exercisable warrants common stock shares 50,000
Common Stock [Member]  
Equity (Details) [Line Items]  
Equity description At September 30, 2021, the Company had 111,070,329 common shares outstanding. Following is a discussion of common stock issuances during the periods presented:   ● February 2020 Issuance of Common Stock Units – In February 2020, the Company issued 250,000 common units for $100,000. Each unit consisted of one share of common stock and a warrant for purchase of one common share for $0.40 per share. The warrant expires March 1, 2022 and contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price. Proceeds of this issuance were used for general corporate purposes.  The common stock issued in the exchange was valued using the trading price of the common stock on February 20, 2020. The warrants were valued at $45,848 using a binomial lattice valuation model using inputs as of the exchange date. Our expected volatility assumption was based on the historical volatility of the Company’s common stock (252%). The expected life assumption was based on the expiration date of the warrant (two years). The risk-free interest rate for the expected term of the warrant was based on the U.S. Treasury yield curve in effect at the time of measurement (1.39%). The warrants are classified within equity in the consolidated balance sheets. Under GAAP, the anti-dilution provisions will be accounted for if and when these provisions are triggered.    ● Acquisition of Certain Assets of Halcyon – the Company issued 6,250,000 shares of common stock valued at $2.5 million (valued at $0.40 per share; restricted from trading for a period of up to one year) in the acquisition. Refer to Note 3.     ● 2021 First Quarter Issuances of Common Stock Units – In the first quarter of 2021, the Company issued 800,000 common stock units for total proceeds of $400,000. Each common stock unit consists of one share of common stock and a warrant for the purchase of two shares of common stock for $0.50 each. Each warrant is exercisable any time before its expiration on the second anniversary of its issuance. The Company allocated the total proceeds based on the relative fair values of the common stock and warrants. The fair value of the warrants was determined using an options valuation model with key assumptions including a risk-free interest rate of 0.11% and historical volatility of 272%. A total of $263,293 was allocated to the warrants and reported in additional paid-in capital.       ● Warrant Exercises – In the first quarter of 2021, the Company received $2,967,000 for the exercise of 8,428,976 outstanding warrants.     ● Issuances for Exchange or Conversion of Debt – The Company issued a total of 1,618,660 common shares for the exchange or conversion of outstanding debt. Refer to Note 5.     ● Issuance to Vendor for Services – In the third quarter of 2021, the Company issued 125,000 common shares to a vendor for services performed.     ● Issuance for Extension of Secured Note – The Company issued 20,000 common shares as consideration to extend the maturity of a senior note in the third quarter of 2021. Refer to Note 5.     ● Issuance for Conversion of Series A Preferred Stock – As noted above, in the third quarter of 2021, the Company issued 75,947,376 common shares for the conversion of all outstanding shares of its Series A Preferred Stock.   ●Stock-based Compensation – The Company issued 500,000 restricted common shares as incentive compensation to two executives who joined the Company in the first quarter of 2021.
Series A Preferred Stock [Member]  
Equity (Details) [Line Items]  
Shares of series A preferred stock 6,328,948
Shares of common stock 75,947,376
Series B Preferred Stock [Member]  
Equity (Details) [Line Items]  
Preferred stock converted into common stock 25,000
Annual dividend rate 6.00%
Preferred stock stated value (in Dollars) | $ $ 10,000
Annual rate, description Initially, redemption payments of 12.5% each of the total amount of Series B Preferred Stock then outstanding plus accrued dividends were due from the Company to each Holder of Series B Preferred Stock at the end of each calendar quarter of 2021. The first required redemption payments totaling $137,500 were made in April 2021.
XML 53 R41.htm IDEA: XBRL DOCUMENT v3.21.2
Equity (Details) - Schedule of warrants outstanding
9 Months Ended
Sep. 30, 2021
$ / shares
shares
Class of Warrant or Right [Line Items]  
Number of warrants | shares 16,159,656
Exercise Price (each) | $ / shares $ 0.6
Issued in December 2020 [Member] | Subordinated Note to Investor [Member]  
Class of Warrant or Right [Line Items]  
Number of warrants | shares 500,000 [1]
Exercise Price (each) | $ / shares $ 0.352 [1]
Expiration Date December 30, 2022 [1]
Method of Exercise Cash [1]
Common Stock Units [Member] | Issued in February 2020 [Member]  
Class of Warrant or Right [Line Items]  
Number of warrants | shares 250,000 [2]
Exercise Price (each) | $ / shares $ 0.4 [2]
Expiration Date March 1, 2022 [2]
Method of Exercise Cash [2]
Common Stock Unites [Member] | March Two Thousand Twenty One [Member]  
Class of Warrant or Right [Line Items]  
Number of warrants | shares 1,600,000 [1]
Exercise Price (each) | $ / shares $ 0.5 [1]
Expiration Date Jan-Feb, 2023 [1]
Method of Exercise Cash [1]
Series C Preferred Stock [Member] | Issued upon exchange of EHR [Member]  
Class of Warrant or Right [Line Items]  
Number of warrants | shares 1,065,340 [1]
Exercise Price (each) | $ / shares $ 0.352 [1]
Expiration Date November 27, 2021 [1]
Method of Exercise Cash [1]
Series C Preferred Stock [Member] | Issued upon exchange of EHR One [Member]  
Class of Warrant or Right [Line Items]  
Number of warrants | shares 7,244,316 [1]
Exercise Price (each) | $ / shares $ 0.352 [1]
Expiration Date November 27, 2021 [1]
Method of Exercise Cashless [1]
Series B Preferred Units [Member] | Issued in December 2020 [Member]  
Class of Warrant or Right [Line Items]  
Number of warrants | shares 5,500,000 [1]
Exercise Price (each) | $ / shares $ 0.352 [1]
Expiration Date December 30, 2022 [1]
Method of Exercise Cash [1]
[1] May be redeemed for $0.0001 per warrant at the Company’s option with 30 days advanced notice should the weighted average market price of common stock exceed $1.00 for any five out of seven consecutive trading days with a minimum average daily trading volume for such seven-day period of at least 25,000 shares of common stock.
[2] Contains certain anti-dilution provisions requiring a downward adjustment to the exercise price of the warrant if dilutive instruments are issued at prices less than the warrant exercise price.
XML 54 R42.htm IDEA: XBRL DOCUMENT v3.21.2
Equity (Details) - Schedule of outstanding stock warrants activity - shares
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Schedule of outstanding stock warrants activity [Abstract]    
Warrants, beginning 22,988,632 14,488,632
Issued 1,600,000 250,000
Exercised (8,428,976)  
Warrants, ending 16,159,656 14,738,632
XML 55 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Stock-Based Compensation (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Mar. 31, 2021
Sep. 30, 2021
Apr. 06, 2021
Stock-Based Compensation (Details) [Line Items]        
Diluted common shares outstanding percentage     20.00%  
Compensation expense related to awards $ 38,750   $ 119,750  
Total unrecognized compensation cost     $ 38,750  
Purchase of common stock       $ 750,000
2021 Plan [Member]        
Stock-Based Compensation (Details) [Line Items]        
common stock for issuance (in Shares)     15,000,000  
Number of shares (in Shares)     15,000,000  
Diluted common shares outstanding percentage     13.10%  
Restricted Stock [Member]        
Stock-Based Compensation (Details) [Line Items]        
Restricted shares, issued (in Shares)   500,000    
Restricted shares, value   $ 158,500    
XML 56 R44.htm IDEA: XBRL DOCUMENT v3.21.2
Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information - USD ($)
9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Schedule of supplemental cash flow information [Abstract]    
Cash paid for interest $ 127,812
Cash paid for taxes
Acquisition of certain assets of Halcyon Thruput, LLC    
- issuance of common shares 2,500,000
- issuance of subordinated note 850,000
- assumption of Halcyon bank note 995,614
Series B preferred stock dividend payable 39,137
Issuance of common stock units previously subscribed 50,000
Issuances of common shares for exchange or conversion of debt $ 2,160,269
XML 57 R45.htm IDEA: XBRL DOCUMENT v3.21.2
Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Numerator        
Loss from continuing operations attributable to common stockholders (in Dollars) $ (1,376,030) $ (171,367) $ (4,356,315) $ (1,146,592)
Loss from discontinued operations (in Dollars) (1,528) (7,489) (10,639) (5,115)
Less: preferred stock dividends (in Dollars) (16,125) (56,625)
Net loss attributable to common stockholders (in Dollars) $ (1,393,683) $ (178,856) $ (4,423,579) $ (1,151,707)
Denominator        
Weighted average shares used to compute basic EPS (in Shares) 54,109,797 17,380,317 38,693,679 17,500,308
Dilutive effect of convertible note (in Shares)
Dilutive effect of preferred stock (in Shares) 59,913,657 75,947,376 72,641,084 75,947,376
Dilutive effect of common stock warrants (in Shares) 9,042,419 11,126,327
Weighted average shares used to compute diluted EPS (in Shares) 123,065,873 93,327,693 122,461,090 93,447,684
Loss from continuing operations        
Basic $ (0.03) $ (0.01) $ (0.11) $ (0.07)
Diluted (0.03) (0.01) (0.11) (0.07)
(Loss) income from discontinued operations        
Basic
Diluted
Earnings (loss) per share        
Basic (0.03) (0.01) (0.11) (0.07)
Diluted $ (0.03) $ (0.01) $ (0.11) $ (0.07)
XML 58 R46.htm IDEA: XBRL DOCUMENT v3.21.2
Subsequent Events (Details) - USD ($)
1 Months Ended 9 Months Ended
Oct. 31, 2021
Sep. 30, 2021
Subsequent Events (Details) [Line Items]    
Common stock per share (in Dollars per share)   $ 0.0001
Subsequent event, description   As disclosed in Note 5 above, (i) we amended the subordinated note to our CEO in the amount of $490,000 to a new maturity date of January 31, 2022, (ii) we amended the secured promissory note to Coventry Asset Management, LTD. to a new maturity date of January 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed and granted the holder a limited option to convert part of the principal to common stock and (iii) we amended the subordinated promissory note with an investor to a new maturity date of March 31, 2022 with an earlier maturity date of December 31, 2021 in the event of a new equity capital raise is completed. 
Interest Rate 10.00%  
Maturity date Jan. 01, 2022  
Subsequent Event [Member]    
Subsequent Events (Details) [Line Items]    
Common stock units (in Shares) 416,667  
Investor total proceeds $ 250,000  
Common stock per share (in Dollars per share) $ 0.6  
Advanced $ 15,000  
Convertible promissory note $ 635,000  
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 167 402 1 true 35 0 false 5 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.genhempinc.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Unaudited Condensed Consolidated Balance Sheets Sheet http://www.genhempinc.com/role/ConsolidatedBalanceSheet Unaudited Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Sheet http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals Unaudited Condensed Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Unaudited Condensed Consolidated Statements of Operations Sheet http://www.genhempinc.com/role/ConsolidatedIncomeStatement Unaudited Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Unaudited Condensed Consolidated Statements of Equity Sheet http://www.genhempinc.com/role/ShareholdersEquityType2or3 Unaudited Condensed Consolidated Statements of Equity Statements 5 false false R6.htm 005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows Sheet http://www.genhempinc.com/role/ConsolidatedCashFlow Unaudited Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Business Sheet http://www.genhempinc.com/role/Business Business Notes 7 false false R8.htm 007 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Acquisition Sheet http://www.genhempinc.com/role/Acquisition Acquisition Notes 9 false false R10.htm 009 - Disclosure - Discontinued Operations Sheet http://www.genhempinc.com/role/DiscontinuedOperations Discontinued Operations Notes 10 false false R11.htm 010 - Disclosure - Notes Payable ??? Related Parties Notes http://www.genhempinc.com/role/NotesPayableRelatedParties Notes Payable ??? Related Parties Notes 11 false false R12.htm 011 - Disclosure - Other Indebtedness Sheet http://www.genhempinc.com/role/OtherIndebtedness Other Indebtedness Notes 12 false false R13.htm 012 - Disclosure - Commitments and Contingencies Sheet http://www.genhempinc.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 13 false false R14.htm 013 - Disclosure - Equity Sheet http://www.genhempinc.com/role/Equity Equity Notes 14 false false R15.htm 014 - Disclosure - Stock-Based Compensation Sheet http://www.genhempinc.com/role/StockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 015 - Disclosure - Income Taxes Sheet http://www.genhempinc.com/role/IncomeTaxes Income Taxes Notes 16 false false R17.htm 016 - Disclosure - Supplemental Cash Flow Information Sheet http://www.genhempinc.com/role/SupplementalCashFlowInformation Supplemental Cash Flow Information Notes 17 false false R18.htm 017 - Disclosure - Earnings (Loss) Per Share Sheet http://www.genhempinc.com/role/EarningsLossPerShare Earnings (Loss) Per Share Notes 18 false false R19.htm 018 - Disclosure - Subsequent Events Sheet http://www.genhempinc.com/role/SubsequentEvents Subsequent Events Notes 19 false false R20.htm 019 - Disclosure - Accounting Policies, by Policy (Policies) Sheet http://www.genhempinc.com/role/AccountingPoliciesByPolicy Accounting Policies, by Policy (Policies) Policies http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies 20 false false R21.htm 020 - Disclosure - Acquisition (Tables) Sheet http://www.genhempinc.com/role/AcquisitionTables Acquisition (Tables) Tables http://www.genhempinc.com/role/Acquisition 21 false false R22.htm 021 - Disclosure - Discontinued Operations (Tables) Sheet http://www.genhempinc.com/role/DiscontinuedOperationsTables Discontinued Operations (Tables) Tables http://www.genhempinc.com/role/DiscontinuedOperations 22 false false R23.htm 022 - Disclosure - Notes Payable ??? Related Parties (Tables) Notes http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables Notes Payable ??? Related Parties (Tables) Tables http://www.genhempinc.com/role/NotesPayableRelatedParties 23 false false R24.htm 023 - Disclosure - Other Indebtedness (Tables) Sheet http://www.genhempinc.com/role/OtherIndebtednessTables Other Indebtedness (Tables) Tables http://www.genhempinc.com/role/OtherIndebtedness 24 false false R25.htm 024 - Disclosure - Equity (Tables) Sheet http://www.genhempinc.com/role/EquityTables Equity (Tables) Tables http://www.genhempinc.com/role/Equity 25 false false R26.htm 025 - Disclosure - Supplemental Cash Flow Information (Tables) Sheet http://www.genhempinc.com/role/SupplementalCashFlowInformationTables Supplemental Cash Flow Information (Tables) Tables http://www.genhempinc.com/role/SupplementalCashFlowInformation 26 false false R27.htm 026 - Disclosure - Earnings (Loss) Per Share (Tables) Sheet http://www.genhempinc.com/role/EarningsLossPerShareTables Earnings (Loss) Per Share (Tables) Tables http://www.genhempinc.com/role/EarningsLossPerShare 27 false false R28.htm 027 - Disclosure - Business (Details) Sheet http://www.genhempinc.com/role/BusinessDetails Business (Details) Details http://www.genhempinc.com/role/Business 28 false false R29.htm 028 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details 29 false false R30.htm 029 - Disclosure - Acquisition (Details) Sheet http://www.genhempinc.com/role/AcquisitionDetails Acquisition (Details) Details http://www.genhempinc.com/role/AcquisitionTables 30 false false R31.htm 030 - Disclosure - Acquisition (Details) - Schedule of amortizable tangible and intangible assets Sheet http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable Acquisition (Details) - Schedule of amortizable tangible and intangible assets Details http://www.genhempinc.com/role/AcquisitionTables 31 false false R32.htm 031 - Disclosure - Acquisition (Details) - Schedule of pro forma consolidated results of operations Sheet http://www.genhempinc.com/role/ScheduleofproformaconsolidatedresultsofoperationsTable Acquisition (Details) - Schedule of pro forma consolidated results of operations Details http://www.genhempinc.com/role/AcquisitionTables 32 false false R33.htm 032 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities Sheet http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities Details http://www.genhempinc.com/role/DiscontinuedOperationsTables 33 false false R34.htm 033 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations Sheet http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations Details http://www.genhempinc.com/role/DiscontinuedOperationsTables 34 false false R35.htm 034 - Disclosure - Notes Payable ??? Related Parties (Details) Notes http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails Notes Payable ??? Related Parties (Details) Details http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables 35 false false R36.htm 035 - Disclosure - Notes Payable ??? Related Parties (Details) - Schedule of notes payable related parties Notes http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable Notes Payable ??? Related Parties (Details) - Schedule of notes payable related parties Details http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables 36 false false R37.htm 036 - Disclosure - Other Indebtedness (Details) Sheet http://www.genhempinc.com/role/OtherIndebtednessDetails Other Indebtedness (Details) Details http://www.genhempinc.com/role/OtherIndebtednessTables 37 false false R38.htm 037 - Disclosure - Other Indebtedness (Details) - Schedule of other indebtedness Sheet http://www.genhempinc.com/role/ScheduleofotherindebtednessTable Other Indebtedness (Details) - Schedule of other indebtedness Details http://www.genhempinc.com/role/OtherIndebtednessTables 38 false false R39.htm 038 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.genhempinc.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.genhempinc.com/role/CommitmentsandContingencies 39 false false R40.htm 039 - Disclosure - Equity (Details) Sheet http://www.genhempinc.com/role/EquityDetails Equity (Details) Details http://www.genhempinc.com/role/EquityTables 40 false false R41.htm 040 - Disclosure - Equity (Details) - Schedule of warrants outstanding Sheet http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable Equity (Details) - Schedule of warrants outstanding Details http://www.genhempinc.com/role/EquityTables 41 false false R42.htm 041 - Disclosure - Equity (Details) - Schedule of outstanding stock warrants activity Sheet http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable Equity (Details) - Schedule of outstanding stock warrants activity Details http://www.genhempinc.com/role/EquityTables 42 false false R43.htm 042 - Disclosure - Stock-Based Compensation (Details) Sheet http://www.genhempinc.com/role/StockBasedCompensationDetails Stock-Based Compensation (Details) Details http://www.genhempinc.com/role/StockBasedCompensation 43 false false R44.htm 043 - Disclosure - Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information Sheet http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information Details http://www.genhempinc.com/role/SupplementalCashFlowInformationTables 44 false false R45.htm 044 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share Sheet http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share Details http://www.genhempinc.com/role/EarningsLossPerShareTables 45 false false R46.htm 045 - Disclosure - Subsequent Events (Details) Sheet http://www.genhempinc.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.genhempinc.com/role/SubsequentEvents 46 false false All Reports Book All Reports f10q0921_generation.htm f10q0921ex10-7_generation.htm f10q0921ex10-8_generation.htm f10q0921ex10-9_generation.htm f10q0921ex31-1_generation.htm f10q0921ex32-1_generation.htm genh-20210930.xsd genh-20210930_cal.xml genh-20210930_def.xml genh-20210930_lab.xml genh-20210930_pre.xml http://fasb.org/srt/2021-01-31 http://xbrl.sec.gov/dei/2021 http://fasb.org/us-gaap/2021-01-31 true true JSON 65 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "f10q0921_generation.htm": { "axisCustom": 0, "axisStandard": 14, "contextCount": 167, "dts": { "calculationLink": { "local": [ "genh-20210930_cal.xml" ] }, "definitionLink": { "local": [ "genh-20210930_def.xml" ] }, "inline": { "local": [ "f10q0921_generation.htm" ] }, "labelLink": { "local": [ "genh-20210930_lab.xml" ] }, "presentationLink": { "local": [ "genh-20210930_pre.xml" ] }, "schema": { "local": [ "genh-20210930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd" ] } }, "elementCount": 478, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 144, "http://www.genhempinc.com/20210930": 43, "http://xbrl.sec.gov/dei/2021": 5, "total": 192 }, "keyCustom": 117, "keyStandard": 285, "memberCustom": 23, "memberStandard": 11, "nsprefix": "genh", "nsuri": "http://www.genhempinc.com/20210930", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.genhempinc.com/role/DocumentAndEntityInformation", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Discontinued Operations", "role": "http://www.genhempinc.com/role/DiscontinuedOperations", "shortName": "Discontinued Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:NotePayableRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Notes Payable \u2013 Related Parties", "role": "http://www.genhempinc.com/role/NotesPayableRelatedParties", "shortName": "Notes Payable \u2013 Related Parties", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:NotePayableRelatedPartyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Other Indebtedness", "role": "http://www.genhempinc.com/role/OtherIndebtedness", "shortName": "Other Indebtedness", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MortgageNotesPayableDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Commitments and Contingencies", "role": "http://www.genhempinc.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Equity", "role": "http://www.genhempinc.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Stock-Based Compensation", "role": "http://www.genhempinc.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Income Taxes", "role": "http://www.genhempinc.com/role/IncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Supplemental Cash Flow Information", "role": "http://www.genhempinc.com/role/SupplementalCashFlowInformation", "shortName": "Supplemental Cash Flow Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Earnings (Loss) Per Share", "role": "http://www.genhempinc.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Subsequent Events", "role": "http://www.genhempinc.com/role/SubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Unaudited Condensed Consolidated Balance Sheets", "role": "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "shortName": "Unaudited Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "lang": null, "name": "us-gaap:AccountsReceivableNetCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Accounting Policies, by Policy (Policies)", "role": "http://www.genhempinc.com/role/AccountingPoliciesByPolicy", "shortName": "Accounting Policies, by Policy (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Acquisition (Tables)", "role": "http://www.genhempinc.com/role/AcquisitionTables", "shortName": "Acquisition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuantitativeInformationAboutFinancialAssetsAndAssociatedLiabilitiesAccountedForAsSecuredBorrowingsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Discontinued Operations (Tables)", "role": "http://www.genhempinc.com/role/DiscontinuedOperationsTables", "shortName": "Discontinued Operations (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfQuantitativeInformationAboutFinancialAssetsAndAssociatedLiabilitiesAccountedForAsSecuredBorrowingsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Notes Payable \u2013 Related Parties (Tables)", "role": "http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables", "shortName": "Notes Payable \u2013 Related Parties (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Other Indebtedness (Tables)", "role": "http://www.genhempinc.com/role/OtherIndebtednessTables", "shortName": "Other Indebtedness (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Equity (Tables)", "role": "http://www.genhempinc.com/role/EquityTables", "shortName": "Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Supplemental Cash Flow Information (Tables)", "role": "http://www.genhempinc.com/role/SupplementalCashFlowInformationTables", "shortName": "Supplemental Cash Flow Information (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Earnings (Loss) Per Share (Tables)", "role": "http://www.genhempinc.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c99", "decimals": "2", "first": true, "lang": null, "name": "genh:OwnsApproximatelysPercent", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Business (Details)", "role": "http://www.genhempinc.com/role/BusinessDetails", "shortName": "Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c99", "decimals": "2", "first": true, "lang": null, "name": "genh:OwnsApproximatelysPercent", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c101", "decimals": "2", "first": true, "lang": null, "name": "genh:ServiceRevenuePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Summary of Significant Accounting Policies (Details)", "role": "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails", "shortName": "Summary of Significant Accounting Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c101", "decimals": "2", "first": true, "lang": null, "name": "genh:ServiceRevenuePercentage", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "5", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "role": "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "shortName": "Unaudited Condensed Consolidated Balance Sheets (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Acquisition (Details)", "role": "http://www.genhempinc.com/role/AcquisitionDetails", "shortName": "Acquisition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c106", "decimals": "0", "lang": null, "name": "genh:PromissoryNoteAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c107", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "030 - Disclosure - Acquisition (Details) - Schedule of amortizable tangible and intangible assets", "role": "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable", "shortName": "Acquisition (Details) - Schedule of amortizable tangible and intangible assets", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c107", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "031 - Disclosure - Acquisition (Details) - Schedule of pro forma consolidated results of operations", "role": "http://www.genhempinc.com/role/ScheduleofproformaconsolidatedresultsofoperationsTable", "shortName": "Acquisition (Details) - Schedule of pro forma consolidated results of operations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:BusinessAcquisitionProFormaInformationTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfQuantitativeInformationAboutFinancialAssetsAndAssociatedLiabilitiesAccountedForAsSecuredBorrowingsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OilAndGasPropertyFullCostMethodNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "032 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities", "role": "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable", "shortName": "Discontinued Operations (Details) - Schedule of discontinued operations to assets and liabilities", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfQuantitativeInformationAboutFinancialAssetsAndAssociatedLiabilitiesAccountedForAsSecuredBorrowingsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OilAndGasPropertyFullCostMethodNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfDiscontinuedOperationsShownInConsolidatedStatementsOfOperationsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "genh:OilAndGasSales", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "033 - Disclosure - Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations", "role": "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable", "shortName": "Discontinued Operations (Details) - Schedule of discontinued operations shown in the consolidated statements of operations", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfDiscontinuedOperationsShownInConsolidatedStatementsOfOperationsTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "genh:OilAndGasSales", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c108", "decimals": "0", "first": true, "lang": null, "name": "genh:ExchangeOfCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "034 - Disclosure - Notes Payable \u2013 Related Parties (Details)", "role": "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "shortName": "Notes Payable \u2013 Related Parties (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c108", "decimals": "0", "first": true, "lang": null, "name": "genh:ExchangeOfCommonShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "035 - Disclosure - Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable related parties", "role": "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable", "shortName": "Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable related parties", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "genh:ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DueToRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:MortgagePayableDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "036 - Disclosure - Other Indebtedness (Details)", "role": "http://www.genhempinc.com/role/OtherIndebtednessDetails", "shortName": "Other Indebtedness (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:MortgagePayableDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TransferMortgagePayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "037 - Disclosure - Other Indebtedness (Details) - Schedule of other indebtedness", "role": "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable", "shortName": "Other Indebtedness (Details) - Schedule of other indebtedness", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TransferMortgagePayable", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "genh:NewMonthlyPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "038 - Disclosure - Commitments and Contingencies (Details)", "role": "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails", "shortName": "Commitments and Contingencies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "genh:NewMonthlyPayment", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "genh:PostharvestAndMidstreamServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Unaudited Condensed Consolidated Statements of Operations", "role": "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "shortName": "Unaudited Condensed Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "genh:PostharvestAndMidstreamServices", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:PreferredStockDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "039 - Disclosure - Equity (Details)", "role": "http://www.genhempinc.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "genh:PreferredStockDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "040 - Disclosure - Equity (Details) - Schedule of warrants outstanding", "role": "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable", "shortName": "Equity (Details) - Schedule of warrants outstanding", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "041 - Disclosure - Equity (Details) - Schedule of outstanding stock warrants activity", "role": "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable", "shortName": "Equity (Details) - Schedule of outstanding stock warrants activity", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfStockByClassTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c3", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "genh:CommonSharesDiluted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "042 - Disclosure - Stock-Based Compensation (Details)", "role": "http://www.genhempinc.com/role/StockBasedCompensationDetails", "shortName": "Stock-Based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "2", "first": true, "lang": null, "name": "genh:CommonSharesDiluted", "reportCount": 1, "unique": true, "unitRef": "pure", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "043 - Disclosure - Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information", "role": "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable", "shortName": "Supplemental Cash Flow Information (Details) - Schedule of supplemental cash flow information", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:InterestPaid", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "genh:NetLossFromContinuingOperationsAttributableToCommonStockholders", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "044 - Disclosure - Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share", "role": "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable", "shortName": "Earnings (Loss) Per Share (Details) - Schedule of earnings (loss) per basic and diluted share", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c8", "decimals": "0", "first": true, "lang": null, "name": "genh:NetLossFromContinuingOperationsAttributableToCommonStockholders", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c2", "decimals": "4", "first": true, "lang": null, "name": "us-gaap:SaleOfStockPricePerShare", "reportCount": 1, "unitRef": "usdPershares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "045 - Disclosure - Subsequent Events (Details)", "role": "http://www.genhempinc.com/role/SubsequentEventsDetails", "shortName": "Subsequent Events (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "lang": "en-US", "name": "us-gaap:SubsequentEventDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c17", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Unaudited Condensed Consolidated Statements of Equity", "role": "http://www.genhempinc.com/role/ShareholdersEquityType2or3", "shortName": "Unaudited Condensed Consolidated Statements of Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c24", "decimals": "0", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Unaudited Condensed Consolidated Statements of Cash Flows", "role": "http://www.genhempinc.com/role/ConsolidatedCashFlow", "shortName": "Unaudited Condensed Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": "0", "lang": null, "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Business", "role": "http://www.genhempinc.com/role/Business", "shortName": "Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Summary of Significant Accounting Policies", "role": "http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Acquisition", "role": "http://www.genhempinc.com/role/Acquisition", "shortName": "Acquisition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "f10q0921_generation.htm", "contextRef": "c0", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 35, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.genhempinc.com/role/DocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "genh_AccreditedInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AccreditedInvestorMember", "terseLabel": "Accredited Investor [Member]" } } }, "localname": "AccreditedInvestorMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "genh_AccruedAndUnpaidInterestDueDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued and unpaid interest due date.", "label": "AccruedAndUnpaidInterestDueDate", "terseLabel": "Accrued and unpaid interest due date" } } }, "localname": "AccruedAndUnpaidInterestDueDate", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "dateItemType" }, "genh_AcquisitionDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition (Details) [Line Items]" } } }, "localname": "AcquisitionDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "genh_AcquisitionDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Acquisition (Details) [Table]" } } }, "localname": "AcquisitionDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "genh_AcquisitionOfCertainAssetsOfHalcyonThruputLlcAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AcquisitionOfCertainAssetsOfHalcyonThruputLlcAbstract", "terseLabel": "Acquisition of certain assets of Halcyon Thruput, LLC" } } }, "localname": "AcquisitionOfCertainAssetsOfHalcyonThruputLlcAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "stringItemType" }, "genh_AcquisitionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AcquisitionsMember", "terseLabel": "Acquisitions [Member]" } } }, "localname": "AcquisitionsMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "domainItemType" }, "genh_AdvancesTotaling": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "AdvancesTotaling", "terseLabel": "Advanced" } } }, "localname": "AdvancesTotaling", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "genh_AggregateGrossProceeds": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of proceeds from the gross.", "label": "AggregateGrossProceeds", "terseLabel": "Aggregate gross proceeds (in Dollars)" } } }, "localname": "AggregateGrossProceeds", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "genh_AnnualRateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AnnualRateDescription", "terseLabel": "Annual rate, description" } } }, "localname": "AnnualRateDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_AssetRetirementObligationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "AssetRetirementObligationsAbstract", "terseLabel": "Asset retirement obligations -" } } }, "localname": "AssetRetirementObligationsAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "stringItemType" }, "genh_AssetsAcquired": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Assets acquired.", "label": "AssetsAcquired", "terseLabel": "Assets acquired" } } }, "localname": "AssetsAcquired", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "genh_AssumptionOfHalcyonBankNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Assumption of Halcyon bank note.", "label": "AssumptionOfHalcyonBankNote", "terseLabel": "- assumption of Halcyon bank note" } } }, "localname": "AssumptionOfHalcyonBankNote", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted", "terseLabel": "Basic and diluted (in Dollars per share)" } } }, "localname": "BusinessAcquisitionProFormaEarningsPerShareBasicAndDiluted", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofproformaconsolidatedresultsofoperationsTable" ], "xbrltype": "perShareItemType" }, "genh_ChangeInFairValueOfMarketableSecurity": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of marketable security.", "label": "ChangeInFairValueOfMarketableSecurity", "terseLabel": "Change in fair value of marketable security" } } }, "localname": "ChangeInFairValueOfMarketableSecurity", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_CommitmentsandContingenciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Line Items]" } } }, "localname": "CommitmentsandContingenciesDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "genh_CommitmentsandContingenciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies (Details) [Table]" } } }, "localname": "CommitmentsandContingenciesDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "genh_CommonSharesDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonSharesDiluted", "terseLabel": "Diluted common shares outstanding percentage" } } }, "localname": "CommonSharesDiluted", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "percentItemType" }, "genh_CommonStockForIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock for issuance.", "label": "CommonStockForIssuance", "terseLabel": "common stock for issuance (in Shares)" } } }, "localname": "CommonStockForIssuance", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "genh_CommonStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStockUnitsMember", "terseLabel": "Common Stock Units [Member]" } } }, "localname": "CommonStockUnitsMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_CommonStockValued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amount of common stock.", "label": "CommonStockValued", "terseLabel": "Common stock, value" } } }, "localname": "CommonStockValued", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "genh_CommonStockValues": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of common stock Value.", "label": "CommonStockValues", "terseLabel": "Common stock, no par value; 100,000,000 shares authorized, 17,380,317 shares issued and outstanding at December 31, 2020" } } }, "localname": "CommonStockValues", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "genh_CommonStocksSharesIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CommonStocksSharesIssued", "terseLabel": "Common stock shares Issued" } } }, "localname": "CommonStocksSharesIssued", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "genh_CompensationDecreasesPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Compensation decreases percentage.", "label": "CompensationDecreasesPercentage", "terseLabel": "Compensation decreases percentage" } } }, "localname": "CompensationDecreasesPercentage", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "percentItemType" }, "genh_CompensationLevelsAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "CompensationLevelsAmount", "terseLabel": "Compensation levels amount" } } }, "localname": "CompensationLevelsAmount", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_ConventryAssetManagementLTDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConventryAssetManagementLTDMember", "terseLabel": "Conventry Asset Management, LTD. [Member]" } } }, "localname": "ConventryAssetManagementLTDMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "genh_ConversionOfSeriesAPreferredStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of conversion of series A preferred stock.", "label": "ConversionOfSeriesAPreferredStock", "terseLabel": "Conversion of Series A preferred stock" } } }, "localname": "ConversionOfSeriesAPreferredStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "genh_ConversionOfSeriesAPreferredStockinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The share of conversion of series A preferred stock.", "label": "ConversionOfSeriesAPreferredStockinShares", "terseLabel": "Conversion of Series A preferred stock (in Shares)" } } }, "localname": "ConversionOfSeriesAPreferredStockinShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_ConvertedIntoCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Converted into common shares.", "label": "ConvertedIntoCommonShares", "terseLabel": "Converted into common shares (in Shares)" } } }, "localname": "ConvertedIntoCommonShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "genh_ConvertiblePromissoryNote": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Convertible Promissory Note.", "label": "ConvertiblePromissoryNote", "terseLabel": "Convertible promissory note" } } }, "localname": "ConvertiblePromissoryNote", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "genh_ConvertiblePromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ConvertiblePromissoryNoteMember", "terseLabel": "Convertible Promissory Note [Member]" } } }, "localname": "ConvertiblePromissoryNoteMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_CostOfDyeingEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cost of dyeing equipment.", "label": "CostOfDyeingEquipment", "terseLabel": "Cost of drying equipment total" } } }, "localname": "CostOfDyeingEquipment", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_CostsAndExpenseTotal": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs and expenses.", "label": "CostsAndExpenseTotal", "terseLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenseTotal", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "genh_CostsAndExpensesAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CostsAndExpensesAbstract0", "terseLabel": "Costs and Expenses" } } }, "localname": "CostsAndExpensesAbstract0", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "stringItemType" }, "genh_CurrentLiabilitiesOfDiscontinuedOperationsHeldForSale": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 8.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Current liabilities of discontinued operations held for sale.", "label": "CurrentLiabilitiesOfDiscontinuedOperationsHeldForSale", "terseLabel": "Current liabilities of discontinued operations held for sale" } } }, "localname": "CurrentLiabilitiesOfDiscontinuedOperationsHeldForSale", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "genh_CustomerOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CustomerOneMember", "terseLabel": "One Customer [Member]" } } }, "localname": "CustomerOneMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "domainItemType" }, "genh_CustomerRelationships": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of customer relationships.", "label": "CustomerRelationships", "terseLabel": "Customer relationships" } } }, "localname": "CustomerRelationships", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "genh_DecemberTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DecemberTwoThousandTwentyMember", "terseLabel": "Issued in December 2020 [Member]" } } }, "localname": "DecemberTwoThousandTwentyMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_DecemberTwoThousedTwoZeroIssuanceOfSeriesBPreferredStockUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DecemberTwoThousedTwoZeroIssuanceOfSeriesBPreferredStockUnitsMember", "terseLabel": "December 2020 Issuance of Series B Preferred Stock Units [Member]" } } }, "localname": "DecemberTwoThousedTwoZeroIssuanceOfSeriesBPreferredStockUnitsMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "genh_DenominatorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DenominatorAbstract", "terseLabel": "Denominator" } } }, "localname": "DenominatorAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_DepreciationDepletionAmortization": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Depreciation, depletion &amp; amortization.", "label": "DepreciationDepletionAmortization", "terseLabel": "Depreciation, depletion & amortization" } } }, "localname": "DepreciationDepletionAmortization", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "genh_DescriptionOfBusinessDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DescriptionOfBusinessDescription", "terseLabel": "Description of business, description" } } }, "localname": "DescriptionOfBusinessDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "stringItemType" }, "genh_DilutiveEffectOfCommonStockWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DilutiveEffectOfCommonStockWarrants", "terseLabel": "Dilutive effect of common stock warrants (in Shares)" } } }, "localname": "DilutiveEffectOfCommonStockWarrants", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "genh_DilutiveEffectOfConvertibleNote": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Dilutive effect of convertible note.", "label": "DilutiveEffectOfConvertibleNote", "terseLabel": "Dilutive effect of convertible note (in Shares)" } } }, "localname": "DilutiveEffectOfConvertibleNote", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "genh_DilutiveEffectOfPreferredStock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "DilutiveEffectOfPreferredStock", "terseLabel": "Dilutive effect of preferred stock (in Shares)" } } }, "localname": "DilutiveEffectOfPreferredStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "genh_DocumentAndEntityInformationAbstract": { "auth_ref": [], "localname": "DocumentAndEntityInformationAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_EarningsLossPerCommonShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EarningsLossPerCommonShareAbstract", "terseLabel": "Earnings (loss) per common share:" } } }, "localname": "EarningsLossPerCommonShareAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofproformaconsolidatedresultsofoperationsTable" ], "xbrltype": "stringItemType" }, "genh_EarningsLossPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EarningsLossPerShareAbstract", "terseLabel": "Earnings (loss) per share" } } }, "localname": "EarningsLossPerShareAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "genh_EarningsLossPerShareAbstract0": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EarningsLossPerShareAbstract0", "terseLabel": "Earnings (loss) per share:" } } }, "localname": "EarningsLossPerShareAbstract0", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_EarningsLossPerShareAbstract00": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "EarningsLossPerShareAbstract00", "terseLabel": "Earnings (loss) per share" } } }, "localname": "EarningsLossPerShareAbstract00", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_EmployeeTerminatesDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee terminates, description.", "label": "EmployeeTerminatesDescription", "terseLabel": "Employee terminates, description" } } }, "localname": "EmployeeTerminatesDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "genh_EquityCapitalAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity capital amount.", "label": "EquityCapitalAmount", "terseLabel": "Equity capital amount" } } }, "localname": "EquityCapitalAmount", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "genh_EquityDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity description.", "label": "EquityDescription", "terseLabel": "Equity description" } } }, "localname": "EquityDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_EquityDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) [Line Items]" } } }, "localname": "EquityDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_EquityDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity (Details) [Table]" } } }, "localname": "EquityDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_ExchangeOfCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange of common shares.", "label": "ExchangeOfCommonShares", "terseLabel": "Exchange of common shares (in Shares)" } } }, "localname": "ExchangeOfCommonShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "genh_ExercisableWarrantsCommonStockPerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercisable warrants common stock shares1\r \n.", "label": "ExercisableWarrantsCommonStockPerShares", "terseLabel": "Exercisable warrants common stock shares (in Dollars per share)" } } }, "localname": "ExercisableWarrantsCommonStockPerShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "genh_ExercisableWarrantsCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ExercisableWarrantsCommonStockShares", "terseLabel": "Extension fee (in Shares)", "verboseLabel": "Exercisable warrants common stock shares" } } }, "localname": "ExercisableWarrantsCommonStockShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "genh_ExtensionFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount extension fees.", "label": "ExtensionFees", "terseLabel": "Extension fee" } } }, "localname": "ExtensionFees", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_FebruaryTwoThousandTwentyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FebruaryTwoThousandTwentyMember", "terseLabel": "Issued in February 2020 [Member]" } } }, "localname": "FebruaryTwoThousandTwentyMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_FeesExceeding": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fees Exceeding.", "label": "FeesExceeding", "terseLabel": "Fees Exceeding" } } }, "localname": "FeesExceeding", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_FinancingObligations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of financing obligations.", "label": "FinancingObligations", "terseLabel": "Financing obligations" } } }, "localname": "FinancingObligations", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "monetaryItemType" }, "genh_GainLossChangeInFairValueOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Change in fair value of marketable securities.", "label": "GainLossChangeInFairValueOfMarketableSecurities", "negatedLabel": "Change in fair value of marketable securities" } } }, "localname": "GainLossChangeInFairValueOfMarketableSecurities", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_GrandTraverseHoldingsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "GrandTraverseHoldingsLLCMember", "terseLabel": "Grand Traverse Holdings, LLC [Member]" } } }, "localname": "GrandTraverseHoldingsLLCMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "genh_HalcyonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "HalcyonMember", "terseLabel": "Halcyon [Member]" } } }, "localname": "HalcyonMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "domainItemType" }, "genh_IncomeTaxesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "localname": "IncomeTaxesLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "genh_IncomeTaxesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Taxes [Table]" } } }, "localname": "IncomeTaxesTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/IncomeTaxes" ], "xbrltype": "stringItemType" }, "genh_IntangiblesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IntangiblesAbstract", "terseLabel": "Intangibles:" } } }, "localname": "IntangiblesAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "stringItemType" }, "genh_InterestAndAttorneyFees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest and attorney fees.", "label": "InterestAndAttorneyFees", "terseLabel": "Interest and attorney fees" } } }, "localname": "InterestAndAttorneyFees", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_InterestExpenses": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Interest expense.", "label": "InterestExpenses", "terseLabel": "Interest expense" } } }, "localname": "InterestExpenses", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_InterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate.", "label": "InterestRate", "terseLabel": "Interest rate" } } }, "localname": "InterestRate", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "percentItemType" }, "genh_InvestmentIncomeInterests": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "InvestmentIncomeInterests", "terseLabel": "Interest and other income" } } }, "localname": "InvestmentIncomeInterests", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_InvestorTotalProceeds": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "InvestorTotalProceeds", "terseLabel": "Investor total proceeds" } } }, "localname": "InvestorTotalProceeds", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfCommonShares": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common shares.", "label": "IssuanceOfCommonShares", "terseLabel": "- issuance of common shares" } } }, "localname": "IssuanceOfCommonShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfCommonSharesForExtensionOfSecuredNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of issuance of common shares for extension of secured note.", "label": "IssuanceOfCommonSharesForExtensionOfSecuredNote", "terseLabel": "Issuance of common shares for extension of secured note" } } }, "localname": "IssuanceOfCommonSharesForExtensionOfSecuredNote", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfCommonSharesForExtensionOfSecuredNoteinShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The shares of issuance for common shares for extension of secured note.", "label": "IssuanceOfCommonSharesForExtensionOfSecuredNoteinShares", "terseLabel": "Issuance of common shares for extension of secured note (in Shares)" } } }, "localname": "IssuanceOfCommonSharesForExtensionOfSecuredNoteinShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_IssuanceOfCommonStockUnits": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "IssuanceOfCommonStockUnits", "terseLabel": "Issuance of common stock units" } } }, "localname": "IssuanceOfCommonStockUnits", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfCommonStockUnitsPreviouslySubscribed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common stock units previously subscribed.", "label": "IssuanceOfCommonStockUnitsPreviouslySubscribed", "terseLabel": "Issuance of common stock units previously subscribed" } } }, "localname": "IssuanceOfCommonStockUnitsPreviouslySubscribed", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_IssuanceOfRestrictedCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of Restricted common stock.", "label": "IssuanceOfRestrictedCommonStock", "terseLabel": "Issuance of restricted common stock (in Shares)" } } }, "localname": "IssuanceOfRestrictedCommonStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "sharesItemType" }, "genh_IssuanceOfSubordinatedNote": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of subordinated note", "label": "IssuanceOfSubordinatedNote", "terseLabel": "- issuance of subordinated note" } } }, "localname": "IssuanceOfSubordinatedNote", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_IssuancesOfCommonSharesForExchangeOrConversionOfDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuances of common shares for exchange or conversion of debt.", "label": "IssuancesOfCommonSharesForExchangeOrConversionOfDebt", "terseLabel": "Issuances of common shares for exchange or conversion of debt" } } }, "localname": "IssuancesOfCommonSharesForExchangeOrConversionOfDebt", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_IssuedUponExchangeOfEHRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedUponExchangeOfEHRMember", "terseLabel": "Issued upon exchange of EHR [Member]" } } }, "localname": "IssuedUponExchangeOfEHRMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_IssuedUponExchangeOfEHROneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "IssuedUponExchangeOfEHROneMember", "terseLabel": "Issued upon exchange of EHR One [Member]" } } }, "localname": "IssuedUponExchangeOfEHROneMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_JohnGallegosMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JohnGallegosMember", "terseLabel": "John Gallegos [Member]" } } }, "localname": "JohnGallegosMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "genh_LeaseAndRentalExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "LeaseAndRentalExpenses", "terseLabel": "Lease and rental expense" } } }, "localname": "LeaseAndRentalExpenses", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_LeaseExpenses": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "LeaseExpenses", "terseLabel": "Lease expense" } } }, "localname": "LeaseExpenses", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_LeaseTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease term.", "label": "LeaseTerm", "terseLabel": "Lease term" } } }, "localname": "LeaseTerm", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "durationItemType" }, "genh_LessDebtDiscountsAndIssuanceCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "LessDebtDiscountsAndIssuanceCosts", "terseLabel": "Less debt discounts" } } }, "localname": "LessDebtDiscountsAndIssuanceCosts", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "genh_LessOtherIndebtednessCurrentPortion": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable": { "order": 2.0, "parentTag": "genh_TotalOtherIndebtednessLongterm", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "LessOtherIndebtednessCurrentPortion", "negatedLabel": "Less current portion" } } }, "localname": "LessOtherIndebtednessCurrentPortion", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable" ], "xbrltype": "monetaryItemType" }, "genh_LessPreferredStockDividends": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "LessPreferredStockDividends", "terseLabel": "Less: preferred stock dividends (in Dollars)" } } }, "localname": "LessPreferredStockDividends", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "genh_LiableForTheAssertedDamages": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "LiableForTheAssertedDamages", "terseLabel": "Liable for the asserted damages" } } }, "localname": "LiableForTheAssertedDamages", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_LitigationSettlementInterestPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Litigation Settlement interest percentage.", "label": "LitigationSettlementInterestPercentage", "terseLabel": "Litigation settlement interest percentage" } } }, "localname": "LitigationSettlementInterestPercentage", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "genh_LossFromContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LossFromContinuingOperationsAbstract", "terseLabel": "Loss from continuing operations" } } }, "localname": "LossFromContinuingOperationsAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_LossIncomeFromDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LossIncomeFromDiscontinuedOperationsAbstract", "terseLabel": "(Loss) income from discontinued operations" } } }, "localname": "LossIncomeFromDiscontinuedOperationsAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_MarchTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MarchTwoThousandTwentyOneMember", "terseLabel": "March Two Thousand Twenty One [Member]" } } }, "localname": "MarchTwoThousandTwentyOneMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_MaturityDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maturity date.", "label": "MaturityDate", "terseLabel": "Maturity date" } } }, "localname": "MaturityDate", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "dateItemType" }, "genh_MergerAndAcquisitionCosts": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 3.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "MergerAndAcquisitionCosts", "terseLabel": "Merger and acquisition costs" } } }, "localname": "MergerAndAcquisitionCosts", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_MortgagePayableDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "MortgagePayableDescription", "terseLabel": "Mortgage payable, description" } } }, "localname": "MortgagePayableDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "stringItemType" }, "genh_NetAcquiredCash": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "NetAcquiredCash", "terseLabel": "Acquisition of certain assets of Halcyon Thruput, LLC, net of acquired cash of $224,530" } } }, "localname": "NetAcquiredCash", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_NetLossFromContinuingOperationsAttributableToCommonStockholders": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetLossFromContinuingOperationsAttributableToCommonStockholders", "terseLabel": "Loss from continuing operations attributable to common stockholders (in Dollars)" } } }, "localname": "NetLossFromContinuingOperationsAttributableToCommonStockholders", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "genh_NewEquityCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NewEquityCapital", "terseLabel": "New equity capital" } } }, "localname": "NewEquityCapital", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "genh_NewMonthlyPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "NewMonthlyPayment", "terseLabel": "Lease monthly payments" } } }, "localname": "NewMonthlyPayment", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_NoncashInvestingAndFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NoncashInvestingAndFinancingActivitiesAbstract", "terseLabel": "Noncash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingActivitiesAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "stringItemType" }, "genh_NoncompetitionAgreements": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of non competition agreements.", "label": "NoncompetitionAgreements", "terseLabel": "Non-competition agreements" } } }, "localname": "NoncompetitionAgreements", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "genh_NonpayrollExpenses": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nonpayroll expenses.", "label": "NonpayrollExpenses", "terseLabel": "Nonpayroll expenses" } } }, "localname": "NonpayrollExpenses", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "percentItemType" }, "genh_NotePayableRelatedPartyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note Payable Related Party [Abstract]" } } }, "localname": "NotePayableRelatedPartyAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_NotePayableRelatedPartyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NotePayableRelatedPartyTextBlock", "terseLabel": "Notes Payable \u2013 Related Parties" } } }, "localname": "NotePayableRelatedPartyTextBlock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedParties" ], "xbrltype": "textBlockItemType" }, "genh_NotesPayableRelatedPartiesClassifiedAsCurrent": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "NotesPayableRelatedPartiesClassifiedAsCurrent", "terseLabel": "Notes payable \u2013 related parties" } } }, "localname": "NotesPayableRelatedPartiesClassifiedAsCurrent", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "genh_NotesPayableRelatedPartiesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) [Line Items]" } } }, "localname": "NotesPayableRelatedPartiesDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "genh_NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable related parties [Line Items]" } } }, "localname": "NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "genh_NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) - Schedule of notes payable related parties [Table]" } } }, "localname": "NotesPayableRelatedPartiesDetailsScheduleofnotespayablerelatedpartiesTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "genh_NotesPayableRelatedPartiesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes Payable \u2013 Related Parties (Details) [Table]" } } }, "localname": "NotesPayableRelatedPartiesDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "genh_NumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares.", "label": "NumberOfShares", "terseLabel": "Number of shares (in Shares)" } } }, "localname": "NumberOfShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "genh_NumeratorAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "NumeratorAbstract", "terseLabel": "Numerator" } } }, "localname": "NumeratorAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "stringItemType" }, "genh_OilAndGasSales": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Oil and gas sales.", "label": "OilAndGasSales", "terseLabel": "Oil and gas sales" } } }, "localname": "OilAndGasSales", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "genh_OperatingLeasesFutureMinimumPaymentsRentDue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsRentDue", "terseLabel": "Minimum future rents" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRentDue", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_OperatingLeasesFutureMinimumPaymentsRentTwelveMonths": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsRentTwelveMonths", "terseLabel": "Minimum future rents twelve months" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRentTwelveMonths", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_OperatingLeasesFutureMinimumPaymentsRentTwoYears": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OperatingLeasesFutureMinimumPaymentsRentTwoYears", "terseLabel": "Minimum future rents two years" } } }, "localname": "OperatingLeasesFutureMinimumPaymentsRentTwoYears", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_OperatingLeasesWeightedAverageDiscountRatePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "OperatingLeasesWeightedAverageDiscountRatePercent", "terseLabel": "Incremental borrowing rate" } } }, "localname": "OperatingLeasesWeightedAverageDiscountRatePercent", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "percentItemType" }, "genh_OtherIndebtednessCurrent": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other indebtedness - current.", "label": "OtherIndebtednessCurrent", "terseLabel": "Other indebtedness - current" } } }, "localname": "OtherIndebtednessCurrent", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "genh_OtherIndebtednessDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Indebtedness (Details) [Line Items]" } } }, "localname": "OtherIndebtednessDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "stringItemType" }, "genh_OtherIndebtednessDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Indebtedness (Details) [Table]" } } }, "localname": "OtherIndebtednessDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "stringItemType" }, "genh_OtherIndebtednessNoncurrent": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other indebtedness - long-term.", "label": "OtherIndebtednessNoncurrent", "terseLabel": "Other indebtedness - long-term" } } }, "localname": "OtherIndebtednessNoncurrent", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "genh_OwnsApproximatelysPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OwnsApproximatelysPercent", "terseLabel": "Owns approximately percentage" } } }, "localname": "OwnsApproximatelysPercent", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "percentItemType" }, "genh_OzCapitalLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "OzCapitalLLCMember", "terseLabel": "Oz Capital, LLC [Member]" } } }, "localname": "OzCapitalLLCMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "genh_PaycheckProtectionProgramLoanAmount": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable": { "order": 2.0, "parentTag": "us-gaap_DebtInstrumentDecreaseForgiveness", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "PaycheckProtectionProgramLoanAmount", "terseLabel": "Paycheck Protection Program Loan" } } }, "localname": "PaycheckProtectionProgramLoanAmount", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable" ], "xbrltype": "monetaryItemType" }, "genh_PaymentOfMortgagePayable": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value of The fair value of transfer of mortgage payable in financing activities.", "label": "PaymentOfMortgagePayable", "negatedLabel": "Payment of mortgage payable" } } }, "localname": "PaymentOfMortgagePayable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_PaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Payment received.", "label": "PaymentReceived", "terseLabel": "Insurance proceeds" } } }, "localname": "PaymentReceived", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "genh_PercentageOfNetProfit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of net profit.", "label": "PercentageOfNetProfit", "terseLabel": "Interest Rate" } } }, "localname": "PercentageOfNetProfit", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "percentItemType" }, "genh_PostharvestAndMidstreamServices": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Post-harvest and midstream services.", "label": "PostharvestAndMidstreamServices", "terseLabel": "Post-harvest and midstream services" } } }, "localname": "PostharvestAndMidstreamServices", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_PppLoanAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "PPP loan amount.", "label": "PppLoanAmount", "terseLabel": "PPP loan amount" } } }, "localname": "PppLoanAmount", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "genh_PreferredStockConvertedIntoCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred Stock converted into common stock.", "label": "PreferredStockConvertedIntoCommonStock", "terseLabel": "Preferred stock converted into common stock" } } }, "localname": "PreferredStockConvertedIntoCommonStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "genh_PreferredStockDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock description.", "label": "PreferredStockDescription", "terseLabel": "Preferred stock description" } } }, "localname": "PreferredStockDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "stringItemType" }, "genh_PreferredStockStatedValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred stock stated value.", "label": "PreferredStockStatedValue", "terseLabel": "Preferred stock, stated value (in Dollars per share)" } } }, "localname": "PreferredStockStatedValue", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "genh_PreferredStockStatedValues": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "PreferredStockStatedValues", "terseLabel": "Preferred stock, Stated Value (in Dollars)", "verboseLabel": "Preferred stock stated value (in Dollars)" } } }, "localname": "PreferredStockStatedValues", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "genh_ProceedsFromSaleOfInvestmentInCommonStock": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from sale of investment in common stock.", "label": "ProceedsFromSaleOfInvestmentInCommonStock", "terseLabel": "Proceeds from sale of investment in common stock" } } }, "localname": "ProceedsFromSaleOfInvestmentInCommonStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_ProceedsFromSbaPppLoan": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "ProceedsFromSbaPppLoan", "terseLabel": "Proceeds from SBA PPP Loan" } } }, "localname": "ProceedsFromSbaPppLoan", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_PromissoryNoteAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Promissory note", "label": "PromissoryNoteAmount", "terseLabel": "Promissory note" } } }, "localname": "PromissoryNoteAmount", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "genh_PropertyAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PropertyAndEquipmentAbstract", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyAndEquipmentAbstract", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "genh_PurchaseOfCommonStock": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "PurchaseOfCommonStock", "terseLabel": "Purchase of common stock" } } }, "localname": "PurchaseOfCommonStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "genh_RealEstateOccupiedDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Real Estate Occupied, description", "label": "RealEstateOccupiedDescription", "terseLabel": "Real estate occupied, description" } } }, "localname": "RealEstateOccupiedDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "stringItemType" }, "genh_RedemptionsOfSeriesBPreferredStock": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "RedemptionsOfSeriesBPreferredStock", "negatedLabel": "Redemptions of Series B preferred stock" } } }, "localname": "RedemptionsOfSeriesBPreferredStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_Rental": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Rental", "terseLabel": "Rental" } } }, "localname": "Rental", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "genh_RepaymentOfSubordinatedNotes": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of subordinated notes.", "label": "RepaymentOfSubordinatedNotes", "negatedLabel": "Repayment of subordinated notes" } } }, "localname": "RepaymentOfSubordinatedNotes", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_RestrictedCommonShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restricted common shares.", "label": "RestrictedCommonShares", "terseLabel": "Restricted common shares (in Shares)" } } }, "localname": "RestrictedCommonShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "genh_RevenuePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue payable.", "label": "RevenuePayable", "terseLabel": "Revenue payable" } } }, "localname": "RevenuePayable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "genh_SaleOfPreferredStockUnits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of preffered stock units.", "label": "SaleOfPreferredStockUnits", "terseLabel": "Sale of preferred stock units (in Dollars)" } } }, "localname": "SaleOfPreferredStockUnits", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "monetaryItemType" }, "genh_ScheduleOfAmortizableTangibleAndIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of amortizable tangible and intangible assets [Abstract]" } } }, "localname": "ScheduleOfAmortizableTangibleAndIntangibleAssetsAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfDiscontinuedOperationsShownInConsolidatedStatementsOfOperationsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfDiscontinuedOperationsShownInConsolidatedStatementsOfOperationsTableTextBlock", "terseLabel": "Schedule of discontinued operations shown in the consolidated statements of operations" } } }, "localname": "ScheduleOfDiscontinuedOperationsShownInConsolidatedStatementsOfOperationsTableTextBlock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "genh_ScheduleOfDiscontinuedOperationsShownInTheConsolidatedStatementsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of discontinued operations shown in the consolidated statements of operations [Abstract]" } } }, "localname": "ScheduleOfDiscontinuedOperationsShownInTheConsolidatedStatementsOfOperationsAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of discontinued operations to assets and liabilities [Abstract]" } } }, "localname": "ScheduleOfDiscontinuedOperationsToAssetsAndLiabilitiesAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfEarningsLossPerBasicAndDilutedShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of earnings (loss) per basic and diluted share [Abstract]" } } }, "localname": "ScheduleOfEarningsLossPerBasicAndDilutedShareAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfNotesPayableRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of notes payable related parties [Abstract]" } } }, "localname": "ScheduleOfNotesPayableRelatedPartiesAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfNotesPayableRelatedPartiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "terseLabel": "Schedule of notes payable related parties" } } }, "localname": "ScheduleOfNotesPayableRelatedPartiesTableTextBlock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesTables" ], "xbrltype": "textBlockItemType" }, "genh_ScheduleOfOtherIndebtednessAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of other indebtedness [Abstract]" } } }, "localname": "ScheduleOfOtherIndebtednessAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfOutstandingStockWarrantsActivityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of outstanding stock warrants activity [Abstract]" } } }, "localname": "ScheduleOfOutstandingStockWarrantsActivityAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfProFormaConsolidatedResultsOfOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of pro forma consolidated results of operations [Abstract]" } } }, "localname": "ScheduleOfProFormaConsolidatedResultsOfOperationsAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfSupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of supplemental cash flow information [Abstract]" } } }, "localname": "ScheduleOfSupplementalCashFlowInformationAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_ScheduleOfWarrantsOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of warrants outstanding [Abstract]" } } }, "localname": "ScheduleOfWarrantsOutstandingAbstract", "nsuri": "http://www.genhempinc.com/20210930", "xbrltype": "stringItemType" }, "genh_SecuredPromissoryNoteToCoventryAssetManagementLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SecuredPromissoryNoteToCoventryAssetManagementLtdMember", "terseLabel": "Secured Promissory Note to Coventry Asset Management, LTD. [Member]" } } }, "localname": "SecuredPromissoryNoteToCoventryAssetManagementLtdMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_SeniorSecuredPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeniorSecuredPromissoryNoteMember", "terseLabel": "Senior Secured Promissory Note [Member]" } } }, "localname": "SeniorSecuredPromissoryNoteMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_SeriesBPreferredStockDividendPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Series B preferred stock dividend payable.", "label": "SeriesBPreferredStockDividendPayable", "terseLabel": "Series B preferred stock dividend payable" } } }, "localname": "SeriesBPreferredStockDividendPayable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "genh_SeriesBPreferredStockDividendsPaid": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Series B preferred stock dividends paid.", "label": "SeriesBPreferredStockDividendsPaid", "terseLabel": "Series B preferred stock dividends paid" } } }, "localname": "SeriesBPreferredStockDividendsPaid", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "genh_SeriesBRedeemablePreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SeriesBRedeemablePreferredStockMember", "terseLabel": "Series B Redeemable Preferred Stock" } } }, "localname": "SeriesBRedeemablePreferredStockMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "genh_ServiceRevenuePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ServiceRevenuePercentage", "terseLabel": "Service revenue percentage" } } }, "localname": "ServiceRevenuePercentage", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "percentItemType" }, "genh_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants, exercised", "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriod", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExpirationsInPeriod", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable" ], "xbrltype": "sharesItemType" }, "genh_SharesOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares of Common stock.", "label": "SharesOfCommonStock", "terseLabel": "Shares of Common stock" } } }, "localname": "SharesOfCommonStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "genh_SquareFootFacility": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Square Foot Facility", "label": "SquareFootFacility", "terseLabel": "Square Foot Facility (in Dollars per Square Foot)" } } }, "localname": "SquareFootFacility", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "perUnitItemType" }, "genh_StockBasedCompensationDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Line Items]" } } }, "localname": "StockBasedCompensationDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "genh_StockBasedCompensationDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stock-Based Compensation (Details) [Table]" } } }, "localname": "StockBasedCompensationDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "genh_StockIssuedDuringPeriodValueIssuanceofCommonSharesForSeniorSecuredPromissoryShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Issuance of common shares for Senior Secured Promissory Note (in Shares)", "label": "StockIssuedDuringPeriodValueIssuanceofCommonSharesForSeniorSecuredPromissoryShares", "terseLabel": "Issuance of common shares for Senior Secured Promissory Note (in Shares)" } } }, "localname": "StockIssuedDuringPeriodValueIssuanceofCommonSharesForSeniorSecuredPromissoryShares", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_StockIssuedDuringSharesOfIssuanceOfCommonSharesForConvertiblePromissoryNote": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during shares of Issuance of common shares for Convertible Promissory Note.", "label": "StockIssuedDuringSharesOfIssuanceOfCommonSharesForConvertiblePromissoryNote", "terseLabel": "Issuance of common shares for Convertible Promissory Note (in Shares)" } } }, "localname": "StockIssuedDuringSharesOfIssuanceOfCommonSharesForConvertiblePromissoryNote", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "genh_StockIssuedDuringThePeriodValueIssuanceOfCommonSharesForSeniorSecuredPromissoryNotes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Issuance of common shares for Senior Secured Promissory Note", "label": "StockIssuedDuringThePeriodValueIssuanceOfCommonSharesForSeniorSecuredPromissoryNotes", "terseLabel": "Issuance of common shares for Senior Secured Promissory Note" } } }, "localname": "StockIssuedDuringThePeriodValueIssuanceOfCommonSharesForSeniorSecuredPromissoryNotes", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "genh_SubordinatedNoteToInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SubordinatedNoteToInvestorMember", "terseLabel": "Subordinated Note to Investor [Member]" } } }, "localname": "SubordinatedNoteToInvestorMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "genh_SubordinatedPromissoryNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SubordinatedPromissoryNoteMember", "terseLabel": "Subordinated Promissory Note to CEO [Member]", "verboseLabel": "Subordinated Promissory Note [Member]" } } }, "localname": "SubordinatedPromissoryNoteMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_SubordinatedPromissoryNoteToInvestorMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SubordinatedPromissoryNoteToInvestorMember", "terseLabel": "Subordinated Promissory Note to Investor [Member]" } } }, "localname": "SubordinatedPromissoryNoteToInvestorMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "genh_SubordinatedPromissouryNoteDueDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subordinated promissoury note due date.", "label": "SubordinatedPromissouryNoteDueDate", "terseLabel": "Subordinated Promissory note due date" } } }, "localname": "SubordinatedPromissouryNoteDueDate", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "dateItemType" }, "genh_SubsequentEventsDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Line Items]" } } }, "localname": "SubsequentEventsDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "genh_SubsequentEventsDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "localname": "SubsequentEventsDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "genh_SummaryofSignificantAccountingPoliciesDetailsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Line Items]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsLineItems", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "genh_SummaryofSignificantAccountingPoliciesDetailsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "genh_TotalOtherIndebtednessLongterm": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "TotalOtherIndebtednessLongterm", "totalLabel": "Total Other Indebtedness - Long-Term" } } }, "localname": "TotalOtherIndebtednessLongterm", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable" ], "xbrltype": "monetaryItemType" }, "genh_TotalUnrecognizedCompensationCost": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total unrecognized compensation cost.", "label": "TotalUnrecognizedCompensationCost", "terseLabel": "Total unrecognized compensation cost" } } }, "localname": "TotalUnrecognizedCompensationCost", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "genh_TwoThousandTwentyOnePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "TwoThousandTwentyOnePlanMember", "terseLabel": "2021 Plan [Member]" } } }, "localname": "TwoThousandTwentyOnePlanMember", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "genh_WarrantToPurchaseOfCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrant to purchase of common stock.", "label": "WarrantToPurchaseOfCommonStock", "terseLabel": "Warrant to purchase of common stock (in Shares)" } } }, "localname": "WarrantToPurchaseOfCommonStock", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "sharesItemType" }, "genh_WarrantsAndRightsOutstandingMaturityDateDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified", "label": "WarrantsAndRightsOutstandingMaturityDateDescription", "terseLabel": "Expiration Date" } } }, "localname": "WarrantsAndRightsOutstandingMaturityDateDescription", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "genh_WeightedAveragePriceExceed": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "weighted average price exceed.", "label": "WeightedAveragePriceExceed", "terseLabel": "Weighted average price exceed (in Dollars per share)" } } }, "localname": "WeightedAveragePriceExceed", "nsuri": "http://www.genhempinc.com/20210930", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r168", "r264", "r265", "r408" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "xbrltype": "stringItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [ "r120", "r268" ], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast [Member]" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r120", "r125", "r268" ], "lang": { "en-us": { "role": { "label": "Scenario [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r120", "r125", "r198", "r268", "r352" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r169", "r345" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]" } } }, "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r48", "r349" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r22", "r36", "r170", "r171" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r59", "r109", "r343", "r346" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Accounts Receivable, Related Parties, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionExpense": { "auth_ref": [ "r190", "r192", "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.", "label": "Accretion Expense", "terseLabel": "Accretion" } } }, "localname": "AccretionExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r50" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": { "auth_ref": [ "r377", "r400" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.", "label": "Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedCapitalizedInterestCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated interest costs capitalized as part of property, plant and equipment cost basis.", "label": "Accumulated Capitalized Interest Costs", "negatedLabel": "Accumulated DD&A" } } }, "localname": "AccumulatedCapitalizedInterestCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r45", "r186" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r37", "r283", "r349" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r112", "r113", "r114", "r280", "r281", "r282", "r320" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock": { "auth_ref": [ "r237", "r254", "r261" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease (increase) in additional paid in capital (APIC) for the increase in carrying amount of redeemable preferred stock.", "label": "Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock", "terseLabel": "Series B preferred stock redemption" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss from continuing operations to net cash from operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfDebtDiscountPremium": { "auth_ref": [ "r81", "r93", "r230", "r334" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.", "label": "Amortization of Debt Discount (Premium)", "terseLabel": "Amortization of debt discount" } } }, "localname": "AmortizationOfDebtDiscountPremium", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetRetirementObligationsNoncurrent": { "auth_ref": [ "r191" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncurrent portion of the carrying amount of a liability for an asset retirement obligation. An asset retirement obligation is a legal obligation associated with the disposal or retirement of a tangible long-lived asset that results from the acquisition, construction or development, or the normal operations of a long-lived asset, except for certain obligations of lessees.", "label": "Asset Retirement Obligations, Noncurrent", "terseLabel": "Asset retirement obligations" } } }, "localname": "AssetRetirementObligationsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r107", "r155", "r158", "r164", "r173", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r309", "r314", "r324", "r347", "r349", "r371", "r391" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r24", "r26", "r63", "r107", "r173", "r201", "r202", "r203", "r205", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r309", "r314", "r324", "r347", "r349" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_AuctionMarketPreferredSecuritiesStockSeriesSharesAuthorized": { "auth_ref": [ "r34", "r255" ], "lang": { "en-us": { "role": { "documentation": "The number of shares of a preferred security the entity has authorized through an auction process.", "label": "Auction Market Preferred Securities, Stock Series, Shares Authorized", "terseLabel": "Shares of series A preferred stock" } } }, "localname": "AuctionMarketPreferredSecuritiesStockSeriesSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r274", "r279" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation" } } }, "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r267", "r269", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r297", "r298" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Schedule of pro forma consolidated results of operations" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax": { "auth_ref": [ "r297", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of pro forma income from continuing operations as if the business combination had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Income (Loss) from Continuing Operations, Net of Tax", "terseLabel": "Income (loss) from continuing operations" } } }, "localname": "BusinessAcquisitionsProFormaIncomeLossFromContinuingOperationsBeforeChangesInAccountingAndExtraordinaryItemsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofproformaconsolidatedresultsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r297", "r298" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Revenue, continuing operations" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofproformaconsolidatedresultsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r301", "r302", "r303" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration value" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "Business Combination Disclosure [Text Block]", "terseLabel": "Acquisition" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/Acquisition" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combinations [Abstract]" } } }, "localname": "BusinessCombinationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_Cash": { "auth_ref": [ "r43", "r349", "r414", "r415" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r21", "r43", "r95" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "periodEndLabel": "Cash, end of period", "periodStartLabel": "Cash, beginning of period", "terseLabel": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r89", "r325" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "terseLabel": "Supplemental Cash Flow Information" } } }, "localname": "CashFlowSupplementalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/SupplementalCashFlowInformation" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations": { "auth_ref": [ "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities of discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Cash Provided by (Used in) Financing Activities, Discontinued Operations", "terseLabel": "Net cash from financing activities \u2013 discontinued operations" } } }, "localname": "CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r13", "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Cash Provided by (Used in) Investing Activities, Discontinued Operations", "terseLabel": "Net cash from investing activities \u2013 discontinued operations" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r13", "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Cash Provided by (Used in) Operating Activities, Discontinued Operations", "terseLabel": "Net cash from operating activities \u2013 discontinued operations" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r104", "r107", "r128", "r129", "r134", "r137", "r139", "r147", "r148", "r149", "r173", "r201", "r206", "r207", "r208", "r212", "r213", "r240", "r241", "r244", "r248", "r324", "r424" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r262", "r272" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise Price (each)", "verboseLabel": "Exercise price per share (in Dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of warrants" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Warrants, ending", "periodStartLabel": "Warrants, beginning" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightReasonForIssuingToNonemployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of reason for issuing warrant or right.", "label": "Warrant or Right, Reason for Issuance, Description", "terseLabel": "Method of Exercise" } } }, "localname": "ClassOfWarrantOrRightReasonForIssuingToNonemployees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r262", "r272" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r57", "r197", "r378", "r399" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r194", "r195", "r196", "r199", "r418" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r112", "r113", "r320" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "netLabel": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common Stock Unites [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Per share value (in Dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails", "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "verboseLabel": "Company common stock (in Shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AcquisitionDetails", "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r35", "r254" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r35", "r349" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.00001 par value; 200,000,000 shares authorized, 111,070,329 shares issued and outstanding at September 30, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonUnitIssuanceValue": { "auth_ref": [], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stated value of common units of ownership issued by a limited liability company (LLC).", "label": "Common Unit, Issuance Value", "terseLabel": "Common stock issuable" } } }, "localname": "CommonUnitIssuanceValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r150", "r388" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Major Customer and Concentration of Credit Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConversionOfStockAmountIssued1": { "auth_ref": [ "r97", "r98", "r99" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock, Amount Issued", "terseLabel": "Convertible Promissory Note to CEO" } } }, "localname": "ConversionOfStockAmountIssued1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleDebt": { "auth_ref": [ "r32", "r373", "r393" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company.", "label": "Convertible Debt", "terseLabel": "Convertible debt" } } }, "localname": "ConvertibleDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConvertibleNotesPayable": { "auth_ref": [ "r32", "r373", "r392", "r416" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder.", "label": "Convertible Notes Payable", "terseLabel": "Current liabilities of discontinued operations held for sale" } } }, "localname": "ConvertibleNotesPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r78", "r107", "r173", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r324" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Cost of revenue (exclusive of items shown separately below)" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpenses": { "auth_ref": [ "r76" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total costs of sales and operating expenses for the period.", "label": "Costs and Expenses", "totalLabel": "Total costs and expenses" } } }, "localname": "CostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostsAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Costs and Expenses [Abstract]", "terseLabel": "Costs and Expenses" } } }, "localname": "CostsAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_DebtConversionOriginalDebtInterestRateOfDebt": { "auth_ref": [ "r97", "r99" ], "lang": { "en-us": { "role": { "documentation": "The rate of interest that was being paid on the original debt issue that is being converted in the noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Debt Conversion, Original Debt, Interest Rate of Debt", "terseLabel": "Interest rate" } } }, "localname": "DebtConversionOriginalDebtInterestRateOfDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r30", "r31", "r32", "r106", "r110", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r337", "r372", "r373", "r389" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "auth_ref": [ "r216", "r231" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the debt instrument.", "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price (in Dollars per share)" } } }, "localname": "DebtInstrumentConvertibleConversionPrice1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature": { "auth_ref": [ "r54", "r255", "r258", "r259" ], "lang": { "en-us": { "role": { "documentation": "Description of conversion terms for debt instrument.", "label": "Debt Instrument, Convertible, Terms of Conversion Feature", "terseLabel": "Option exercisable" } } }, "localname": "DebtInstrumentConvertibleTermsOfConversionFeature", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentDecreaseForgiveness": { "auth_ref": [ "r106" ], "calculation": { "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable": { "order": 1.0, "parentTag": "genh_TotalOtherIndebtednessLongterm", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Decrease for amounts of indebtedness forgiven by the holder of the debt instrument.", "label": "Debt Instrument, Decrease, Forgiveness", "totalLabel": "Total" } } }, "localname": "DebtInstrumentDecreaseForgiveness", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r214", "r232", "r233", "r335", "r337", "r338" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "auth_ref": [ "r106" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.", "label": "Debt Instrument, Increase, Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DebtInstrumentIncreaseAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r52", "r215" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Bears interest" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentMaturityDate": { "auth_ref": [ "r53", "r217", "r323" ], "lang": { "en-us": { "role": { "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.", "label": "Debt Instrument, Maturity Date", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "dateItemType" }, "us-gaap_DebtInstrumentMaturityDateDescription": { "auth_ref": [ "r53" ], "lang": { "en-us": { "role": { "documentation": "Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.", "label": "Debt Instrument, Maturity Date, Description", "terseLabel": "Maturity date" } } }, "localname": "DebtInstrumentMaturityDateDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r55", "r106", "r110", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r232", "r233", "r234", "r235", "r337" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_DepositLiabilitiesAccruedInterest": { "auth_ref": [ "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accrued but unpaid interest on deposit liabilities.", "label": "Deposit Liabilities, Accrued Interest", "terseLabel": "Accrued interest" } } }, "localname": "DepositLiabilitiesAccruedInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r93", "r184" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r93", "r154" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r284" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r10", "r11", "r73", "r403" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, before Income Tax", "terseLabel": "Loss from discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Basic Share", "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "Basic" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation, Net of Tax, Per Diluted Share", "terseLabel": "Diluted (in Dollars per share)", "verboseLabel": "Diluted" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInterestExpense": { "auth_ref": [ "r8", "r9", "r12", "r18" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Interest Expense", "terseLabel": "Interest expense" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r19", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "terseLabel": "Discontinued Operations" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/DiscontinuedOperations" ], "xbrltype": "textBlockItemType" }, "us-gaap_DividendsPreferredStock": { "auth_ref": [ "r261", "r387" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).", "label": "Dividends, Preferred Stock", "negatedLabel": "Series B preferred stock dividend" } } }, "localname": "DividendsPreferredStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrent": { "auth_ref": [ "r48", "r109", "r204", "r206", "r207", "r211", "r212", "r213", "r343" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).", "label": "Due to Related Parties, Current", "terseLabel": "Payables to related parties" } } }, "localname": "DueToRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r109", "r204", "r206", "r207", "r211", "r212", "r213", "r343", "r376", "r401" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.", "label": "Due to Related Parties", "terseLabel": "Total" } } }, "localname": "DueToRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Earnings (loss) per common share:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r75", "r117", "r118", "r119", "r120", "r121", "r126", "r128", "r137", "r138", "r139", "r143", "r144", "r321", "r322", "r383", "r406" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r75", "r117", "r118", "r119", "r120", "r121", "r128", "r137", "r138", "r139", "r143", "r144", "r321", "r322", "r383", "r406" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (in Dollars per share)", "verboseLabel": "Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r140", "r141", "r142", "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Earnings (Loss) per Share" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for employee benefit and equity-based compensation.", "label": "Employee Benefits and Share-based Compensation", "terseLabel": "Compensation expense related to awards" } } }, "localname": "EmployeeBenefitsAndShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r66", "r67", "r68", "r112", "r113", "r114", "r116", "r122", "r124", "r146", "r174", "r254", "r261", "r280", "r281", "r282", "r289", "r290", "r320", "r326", "r327", "r328", "r329", "r330", "r331", "r409", "r410", "r411", "r426" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value Measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_GainLossOnSaleOfProperty": { "auth_ref": [ "r93" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of oil and gas property or timber property.", "label": "Gain (Loss) on Disposition of Oil and Gas and Timber Property", "terseLabel": "Gain on disposal of oil & gas property interests" } } }, "localname": "GainLossOnSaleOfProperty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r93" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r80" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 4.0, "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r177", "r178", "r349", "r369" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r77", "r94", "r117", "r118", "r119", "r120", "r135", "r139", "r307" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent", "totalLabel": "Net loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r72", "r155", "r157", "r160", "r163", "r165", "r368", "r380", "r385", "r407" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "terseLabel": "Loss from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r69", "r75", "r115", "r117", "r118", "r119", "r120", "r128", "r137", "r138", "r322", "r379", "r381", "r383", "r402" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Basic Share", "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "Basic" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": { "auth_ref": [ "r69", "r75", "r115", "r117", "r118", "r119", "r120", "r128", "r137", "r138", "r139", "r322", "r383", "r402", "r405", "r406" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Income (Loss) from Continuing Operations, Per Diluted Share", "terseLabel": "Diluted (in Dollars per share)", "verboseLabel": "Diluted" } } }, "localname": "IncomeLossFromContinuingOperationsPerDilutedShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r4", "r5", "r6", "r7", "r10", "r16", "r17", "r293", "r403" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "negatedLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent [Abstract]", "terseLabel": "Loss from discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r108", "r285", "r287", "r288", "r291", "r292", "r294", "r295", "r296" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationInterestAccrued": { "auth_ref": [ "r286" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of estimated interest accrued as of the balance sheet date arising from income tax examinations.", "label": "Income Tax Examination, Interest Accrued", "terseLabel": "Accrued interest" } } }, "localname": "IncomeTaxExaminationInterestAccrued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r92" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r92" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInterestPayableNet": { "auth_ref": [ "r92" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.", "label": "Increase (Decrease) in Interest Payable, Net", "terseLabel": "Other income - PPP Loan forgiveness" } } }, "localname": "IncreaseDecreaseInInterestPayableNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r92" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r179", "r180" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r70", "r153", "r333", "r336", "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "terseLabel": "Interest expenses" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaid": { "auth_ref": [ "r96" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.", "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities", "terseLabel": "Cash paid for interest" } } }, "localname": "InterestPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofsupplementalcashflowinformationTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestReceivableAndOtherAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest receivable and assets classified as other.", "label": "Interest Receivable and Other Assets", "terseLabel": "Accrued interest" } } }, "localname": "InterestReceivableAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": { "auth_ref": [ "r93" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.", "label": "Issuance of Stock and Warrants for Services or Claims", "terseLabel": "Common shares issued to vendor for services" } } }, "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r79" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "Legal Fees", "terseLabel": "Legal fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r49", "r107", "r159", "r173", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r310", "r314", "r315", "r324", "r347", "r348" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r41", "r107", "r173", "r324", "r349", "r375", "r396" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Equity (Deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r51", "r107", "r173", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r310", "r314", "r315", "r324", "r347", "r348", "r349" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "auth_ref": [ "r2", "r3", "r14", "r15", "r17", "r183", "r188" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Liabilities, Noncurrent", "terseLabel": "Long-term liabilities of discontinued operations held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOtherThanLongtermDebtNoncurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregated carrying amounts of obligations as of the balance sheet date, excluding long-term debt, incurred as part of the normal operations that are expected to be paid after one year or beyond the normal operating cycle, if longer. Alternate captions include Total Deferred Credits and Other Liabilities.", "label": "Liabilities, Other than Long-term Debt, Noncurrent", "terseLabel": "Total liabilities of discontinued operations held for sale" } } }, "localname": "LiabilitiesOtherThanLongtermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedFromOtherParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount awarded from other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded from Other Party", "terseLabel": "Amount of summary judgment" } } }, "localname": "LitigationSettlementAmountAwardedFromOtherParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r55" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r55", "r200" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r61", "r107", "r173", "r201", "r206", "r207", "r208", "r212", "r213", "r324", "r374", "r395" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Stockholders' Equity Attributable to Noncontrolling Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_MortgageNotesPayableDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for mortgage notes payable.", "label": "Mortgage Notes Payable Disclosure [Text Block]", "terseLabel": "Other Indebtedness" } } }, "localname": "MortgageNotesPayableDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtedness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash from financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash Flows From Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations": { "auth_ref": [ "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations", "totalLabel": "Net cash from financing activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash from investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash Flows From Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations": { "auth_ref": [ "r89" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations", "totalLabel": "Net cash from investing activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r89", "r91", "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash from operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash Flows From Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations": { "auth_ref": [ "r89", "r91", "r94" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations", "totalLabel": "Net cash from operating activities \u2013 continuing operations" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r17", "r64", "r65", "r68", "r74", "r94", "r107", "r115", "r117", "r118", "r119", "r120", "r123", "r124", "r135", "r155", "r157", "r160", "r163", "r165", "r173", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r322", "r324", "r382", "r404" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss attributable to Generation Hemp" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r64", "r65", "r68", "r123", "r124", "r312", "r317" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "terseLabel": "Less: net loss attributable to noncontrolling interests" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "auth_ref": [ "r127", "r130", "r131", "r132", "r133", "r136", "r139" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss attributable to common stockholders (in Dollars)" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) from discontinued operations available to common shareholders.", "label": "Net Income (Loss) from Discontinued Operations Available to Common Shareholders, Basic", "terseLabel": "Loss from discontinued operations (in Dollars)" } } }, "localname": "NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r112", "r113", "r114", "r261", "r305" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r47", "r109", "r344" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Notes Payable, Related Parties, Current", "terseLabel": "Total Notes Payable \u2013 Related Parties" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofnotespayablerelatedpartiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OilAndGasPropertyFullCostMethodNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Oil and gas properties, net of depletion, carried under the full cost method.", "label": "Oil and Gas Property, Full Cost Method, Net", "terseLabel": "Oil and natural gas properties held for sale, at cost" } } }, "localname": "OilAndGasPropertyFullCostMethodNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r155", "r157", "r160", "r163", "r165" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseExpense": { "auth_ref": [ "r341" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating lease expense. Excludes sublease income.", "label": "Operating Lease, Expense", "terseLabel": "Lease operating expense" } } }, "localname": "OperatingLeaseExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r340" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Operating lease liability - related party" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r340" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability - related party, net of current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r339" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r20", "r319" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Business" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/Business" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAdditionalCapital": { "auth_ref": [ "r60", "r83" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of additional paid-in capital (APIC) classified as other.", "label": "Other Additional Capital", "terseLabel": "Other working capital" } } }, "localname": "OtherAdditionalCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssets": { "auth_ref": [ "r29", "r370", "r390" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets classified as other.", "label": "Other Assets", "terseLabel": "Other assets - Purchase option on real estate" } } }, "localname": "OtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsCurrent": { "auth_ref": [ "r62", "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current assets classified as other.", "label": "Other Assets, Current", "terseLabel": "Current Assets" } } }, "localname": "OtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r46" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r56" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Noncurrent", "terseLabel": "Long-term liabilities of discontinued operations held for sale" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total other expense" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other expense (income)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "stringItemType" }, "us-gaap_PaymentsForCapitalImprovements": { "auth_ref": [ "r84" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for acquisition of or capital improvements to properties held for investment (operating, managed, leased) or for use.", "label": "Payments for Capital Improvements", "negatedLabel": "Capital expenditures" } } }, "localname": "PaymentsForCapitalImprovements", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForOperatingActivities": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total amount of cash paid for operating activities during the current period.", "label": "Payments for Operating Activities", "terseLabel": "Cash for operating activities" } } }, "localname": "PaymentsForOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/BusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockConvertibleSharesIssuable": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Number of common shares issuable upon conversion of preferred stock.", "label": "Preferred Stock, Convertible, Shares Issuable", "terseLabel": "Shares of common stock" } } }, "localname": "PreferredStockConvertibleSharesIssuable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockDividendRatePercentage": { "auth_ref": [ "r241" ], "lang": { "en-us": { "role": { "documentation": "The percentage rate used to calculate dividend payments on preferred stock.", "label": "Preferred Stock, Dividend Rate, Percentage", "terseLabel": "Annual dividend rate" } } }, "localname": "PreferredStockDividendRatePercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "percentItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r34", "r240" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock par value (in Dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r34", "r240" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r34" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r34", "r349" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock, Value, Issued", "terseLabel": "Series A preferred stock, $0.00001 par value; $1.00 stated value; 6,500,000 shares authorized, none and 6,328,948 shares issued and outstanding at September 30, 2021 and December 31, 2020" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r23", "r25", "r175", "r176" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r85" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds for common stock issuable" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "auth_ref": [ "r85" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).", "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from warrant exercises" } } }, "localname": "ProceedsFromIssuanceOfWarrants", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSubordinatedShortTermDebt": { "auth_ref": [ "r86" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from an obligation which places a lender in a lien position behind debt having a higher priority of repayment (senior loan) in liquidation of the entity's assets scheduled to be repaid within one year or in the normal operating cycle of the entity, if longer.", "label": "Proceeds from Subordinated Short-term Debt", "terseLabel": "Proceeds from subordinated notes" } } }, "localname": "ProceedsFromSubordinatedShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r17", "r64", "r65", "r68", "r88", "r107", "r115", "r123", "r124", "r155", "r157", "r160", "r163", "r165", "r173", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r308", "r311", "r313", "r317", "r318", "r322", "r324", "r385" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 }, "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow", "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r44", "r185" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r27", "r28", "r187", "r349", "r386", "r398" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "totalLabel": "Total Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentOther": { "auth_ref": [ "r187" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of other physical assets used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Property, Plant and Equipment, Other, Gross", "terseLabel": "Property and equipment, other" } } }, "localname": "PropertyPlantAndEquipmentOther", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_ReceivablesNetCurrent": { "auth_ref": [ "r36", "r42", "r349", "r397", "r417" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.", "label": "Receivables, Net, Current", "terseLabel": "Total assets of discontinued operations held for sale" } } }, "localname": "ReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationstoassetsandliabilitiesTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r266", "r342", "r343" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails", "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r266", "r342", "r343", "r346" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [ "r266" ], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r266", "r342", "r346", "r356", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/CommitmentsandContingenciesDetails", "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_RepaymentsOfOtherDebt": { "auth_ref": [ "r87" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for the payment of debt classified as other.", "label": "Repayments of Other Debt", "terseLabel": "Amended, payments" } } }, "localname": "RepaymentsOfOtherDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RepaymentsOfShortTermDebt": { "auth_ref": [ "r87" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.", "label": "Repayments of Short-term Debt", "negatedLabel": "Repayment of Halcyon bank note" } } }, "localname": "RepaymentsOfShortTermDebt", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Restricted Shares [Member]", "verboseLabel": "Restricted Stock [Member]" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number, after shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Shares Issued Net of Shares for Tax Withholdings", "terseLabel": "Restricted shares, issued (in Shares)" } } }, "localname": "RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_RestrictedStockValueSharesIssuedNetOfTaxWithholdings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after value of shares used to satisfy grantee's tax withholding obligation for award under share-based payment arrangement, of restricted shares issued. Excludes cash used to satisfy grantee's tax withholding obligation.", "label": "Restricted Stock, Value, Shares Issued Net of Tax Withholdings", "terseLabel": "Restricted shares, value" } } }, "localname": "RestrictedStockValueSharesIssuedNetOfTaxWithholdings", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r38", "r261", "r283", "r349", "r394", "r412", "r413" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r112", "r113", "r114", "r116", "r122", "r124", "r174", "r280", "r281", "r282", "r289", "r290", "r320", "r409", "r411" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r71", "r107", "r151", "r152", "r156", "r161", "r162", "r166", "r167", "r168", "r173", "r201", "r202", "r203", "r206", "r207", "r208", "r209", "r210", "r212", "r213", "r324", "r385" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedIncomeStatement": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenue" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenue", "verboseLabel": "Revenue -" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedIncomeStatement", "http://www.genhempinc.com/role/ScheduleofdiscontinuedoperationsshownintheconsolidatedstatementsofoperationsTable" ], "xbrltype": "stringItemType" }, "us-gaap_SaleOfStockPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "label": "Sale of Stock, Price Per Share", "terseLabel": "Warrant per share (in Dollars per share)", "verboseLabel": "Common stock per share (in Dollars per share)" } } }, "localname": "SaleOfStockPricePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented.", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "terseLabel": "Schedule of supplemental cash flow information" } } }, "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/SupplementalCashFlowInformationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of earnings (loss) per basic and diluted share" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofamortizabletangibleandintangibleassetsTable" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r181", "r182" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of amortizable tangible and intangible assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AcquisitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": { "auth_ref": [ "r46" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of noncurrent assets.", "label": "Schedule of Other Assets, Noncurrent [Table Text Block]", "terseLabel": "Schedule of other indebtedness" } } }, "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/OtherIndebtednessTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfQuantitativeInformationAboutFinancialAssetsAndAssociatedLiabilitiesAccountedForAsSecuredBorrowingsTextBlock": { "auth_ref": [ "r354" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the carrying amount and classification of assets and liabilities recognized in the transferor's statement of financial position at the end of each period presented.", "label": "Schedule of Assets and Associated Liabilities Accounted for as Secured Borrowings [Table Text Block]", "terseLabel": "Schedule of discontinued operations to assets and liabilities" } } }, "localname": "ScheduleOfQuantitativeInformationAboutFinancialAssetsAndAssociatedLiabilitiesAccountedForAsSecuredBorrowingsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/DiscontinuedOperationsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTextBlock": { "auth_ref": [ "r33", "r34", "r35", "r236", "r238", "r239", "r255", "r256", "r257", "r258", "r259", "r260", "r261" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.", "label": "Schedule of Stock by Class [Table Text Block]", "terseLabel": "Schedule of outstanding stock warrants activity" } } }, "localname": "ScheduleOfStockByClassTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "auth_ref": [ "r262", "r272" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of warrants outstanding" } } }, "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock", "verboseLabel": "Series A Preferred Stock [Member]" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/EquityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Units [Member]", "verboseLabel": "Series B Preferred Stock [Member]" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock [Member]" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r92" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedCashFlow": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedCashFlow" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "auth_ref": [ "r279" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued under share-based payment arrangement.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period", "terseLabel": "Issued" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofoutstandingstockwarrantsactivityTable" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r272", "r275" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/StockBasedCompensationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationForfeituresPolicyTextBlock": { "auth_ref": [ "r270", "r271", "r278" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy election for determining cost for share-based payment arrangement by either estimating forfeiture expected to occur or by recognizing effect of forfeiture upon occurrence.", "label": "Share-based Payment Arrangement, Forfeiture [Policy Text Block]", "terseLabel": "Stock-based Compensation" } } }, "localname": "ShareBasedCompensationForfeituresPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/AccountingPoliciesByPolicy" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in Shares)", "periodStartLabel": "Balance (in Shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r101", "r111" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/SummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r33", "r34", "r35", "r104", "r107", "r128", "r129", "r134", "r137", "r139", "r147", "r148", "r149", "r173", "r201", "r206", "r207", "r208", "r212", "r213", "r240", "r241", "r244", "r248", "r254", "r324", "r424" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r58", "r66", "r67", "r68", "r112", "r113", "r114", "r116", "r122", "r124", "r146", "r174", "r254", "r261", "r280", "r281", "r282", "r289", "r290", "r320", "r326", "r327", "r328", "r329", "r330", "r331", "r409", "r410", "r411", "r426" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/EquityDetails", "http://www.genhempinc.com/role/ScheduleofwarrantsoutstandingTable", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r112", "r113", "r114", "r146", "r355" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesAcquisitions": { "auth_ref": [ "r34", "r35", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of stock issued during the period pursuant to acquisitions.", "label": "Stock Issued During Period, Shares, Acquisitions", "terseLabel": "Acquisition of Certain Assets of Halcyon Thruput, LLC (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfUnits": { "auth_ref": [ "r34", "r35", "r254", "r255", "r261" ], "lang": { "en-us": { "role": { "documentation": "The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).", "label": "Stock Issued During Period, Shares, Conversion of Units", "terseLabel": "Series B preferred stock redemption (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfUnits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.", "label": "Stock Issued During Period, Shares, Issued for Services", "terseLabel": "Common shares issued to vendor for services (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r34", "r35", "r254", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period, Shares, New Issues", "terseLabel": "Issuances of common stock units (in Shares)", "verboseLabel": "Common stock units (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3", "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r254", "r261" ], "lang": { "en-us": { "role": { "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).", "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r34", "r35", "r254", "r261", "r276" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Warrant exercises (in Shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r58", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Acquisition of Certain Assets of Halcyon Thruput, LLC" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r58", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "terseLabel": "Issuance of common shares for Convertible Promissory Note" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.", "label": "Stock Issued During Period, Value, Issued for Services", "terseLabel": "Common shares issued to vendor for services" } } }, "localname": "StockIssuedDuringPeriodValueIssuedForServices", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r34", "r35", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Issuances of common stock units" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "auth_ref": [ "r34", "r35", "r261", "r273", "r277" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).", "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture", "terseLabel": "Stock-based compensation" } } }, "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r58", "r254", "r261" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Warrant exercises" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockRedeemedOrCalledDuringPeriodValue": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of stock bought back by the entity at the exercise price or redemption price.", "label": "Stock Redeemed or Called During Period, Value", "terseLabel": "Change in common stock par value due to change in corporate domicile" } } }, "localname": "StockRedeemedOrCalledDuringPeriodValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r35", "r39", "r40", "r107", "r172", "r173", "r324", "r349" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "totalLabel": "Generation Hemp equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r0", "r1", "r67", "r107", "r112", "r113", "r114", "r116", "r122", "r173", "r174", "r261", "r280", "r281", "r282", "r289", "r290", "r305", "r306", "r316", "r320", "r324", "r326", "r327", "r331", "r410", "r411", "r426" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Equity (Deficit)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet", "http://www.genhempinc.com/role/ShareholdersEquityType2or3" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r105", "r241", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r261", "r263" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventDescription": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.", "label": "Subsequent Event, Description", "terseLabel": "Subsequent event, description" } } }, "localname": "SubsequentEventDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r332", "r351" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r332", "r351" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r332", "r351" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails", "http://www.genhempinc.com/role/SubsequentEventsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r350", "r353" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r201", "r206", "r207", "r208", "r212", "r213" ], "calculation": { "http://www.genhempinc.com/role/ConsolidatedBalanceSheet": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity, Carrying Amount, Attributable to Parent", "terseLabel": "Series B redeemable preferred stock, no par value, $10,000 stated value, 300 shares authorized, 118 and 135 shares issued and outstanding at September 30, 2021 and December 31, 2020" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransferMortgagePayable": { "auth_ref": [ "r97", "r98", "r99" ], "calculation": { "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable": { "order": 1.0, "parentTag": "us-gaap_DebtInstrumentDecreaseForgiveness", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The fair value of transfer of mortgage payable in noncash investing or financing activities.", "label": "Transfer Mortgage Payable", "terseLabel": "Mortgage Payable" } } }, "localname": "TransferMortgagePayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofotherindebtednessTable" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantExercisePriceIncrease": { "auth_ref": [ "r255" ], "lang": { "en-us": { "role": { "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision.", "label": "Warrant, Exercise Price, Increase", "terseLabel": "Exercise price (in Dollars per share)" } } }, "localname": "WarrantExercisePriceIncrease", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/NotesPayableRelatedPartiesDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r127", "r139" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average shares used to compute diluted EPS (in Shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r126", "r139" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average shares used to compute basic EPS (in Shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.genhempinc.com/role/ScheduleofearningslossperbasicanddilutedshareTable" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r100": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "230", "URI": "http://asc.fasb.org/topic&trid=2134446" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r111": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=26872618&loc=d3e7436-122677" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2510-110228" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r19": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/subtopic&trid=2122178" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "410", "URI": "http://asc.fasb.org/extlink&oid=6392692&loc=d3e7535-110849" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r196": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349" }, "r199": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759" }, "r20": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 3.C)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177168-122764" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "50", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775" }, "r263": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=SL116886442-113899" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4549-113899" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a),(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(m)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r284": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r296": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479" }, "r304": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "http://asc.fasb.org/topic&trid=2303972" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613673-111683" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r319": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662" }, "r353": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(3),(4))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(5))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e603758-122996" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-06(3))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r421": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r422": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r423": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r424": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r425": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.3(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.30(a)(2))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.8)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868656-224227" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1060-107759" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.T)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868742-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1063-107759" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)-(g)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" } }, "version": "2.1" } ZIP 66 0001213900-21-058900-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-058900-xbrl.zip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

*=VMB'.9^#4@26I(Y"NR.9N'H2XM M02;H-$8Y+M#LCOX2!C0XVW_(:' =UZ[44S\/7XI$;%>B.1$EA C_-(P5,NUS MQ2EDNO9 $J^>C/SFU]]\=7+RO4;@<>[_,TA5SV$PE<26USGSE9&_AL.6?&LI M_S3D>)K,+B"?U_$+S0Y+@YNB=#AR;(BQD6R'U5R?L@8?*54&7\,8$B_^A2!_ M#8D&+_ZU?;%Q^])\9M^B]E]/+U8HNY&MVO 6,I"2W6U1] M;&(HLY7$9X<;8L$1W4Y"KWNVV(852VQZ.)PR%9.F>[;<7[QHMTQ6J-G*:"D M1NA!Y0<8T!OR1-=A' OS:46*5?$_#&->]^79C!88603&V,DR"PI6T3B0,.F_ M)8N.W6=]&N,F>]=ZWCE/_ENRY,1:>Y_Z?K+C%Y/U71*%/G]^N&3T7K&@9V*HNI-V[_9.ALEX4QS=@M=_/$[A'B=KNH)"D7=)@' MHL(#RODK04@;YH#>G9KPLBU46A*,3@19T_CYG[R6<["+Z.WJ=,-?Z/\B'N8S M0H;L?YE:O([SZA^B7IY0SCYI]B4O32O+,( I?5Z32USF:J/H]3GYWA957@I3(NH;40%&(/!9TN M; T?IEFBJD& ;S(-*-OS5.5WER972;KQSIE696=VP NYLZO_CDG#[:IQ)5MJ MO[&S.TG:G8:C@0;:1!H@)MJ#HAJ>XB MS,IP$ U:L\8VOX\=GVCY!ZDC:ODS[1H[6;VDWM[!O//-+WW&7YCF\.5_T*#!Q0)9E"D!",E'!& !^ ?&\.C6L9,Z##U MBLC7R(:+V)L>!A,B*%0]5@:*,N:3D&TI8FDI8MMBGD/3?>:,E>@T0W)-Z#"2 MQ.N;6D"SEN("## 1 W/O2(CR5\\!O"AP]\6AAU217\ZM0B MA;9J&V3D$_$3-DJR74J7O>++EW)\DYU.NV2+ M4F/7<<#FIX'PK]H=9_ \;N3"%!V#XZNH'1>V@-$%9BS3)$>5FB*6":A<+*]C M-L^.&^M5&MP5VUKX0ODBBRD@]:JN2VAI,5(5*\37048L[*LC_7[M;&Y!DX&T M5@>FD5K23.$P6=X '64=2P%%VF#DB CCYY&!(BHC,R[5>LB !+8Y\,EF$^;" M5\#SN(2'@2W)\VX80_N#.+!J["J6:LX5$=$L]CZ79 M?.V^^(URX>(^RB6=]XQ380,6^8%J! K?UF%(H1EKU>U3!K08*V<]&_!'+TT] M[E1MZIU9FONJF3#B8PI\#"S^UQ*:) TX=LFH\:R3&/TZLDQ(-FA[6A_9(AE_ MMI?$V=F^XX-=RE\U8GFWC@ESQ #![+ODT7U:XSG=[:,QBAZV5F#1A+.4]]OT M/EP_YXL)'[R::^L.0D374V;48>2,XHS"/80S%;IFCK(!7F6G7 EN^YQ\61+:;%<:8:8F?B6VT9 M6)EH^US;7N6S_X.)0MLS7>9]'4/".<_ I>N!:Q?%>QNLP0R0UHHSK:?!AWR&6V-<=;]Q2MRM>?)HR,YM;V:6)+7J7 MB5+G3U[&+>Y]X=Q:.A%\ DKN\\+MD87./0YP)"!("4)..?O7JBZ82-GATZ6G MGRP^D9Z3&K$^>A\=.?]5Z[F5804FZKZL#$2;'(%7NUK)RF'1:GC_MFU5=MMM M)#Y8+ZIJL%\6OUBX"K_)PBY?])L@!*G"%FA3EI]4T.CY%3;,[KCN34ECF;7< M7"1D*UW'XJ&=>!)I=_\TG14A(]40-8.[9]86PJ+P'!?"L)D,70ZG,5MR[QQ# M/?LLU4LOY?5GHBZ>>T8Z_SH&_<>U),V9F1\$4>PP-#ATJ$;@G/J7(I F*20O9.ZRWE18B M(#E_QA+3.I%F]Y31GW>\ ]>+ \L<6,QMNS4 "] $KX:38CQV@H,IZ[IVMF+/ M%LD, 0W_>9'X(D;$GV$HQ"6C_A?KY.5+!E)("OM!"(@0C<%$D>1D?JVK/\>>>EC&31_IYNDU2E!'E\WSJW1D7R"LW$8D.$CJ!* :3 M2UZJA W'5@52EO1%8;C!D=9M>[*K,/.]Z*_,+KMBOU'E=YB+07].'-70PT(G M"<5PPL<3 8 5;3?@3E\B9%N=>OSSW+2P"%+,=F8,)G5Y1U8AHC43ZO']@P/+ M9@#8,[ ?9!L=>ZO@$U[&>9COK\*(OM]MGF@Z21X&DSD^*OKK0UXJ,8SP<:08 MB*D3( Y4+)=NRN)D*.:YI^N07R;B_+VWF68=2"=T5M ;PD#-\V8LX8-QW& Z M;G0Y+]G>>!=V,QV/'Z9,90C'N"A <\[K.*?[\R280Q[4\R.(AQ(AM;1T0-\0 M 4V*A% MBF&WDH*OK,Q/48[YK.,UA5G![NP"IK=L+]$ M=\])/(>G:S"9XP^\OSY8/Y#[OL6X _!T01RH^"S=E,5W^T#]7K"]*5?^\UV:TC@OXESB8;&73PQH*R?&N-O)45'; MZB4,J8%( 84?RU)SK&NO*W8^Z7)W'3.RB[?V],++O7*96>(;THDQI$:.BBZD M4HIL *:D18TNO"8,+-W1=$1P^;L M.=W0.! YOI$W38BZ,[G5(YVU <&HQQ ^".\,D5*\XO1P(Y8:H[R*-)G;<[S# M "=UK1T@1*#84NFB:.?@#YYDN \U:5A4AYU4F[7YYKMI_<5SC[E?9[1G=>K: M!-$P?*!1OM@9/-% ?:$AX9'\C49_OY, M.3O:+[8EFYE0=+Z8K3Q_'$A!?R5G!X<2#8U1<4BB ;!J*"&R+=H7)#KU?9ZW MG]U3GX8OO#OG>YKK0QT3Q$6UH"O7E@DRD#HI04A:PZ 6A3!A8$>(=%L>[=VJ M9KY+Z=8+@\N/O(@E75*&Y"LY5SE2- "Q*<<26@S.4&5&R:FVL, [M"S/=Y?R MWN[Y_C0.>..>[08\G8#Z2,H)7-YEM=B @E" B*I&-1!>XQP3CM3EBK3[M:U* M5$U\QVB5MV=_FR8+]<;4+(E1HTV-DHE 452!&L?-KJ+1[MQ6M&[9Q![/"[GA MG3>+:N*K#QD5UM0BDJ5>T?TU28D/(%4U#(DX$$DYU%&R.MJQ?W@<$+?^GQ%7 MVQ*F)\*$V]9UG#/BARO;XL*5UN G,J/1D:J/V,VK53Q?^_.VR+NJCCSWAQ#%/:%#GHU5,#7E_4F(G]V05=A7Z8?XYJ7H_E>EL* M1]'%UN1N+>+" ZU8SKD2@W'1^*);@-@.:3W[ (E:QC5]Y^VYF]*%4[JWE,,@ MIQH3G2]Z6XS&/0G5_)+YH"6;M(UV^GZZH\%0%I<2%V UC*,.Q :6&CZ>1'*- M@R,Y:N[UA$>Q7>N^<#OZF+3Z+"\L08KEG!]9,"Z0Q['X;#.2)R0M>W!O"T!< M#:1G8J?UFGK?]@=7U]54":HJ"VQ4D5[BF_3W):'9$],>4M,L-52(-3N98"@F?C9G1H_8S'#A L,4=E#I'? M_/J;KTY.OE?A-BNFUO&W\22RZ6XC/!4\!^V)S<^?1XV1,1#8V;FF1$/I M3PI;XYDF\H?O6EV+BXX5M60H]VM_E!4/%S[$87Z=93N/(?L7+]JI4M$G-,@& MUG)]E %X0/?WLB>6:-$>&]@]$]Q2,A/)ZF(:886RO9XM%2;P^8BMM#LH: MDT?\C/8](=NDKPZW"5/W;]-DM[V.R_0"J9)<.(P\ UJ8X1I+G,&RB:6\3CVZ M<>,_$^4+B!--(?6TNTR8%YW&X^!<+,0^59\AM-A]!EH/(;*D0$=QM2DA1!"\ M X.9?&/ R?X=1[5SRYC3(]WP!ACIOHB_K?[, M;_0,CO\V:6HV$"\G#TQ(*:\QRV9[0SAWQ*@+ZI>_/1&_/<:V:JW%M/T)V7%P M@HUS5[%5I*BP.6]34;T]$.Z)JI/W(E^4X=*NW5)F:,'/C]I?2?.%D,_"F%PD M4>2EF6BY+>3^=*IB2R\VUU%VC-W;,@P,=+(+@K:=+@828^93.( M@/RE+T*?HSJ=].QIO612DF#V,_*%ID^)-4N.#3[I]@D'L.23Y L?$5(ZV+]A'$Y]+;VX5@?,B[JQ*FU\7FUEEG-P'DEJE]($%VL]&4$(=E*)"4$#T3 M@ *"8^A@+VJ.GXUH'HHX%;#1[T(.ZAW(N)FZJ[\GOWOSVN'1?#9U5,>_(Q#U.OWOS M]5??O/GVW[]9P&>%KA_!Q!6(#Q8^)_4%9-K-WGD6)8B)\6D)W"-EWJ%#NN.; M7RFG./U;E7R7SH3KJ3F$'#BMBFLGO\G5VE>% H.4V,G)R9OCWQ\S#?:MC?8Z MB#P[M9Z24G)J0J9[I[C)NAA^#0.\C&3WD!WB(W@.2)[6%>[(U3D2-:G;LV+) M_U!V'=M7E!A4H5_8#:I:#RD! D#'2$6HG)^X8F;B^-3M?KH]M+C'$UH+YX& MJ:M3*D0]/R>^_:)S=*KV[#)89H"/[-0H&[D0O_U:@Q\=!?#G!_8I6_%A2I#, MLC_-C-]RS]&,^T'KG[4BI-Z68?1"$/!78 MB^Z\,+B.S[UMF'O+%+V#UG)>FER.!U33HQY->,'F(W:R^04 =FD/->LZA3T4 M.[:^\]S3W MC&EQZ:;G7B,5,9P%I$B@V7=AR[T2,$58ZJ!)"A& MXAI,YEQM"YCA_BX?[&(#%&&+^G(/-&?&#+"Q' M(VLDB$=M29%NT-ZZOJ :T,#N6GI/X\'] 9"*D*((A./],J.,\N>F.!B[DUS"!70[Y"5;S(O#Z&? MD(YK74>38J<33&\^[^VJ/%46$Y=F!?<^RM;J"K'@;\S3T@SXC/)V UGX0OEO MPYQN,I(])Z\Q.PVV7LHN/M&>L%625]Q$1BGO^D+3W;RUAKF@VY3ZH7A:SL3P M=,-KC_PB_KF(U*C60PB"*M"!NNRV((3*\5HPF'%V TYVRGUJ=FY3*>\=3=-D)+66RJ[,K),P(X*-HK M9CLF#[K,F!'#[NI\'?/[."^F4LQ1.66PI#LR?K.72B=FR3+KA@.10&N'3N;FO*M M9W25I+08]^A]I-GE1W90)6D0QEZZO^:>BVXT<=$(ZY+X(C3C7&PS8.W#+"-< MVHA?K]8J=8AJSSL0Q6X+T&6);W^/D-9:[*(K'=+#=QF?V4RXN6^E,P_BVN\* M*"**G%DQLTAUG'"S:B7>?BN491M@?@K6CH23FICKSJI%O4LCED>(FYAC-]4H.DRK2.5S Mⅅ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